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Abstract
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In recent years, HIV-associated cancers have proven to be the bane of our time, since HIV is
decimating humanity across the globe, even in the twilight of the last century. Cancer rates
continue to rise in developing countries, where 95% of the world’s HIV-infected population
lives, yet less than 1% have access to antiretroviral therapy. HIV-infected individuals have
a higher proclivity to develop cancers, mainly from immunosuppression. An understanding
of the immunopathogenesis of HIV-related cancers (HRC) is therefore a major prerequisite
for rationally developing and/or improving therapeutic strategies, developing immunother-
apeutics and proplylatic vaccines. In this study, we explore the pathology of HIV-related
cancer malignancies, taking into account the pathogenic mechanisms and their potential
for improving the treatment of management of these malignancies especially in developing
countries. We mathematically model the dynamics of malignant tumors in an HIV-free envi-
ronment, investigate the impact of cancer malignancies on HIV-positive patients and explore
the benefits of various therapeutic intervention strategies in the management of HIV-related
cancers. We present two deterministic models of infectious diseases to implement these, and
they were analysed. We use HIV-related lymphomas in the Western Cape of South Africa
as a case study. We validated the proposed models using lymphoma incidence data from
the Tygerberg Lymphoma Study Group (TLSG), Tygerberg Hospital, Western Cape, South
Africa. We show that the increasing prevalence of HIV increases lymphoma cases, and thus,
other HIV-related cancers. Our models also suggests that an increase in the roll-out of the
HAART program can reduce the number of lymphoma cases in the nearest future, while it
averts many deaths. Furthermore, the results indicate that a highly crucial factor to con-
sider in the prognosis of the incidence of lymphoma (and other cancer types) in HIV-infected
patients is their CD4 cell count, irrespective of whether the patient has developed an HRC
or not.
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Chapter 1
Introduction
1.1 Cancer
Cancer is a group of diseases typified by the uncontrolled growth, division and
proliferation of abnormal cells [1; 2]. Cancerous cells are also referred to as
malignant cells [3]. Cancerous cells develop when there is an uncontrollable
proliferation of abnormal cells in the body. These abnormal cells are formed
when there is a mutation (result of deoxyribonucleic acid (DNA) damage or
errors) or transformation of normal cells, which after proliferation, starts to
aggregate to form malignant tumours or lumps known as cancers. Every cancer
type is attributed to the malfunction of the genes responsible for cell growth,
division and death control [2].
The malignancy of these tumours causes them to overtake the space they are
in, deprive other surrounding healthy cells of their space, nutrients and oxygen
which causes them to malfunction. They eventually spread to, and invade other
parts of the body, thereby causing destruction to invaded tissues [1; 4–6]. This
spread of the tumour(s) can be facilitated by the entering of cancerous cells
into the body’s bloodstream or lymphatic vessels. These tumours eventually
displace the normal tissues(s) originally located at the cancer sites. The process
of this spread and displacement is called metastatis [1], and such tumours are
caled metastatic tumours. They contain cancerous cells of the tumour(s) in
the original (primary) site, and are thus named with respect to their site of
origin [1; 7]. An example is a breast cancer that has spread to the liver, it is
called metastatic breast cancer [1], or breast metastasis, or breast metastases
if tht tumour is more than one. It is imperative to mention that not all
tumours are malignant (cancerous). Such tumours are said to be benign (or
non-malignant). They can grow very large but they do not spread to, or invade
other tissues [1; 7].
There are so many different types of cancers. Cancers are usually classified
1
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by the organs of their primary locations (site of origin) or by their tissue
types. According to the National Cancer Institute (NCI), there are five main
categories of cancers with respect to their tissue type, viz: carcinoma, sarcoma,
leukemia, lymphoma and myeloma, and central nervous system cancers [7].
Carcinoma is a group of cancers that originates from the epithelia tissues (the
layer of cells that line or cover internal organs and tubes). Sarcoma is the
group of cancers that originates from the bone (sometimes termed osteosar-
coma), cartilage, fat, blood vessels, or other connective or supportive tissues.
Leukemia are cancers that originate from blood-forming tissues such as bone
marrow and causes large number of abnormal blood cells to be produced and
enter the blood. They are grouped under blood cancers and are sometimes
referred to as “liquid cancers”. Lymphoma and myeloma are cancers that
originate from cells of the immune system. Lymphomas are cancers of the
lymphatic system while myelomas specifically originate the plasma cells of the
bone marrow. These two cancer types are also blood cancers, however, lym-
phomas are sometimes referred to as “solid cancers”. Central nervous system
cancers are cancers that originate from the tissues of the brain and the spinal
cord [7; 8]. Note that cancers are also classified by the grade and by the stage
in which the cancer is in.
Anybody can develop cancer, since some cancers have genetic factors that are
not necessarily hereditary. Most genetic aberrants that predisposes an individ-
ual to cancer are antecedents of genetic mutations which may be a consequence
of internal or external factors [2], such as the metabolism of cell nutrients
[2], menopause hormone therapy (treatment to relieve women of repercus-
sions of menopause by suing artificial hormones) and family history of cancer,
for example, hereditary breast and/or ovarian cancer, which is a result of a
deleterious BRCA1 or BRCA2 (human genes) mutation. Compromise in the
body’s immune system and/or viral infection is also an important cause of
cancer. Examples of such viruses or bacteria are the human papillomaviruses
(HPVs) (the leading cause of cervical cancer), human immunodeficiency virus
(HIV), Epstein-Barr virus (EBV), human herpesvirus 8 (HHV8), hepatitis
B (HBV) and hepatitis C viruses (HCV), human T-cell leukemia/lymphoma
virus (HTLV-1), and helicobacter pylori [7]. Old age, diet and body overweight
are other causes of cancer [1]. Some external or environmental carcinogenic
factors include tobacco smoking (including the inhaling of environmental to-
bacco smoke (ETS) or residual tobacco smoke), exposure to ionizing rediation
(e.g. radon, X-rays, cosmic rays), exposure to ultraviolet (UV) radiation, ex-
cessive alcohol consumption, exposure to environmental chemicals or minerals
such as asbestos, nickel, benzene, formaldehyde, vinyl chloride, cadmium, pes-
ticides, fertilizers, etc [1; 7; 9]. Nevertheless, the causes of many cancers are
still unidentified.
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1.1.1 Cancer Types
Signs and symptoms of cancers are numerous and they vary with respect to
their types and location, speed with which they grow, their spread mechanism
and their sizes (some cancers give no sign or symptom until they are large)
[10]. Some general and common signs and symptoms of cancer include local
symptoms (e.g. lump, swelling, bleeding, ulcers or skin sore etc at the primary
site of cancer), other metastatic lumps (e.g. swelling of the lymph nodes near
the primary site of cancer), systemic symptoms such as unexplained weight
loss, fever, fatigue, pain, poor appetite, depression, itchy skin or skin dis-
colouration, excessive sweating at night, etc [8; 10]. Many other symptoms are
specific to the site of origin of the cancer. These include symptoms related to
the gastrointestinal respiratory and cardio-vascular systems. There are also
many neurological. skin-related urological and genital symptoms [8].
In order to detect the presence of cancer in patients, physicians use several
diagnostic procedures and tools. To detect the location or size of a tumour
and the organs affected, several imaging techniques can be used. They include
X-rays, ultrasound scans, PET scans, CT (computed tomography) scans, and
MRI scans. Physicians also conduct an endoscopy to get a camera view of the
affected area. The most common diagnostic procedure is biopsy, in which cells
of the tumour are removed for pathological examination under a microscope.
There are different types of biopsy. They include incisional biopsy (removal
of a sample of tht tissue with a needle, which is either wide; core biopsy
or fine tipped; fine needle aspiration) and surgical excisional biopsy (surgical
removal of an entire lump, suspected tumour or suspicious area) [8; 11]. Some
imaging techniques such as CT scan or ultrasound are also used in directing
the physician to the affected site or organs during the biopsy.
Other diagnostic procedures include sentinel node biopsy (surgical excision
and examination of nodes close to the primary site of cancer), endoscopy,
bone marrow biopsy (in cases of leukemia or lymphoma), chest X-ray and
other molecular diagnosis like blood test; complete blood count (CBC), pap
test (also called pap smear or cervical smear), sputum analysis and bronchial
washing analysis [3; 8].
1.1.2 Cancer Treatment
In treating cancer, several factors such as the cancer type, cancer stage (how
much it has spread or grown), and age of the patient amidst other things are
considered. Most cancers are treated with a combination of different therapies.
Cancer therapies include surgery, radiation therapy, chemotherapy, biological
therapy, hormone therapy, stem cell transplant (peripheral blood, bone mar-
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 1. INTRODUCTION 4
row, and cord clood transplant), photodynamic therapy, and targeted therapy
amidst other upcoming therapies.
As a treatment procedure, surgery, the oldest known cancer therapy, is usu-
ally used to treat (or probably cure) a patient with a cancer that has not
metastasised by surgically removing tumours and identified cancerous tissues.
Examples of non-metastasised cancers that surgery can likely cure are breast,
skin, lung and colon cancers. Surgery cannot be used to treat cancers such as
leukemia and lymphoma.
Radiation therapy is the use of high-energy radiation beams focused on can-
cerous regions, in order to destroy the cancerous cells, or to shrink a tumour.
It does this by stopping the division of cancerous cells. It does have side effects
(especially when relatively early) which include skin burns, fatigue, etc. It is
often used along side some other cancer therapies [3; 8; 11; 12].
Chemotherapy is the use of cytotoxic chemicals or drugs to kill all malignant
and/or proliferating cells in the body. Since the drugs do not discriminate
among the fast-growing cells they destroy, they also interfere with rapidly
growing normal cells such as the bone marrow cells, gastrointestinal tract lining
cells, and hair follicle cells. Thus, some anticancer drugs have side effects such
as bone marrow suppression, hairloss, fatigue, vomiting, and nausea. It is also
often used in combination with other cancer therapies [8; 12].
Biological therapy, also known as immunotherapy, is the administration of
immune cells to the cancer site (local immunotherapy) or the whole body
(systemic immunotherapy), in order to incite and strengthen the immune sys-
tem of the host body to fight, destroy and/or shrink tumours or malignant
cells. Hormone therapies are used in cases where the cancer is directly linked
to the body’s hormones. This is done, e.g., by reducing the oestrogen level in
a breast cancer patient, or testosterone in a prostate cancer patient, with the
use of hormone altering or modulating drugs [8; 12].
Some cancers destroy the bone marrow (the body cell producer). Chemother-
apy and radiation therapy, especially in a high dose, can also destroy the bone
marrow. Hence, some patients, with blood cancers or patients who have had
chemotherapy and/or radiation therapy may need a bone marrow transplant
(stem cells transfusion) for the restoration of their damaged bone marrow.
There are basically three types of bone marrow transplant (BMT), named
with respect to the source of the stem cells used in the procedure. They are
bone marrow transplant, peripheral blood stem cell transplant, and the cord
blood transplant. Bone marrow transplant is that in which stems cells can be
obtained from a healthy donor (allogenic BMT), patient pre-treatment (autol-
ogous transplant), or an identical twin of the patient (syngeneic transplant).
Peripheral blood stem cell transplant is that in which stem cells are obtained
from the peripheral blood (the flowing, circulating blood of the body). Cord
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blood transplant is that in which stem cells are obtained from the umbilical
cords and placenta of newborns [7; 8; 13].
Photodynamic therapy involves the use of drugs called photosensitising agents,
used along with laser light to destroy cancer cells. Targeted therapy is used
when cancer cells alone can be destroyed by specific procedures, without af-
fecting the healthy cells. They are different from, and have less adverse effects
than other anti-cancer drugs [8].
1.2 Lymphoma
Lymphoma can be simply defined as a cancer of the lymphatic system [14].
The lymphatic system is a part of the immune system of the human body. It is
a complex network of vessels (the lymphatic vessels), glands (or lymph nodes)
and other lymphoid tissues (which include the spleen, the thymus gland and the
bone marrow [4]) that convey electrolytes (called lymph), mainly lymphocytes
(a variety of white blood cell) throughout the body.
Lymph nodes are groups of lymph tissues (small swellings; referred to as
‘swollen glands’) located along the lymphatic system at intervals. They are
small and bean-sized. They are the centre of production and storage of lymph
[15]. They serve as filters for the lymph, thus, averting the entrance of foreign
materials (such as viruses, bacteria, or other microbes) from entering the blood
stream where they are processed [4; 14].
Lymphocytes are involved in immunity, as they help the human body to com-
bat a variety of pathogens (infectious agents). They multiply in the local
lymph node of an infection, when an infection occur in that area (the infection
site), so as to fight such infections. Lymphocytes are of two major subtypes; B
lymphocytes and T lymphocytes (also called B cells and T cells respectively).
B cells, which mature in the bone marrow [16], help to shield the body from
pathogens by producing proteins called antibodies. These antibodies attach
to the infectious organism and abnormal cells, while it alerts other immune
system cells and certain blood proteins that can kill the pathogens.
T cells, which mature in the thymus [16; 17], play several roles (that concerns
its many subtypes) in the mechanism of the immune system. Some of them,
when activated kill pathogens directly, or destroy infected cells, or cells that
have changed into cancer cells [4; 18]. Some T cells play a part in either boost-
ing or slowing down the activity (prevention of underactivity or overactivity
respectively) of other cells of the immune system [4; 15]. Some T cells also
keep a memory of particular antigens that have previously attacked the body,
so that they may provide a quick resolute response when such are recognised
[17; 18].
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Lymphoma cells are the malignant transformation of either of the B or T
lymphocytes, or their subtypes [4; 15]. Since these malignant lymphocytes
are transported between the lymphatic system and the circulatory system, the
lymph is eventually returned to the bloodstream via the innominate veins, thus
making lymphomas blood-related cancers [5; 15]. Thus, lymphoma cells are
sometimes found in the blood, the lymph nodes (where they are often confined)
and other lyphatic tissues. They can spread to almost any other organs or
tissues outside the lymphatic tissue. Such lymphoma development is referred
to as extranodal disease. Malignant lymphoma cells, after proliferating, tend to
coagulate into tumours in the lymph system or in other remote organs through
the lymphatic system.
Thus, lymphomas are particular cancers that originate only from the lympho-
cytes in either the lymph nodes or other lymphoid tissues. They can affect
lymph nodes in all parts of the body and other organs involved in the immune
system, which can afterward spread to other remote organs. Most lymphomas
starts in the B cells [14; 15]. However, some other cancer types can spread
to lymph tissues such as the lymph nodes. These are not referred to as lym-
phomas [15].
1.2.1 Lymphoma Types
There are two major types of lymphoma, namely Hodgkin lymphoma (also
Hodgkin’s disease/lymphoma) and Non-Hodgkin lymphoma (also Non-Hodgkin’s
disease/lymphoma).
Hodgkin lymphoma (HL) is a lymphoma that contains abnormal cells known as
the Reed-Sternberg cells (visible under a microscope). This is its major defining
characteristic which makes it different from Non-Hodgkin’s lymphoma. HL
spreads in predictable ways, by contiguity, from one lymph nodal chain to
adjacent nodal sites. It is non-contagious. It is a result of the cancerous
trasformation of B lymphocytes [6].
There are two subtypes of HL: Classical Hodgkin lymphoma and nodular
lymphocyte-predominant Hodgkin lymphoma. The latter often develops more
at an older age than those diagnosed for the classical HL. It is also usually
diagnosed at its early stage and it grows at a slower rate than the classical HL.
The two HL subtypes also have different forms of treaments [19].
The causes of Hodgkin lymphoma is generally unidentified. However, despite
the fact that HL is considered a non-AIDS-defining cancer, HIV/AIDS pa-
tients have about 10-20 times proclivity to develop it in comparison with the
general population [6]. A recent British report on the effect of highly active
antiretroviral therapy (HAART) on the incidence of HL, suggests that there
may be a relation between the HAART and the incidence of HL in HIV/AIDS
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patients on the HAART [20]. In addition, viral infection with viruses such as
Epstein-Barr virus (EBV) have also been observed to be a likely predisposing
factor to deveoping HL. HL is more predominant in men than in women, and
it can occur at any age. However, it occurs mostly in people between the ages
of 15 and 35, or 55 and above [5; 14].
Non-Hodgkin lymphoma (NHL) is simply a general term for any other lym-
phoma that is not Hodgkin’s, i.e its biopsy does not reveal any presence of
Reed-Sternberg cells. There are over five dozens different types of NHL. Cases
of NHLs are more common than HL and it comprise about 90% of all diagnosed
lymphomas [5; 6]. Most NHL patients are people aged over 55, and NHLs are
now the most common cancers in individuals aged 75 and above [5; 14].
The mode with which NHL invades the body is unpredictable. NHL is classi-
fied according to the rate of the growth of the cancerous cells. It is described
as high-grade (aggressive) NHL or low-grade (indolent) NHL. The former de-
scribes a NHL with cells that seem to divide quickly, which is an indication that
the particular diagnosed NHL is fast growing. These lymphomas are either B
cell (more common) or T cell lymphomas. Low-grade NHLs describes a lym-
phoma with cells that seem to divide slowly, which implies that the particular
NHL diagnosed is growing slowly [19].
The causes of NHL are also generally unknown. However, a compromised im-
mune system; immunosuppression or immune deficiency is a definite risk factor
for NHL. Transplant patients are at risk, as well as HIV/AIDS patients. It has
also been observed that past cancer treatment (repercussion of chemotherapy),
after several years can also cause one to be at risk of developing NHL. Several
viral and bacterial infections also predisposes a person to NHL. Such viruses
include the human T cell lymphoma virus 1 (HTLV1), Epstein Barr virus and
hepatitis C virus [21].
Common symptoms of lymphoma include painless swelling (or lump in) the
lymph nodes in the neck, under the arm or groin, unexplained weight loss,
excessive night sweats, unexplained persistent fever, persistent itchy skin, and
other malfunctions or pains in other parts or organs of the body affected by
the lymphoma [4; 11; 13].
There is the need for the identification of the lymphoma subtype a patient
has using biopsy, after which treatments are administered with respect to
that patient’s particular case. Lymphoma treatments include chemotherapy
(most often drug administration), radiotherapy (targetted high energy X-ray
exposure to destroy cancer cells), peripheral blood stem cell or bone marrow
transplant (in very extreme cases and sometimes for relapsed diseases), mono-
clonal antibody therapy (a type of immunotherapy, sometimes used alongside
chemotherapy), immunotherapy (also referred to as biological therapy or bio-
therapy), and radioimmunotherapy [11; 13].
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If lymphoma is diagnosed at a very early stage, then there is a high chance of it
being cured. Nevertheless, there is quite a lot of debate as to whether cancers
can actually be cured. An effective treatment therapy can afford a patient
the chance of being in remission. A cancer patient is said to be in lymphoma
(or cancer) remission after lymphoma (or in general, cancer) treatment if the
lymphoma (cancer) cells in the body are undetectable and cause no symptoms.
The main aim of medical therapy in lymphoma (and other cancer) treatment
is to achieve a complete remission in patients, that is, after the treatment of
lymphoma (cancer), every sign of lymphoma (cancer) is gone [22; 23].
A patient is said to be in a partial remission if a part of the tumour shrinks
after treatment, or if there is a partial response of the lymphoma (cancer) to
any treatment therapy, in that there are still signs of that lymphoma subtype
(cancer) in the patient. A patient that remains in remission for a long period
of time, say for many years, is said to be in a durable remission [23].
Patients can be in remission for a long period of time, as well as for a short
period of time. If lymphoma reoccurs after a patient has been in remission
for sometimes, then the patient is said to have a relapse (of lymphoma), and
there is said to be a lymphoma recurrence. Factors that determine if a patient
will spend months, years, or even a lifetime in remission depends on the stage
and grade of that patient’s lymphoma subtype. The duration of a patient’s
remission can be used to determine how aggressive the lymphoma is [22; 23].
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Chapter 2
HIV-Related Lymphoma (HRL)
2.1 Introduction
Despite the fact that some malignant neoplasms are defined as non-HIV-
defining, they are profusely reported in HIV-positive patients. Such cancers
include Hodgkin lymphoma (HL), multiple myeloma, lung cancer, invasive anal
carcinoma, leukemia and those involving the oral cavity, liver, gastrointesti-
nal tracts, lip, oesophagus, heart, pancreas, vulva, vigina, soft tissues (e.g.
leiomyosarcoma in children), and the stomach [24]. In contrast, some common
carcinomas found in the general population does not siginificantly occur in
PLWHA. They include breast, prostate and colon/rectum carcinomas [24; 25].
People living with HIV/AIDS (PLWHA) have been observed to be at a higher
proclivity of about 60-200 times of developing HIV-related lymphoma (HRL),
in comparison with the general HIV-free population which include some im-
munosuppressed individuals such as organ transplant patients [26–28]. The
overall prevalence of HRL remains significant, even after the introduction and
wide implementation of the HAART. In addition, HRL is still one of the most
frequent causes of mortality in HIV-positive patients [28].
In particular, the incidence of Non-Hodgkin lymphoma (NHL) is increased
by almost 25- to 250-fold in individuals infected with HIV, especially in the
advanced stage, compared to the general/HIV-free population. It is the sec-
ond most common neoplasm that HIV-positive individuals develop [29–33].
This high risk of lymphoma development in PLWHA is most likely a direct
implication of severe immune system dysfunction, cytokin dysregulation, pro-
longed HIV infection, old age, and opportunistic infections (OI) due to intense
immunosuppression of the body from chronic HIV infection [31; 32]. Concor-
mitant oncogenic viruses that are associated with many of the immunological
dysfunctions, especially malignant lymphomas and other OI include Epstein-
9
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 2. HIV-RELATED LYMPHOMA (HRL) 10
Barr (EBV) (which plays a major role as it is found in 40-50% of HRL [25; 31]),
human herpesvirus 8 (HHV-8) and human papilloma virus (HPV) [27; 30–32].
The World Health Organisation (WHO) has classified HRL subtypes into 3
major categories: lymphoma also ocurring in immunocompetent patients, lym-
phoma ocurring more specifically in HIV-positive patients, and lymphoma also
ocurring in other immunodeficiency states [28; 30; 31]. According to this clas-
sification, lymphomas also ocurring expressly in HIV-positive patients include
primary effusion lymphoma (PEL) (and its solid variants) and plasmablastic
lymphoma (PBL) of the oral cavity type [31; 32]. Note that large B-cell lym-
phoma arising in Kaposi Sarcoma herpesvirus (KSHV)-associated multicentric
Castleman disease (MCD) has also been defined as an HRL [27; 34].
Lymphoma also arising in immunocompetent patients include: Burkitt lym-
phoma (BL) and Burkitt-like lymphoma (BLL), diffuse large B-cell lymphoma
(DLBCL); both centroblastic and immunoblastic (including primary central
nervous system (CNS) lymphoma), extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue type (MALT lymphoma - which is rare),
peripheral T-cell lymphoma (also rare) and classical Hodgkin lymphoma. Lym-
phomas also arising in many other immunodeficiency states include polymor-
phic B-cell lymphoma, which is like the post-transplant lymphoproliferative
disorder (PTLD) and it is rare [28; 31].
The most commonly reported cases of HRL are of the B-cell derivation; mostly
represented by DLBCL with immunoblastic-plasmacytoid differentiation (also
involving the CNS) and BL [24; 30–32; 34]. They are distinguished by clinical
aggressiveness, advanced stage, and a high frequency of extranodal involvement
[35].In most studies, DLBCL reportedly accounts for 60-80% of aggressive HRL
cases, of which the median CD4 count on diagnosis is often about 130cells/µL
and a CD4 count of < 200cells/µL in about 30% of all DLBCL cases [31]. EBV
is detected in about 50- to -70% of all DLBCL cases [25]. Extranodal sites com-
mon to DLBCL (especially in HIV-infected individuals) include lymph nodes,
bone marrow, liver, gastrointestinal tract, and virtually any extranodal sites.
The most common of this is the brain, with primary central nervous system
lymphoma (PCNSL) (also known as primary brain lymphoma) accounting for
about 15-30% of HIV-related Non-Hodgkin lymphoma (HIV-NHL) [30–32; 36].
BL and BLL (BL’s morphological variant) accounts for about 35-50% of all
HIV-NHL in several studies [30; 31; 37]. EBV is present in about 30% of all BL
cases. Extranodal sites common to BL include the liver, spleen, bone marrow,
gastrointestinal tract and meningeal involvement [31]. It is pertinent to note
that while BL is common in HIV-infected patients, it has no other association
with other kinds of immunosuppression [30].
PCNSL, also known as primary brain lymphoma is an immunoblastic (or high-
grade) variant of DLBCL. It tends to occur only in PLWHA, especially those
with severe HIV infection (advanced AIDS) [29–31]. It accounts for 15-30% of
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all HIV-NHL. About two-third of PCNSL patients had AIDS-defining-illnesses
(ADI) prior to developing PCNSL. HIV-related PCNSL (HIV-PCNSL) gener-
ally have a median survival of approximately 3 years [29]. Over 95% of PCNSL
cases are closely associated with EBV [25]. PCNSL is associated with severe
immunosuppression, even in people who are iatrogenically immunosuppressed.
The median CD4 count on diagnosis is less that 50cells/µL [24; 29; 31; 32]. The
neoplasm mostly occurs in the cerebrum as multiple lesions, but it can also
involve nonhemispheric brain areas; cerebellum, brain stem or basal ganglia,
periventricular. Extranodal sites frequently common to PCNSL include the
liver, bone marrow, and gastrointestinal tract. PCNSL has a poor prognosis.
Factors that affects this include old age (from 50 years and above), very low
CD4 count, and the involvement of hemispheric brain areas [30]. It also has a
poor median survival of about 4 months [32]. Radiation therapy is the most
common treatment for both HIV-PCNSL and non-HIV-PCNSL [29].
Primary effusion lymphoma (PEL) is a distinct high-grade B-cell neoplasm
that rarely occurs in HIV-negative patients. It comprises less than 5% of
all HIV-NHL. It is consistently associated with infection by Kaposi sarcoma-
associated herpesvirus (also known as HHV-8), with a frequent (> 90%) coin-
fection with EBV [24; 34; 36; 38]. Most cases of PEL are reported to be in
HIV-positive men, who are majorly homosexuals, and with a diminished CD4
count (< 200cells/µL). The median of their ages is between the mid-30s and
mid-40s, of which they commonly have an AIDS history [31; 35; 36].
PEL has two variants; the classic PEL (or “body cavity-based lymphoma”)
and a “solid variant”, otherwise called extracavity PEL. PEL mostly develops
as malignant serous (or lymphomatous) effusions. It is common for PEL to
be metastatic [35; 36; 38]. The extracavity PEL most commonly involves the
gastrointestinal tract or soft tissue, the skin, large bowel, lung and lymph nodes
with similar immunophenotypic features. It is also associated with HHV-8
[24; 30; 31; 36]. Most PEL patients have pre-existing (or subsequent) HHV-
8 related diseases, which include Kaposi sarcoma or multicentric Castleman
disease (MCD). PEL patients are also mostly homosexuals [30; 35; 36].
Plasmablastic lymphoma (PBL) is a rare and distinct NHL subtype, as clas-
sified by the WHO [33], and it is formerly classified as a clinicopathological
variant of immunoblastic DLBCL. It is characterised by blastoid morphology,
plasmacytoid differentiation, a rare immunophenotype of plasma cells (PC),
and a penchant for the oral cavity, especially the mucosa of the jaws of (pre-
dominantly) HIV-infected individuals [24; 30; 39; 40]. It is a HIV-related high-
grade lymphoma that develops mostly in males. It has also been reported in
immunocompetent patients [33; 39]. It is closely associated with latent EBV
infection in most (70%) cases [38; 39; 41].
PBL accounts for 2.6%- to -30% of all HIV-NHL cases [33; 41]. Other extraoral
sites common to PBL include the anal cavity, lung, gastrointestinal tract,
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anorectal region, paranal sinuses, (cervical) lymph nodes, spermatic cord, skin,
testicle, and bone [33; 38; 41]. PBL patients present with a depreciated CD4
count (< 200cells/µL), and the median of their ages is usually between 38 and
48 years [37; 40]. PBL has a prominent propensity for the gastrointestinal tract
and the central nervous system as extranodal (anatomic) sites. Reports also
show that the most common intraoral sites are the gingiva (mostly localised
there), the floor of mouth and the palate [33; 39]. PBL has a poor prognosis
and poor response to therapy, even with polychemotherapy, with, or without
combined radiography. PBL patients have an average survival time of 14
months[39; 41]. A recent study by Hansra et al. [41], suggests that PBL is a
heterogenous group of NHLs with distinct clinicopathology, viral associations
and outcomes. They reported that it has two unique clinical variant entities;
PBL of the oral mucosa and the extraoral PBL.
2.2 HRL in the Post-HAART Era
The highly active antiretroviral therapy (HAART) was globally and publicly
rolled out through expanded access programmes in late 1996 [30; 42]. In the
pre-HAART era, the prognosis for HRL was very poor, and this is due to many
reasons. These include HIV history, low CD4 count (< 100cells/µL), injection
drug use and old age (35 years or older). Complete remission was achieved in
30-60% and the median overall survival was (5-8) months [31]. Also, patients
with DLBCL had significantly higher rates of HIV-related illnesses (HRI), cou-
pled with lower CD4 counts, in comparison with BL patients at HRL diagnosis
[32].
The advent of HAART have precipitously improved HIV-related mortality and
morbidity, in that they have impressively declined. HAART has (generally) ef-
ficaciously reduced the pace at which HIV-infected patients progress to AIDS.
Hence, it has declined the risk of developing some HIV-related cancers (HRC)
in HIV-infected patients. This is strikingly evident in the incidence of KS and
other opportunistic infections (OI) in the post-HAART era [25; 43]. When
HAART regimens are effectively combined and adhered to, it avails HIV pa-
tients with immune restoration, thereby reducing the overall incidence of HRL.
This effect has changed the epidemiological and clinical profile of HRC in gen-
eral [24; 25; 30; 31; 35]. In addition, the incidence of most AIDS-defining
illnesses (ADI) have dramatically declined [25; 32]. An effective HAART regi-
men leads to decreased cytokine stimulation or an improved immune function,
fewer infectious complications, and a significant improvement in the survival
of HIV-infected patients [24; 32].
Since the HAART roll out, there have been a particular decrease in the risk
of lymphoma in people living HIV/AIDS (PLWHA). It has also improved
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clinical outcomes [30]. This diminishing risk is seen to be associated with
improved CD4 counts, which is a consequence of HAART in PLWHA using
it. Thus, there is an improved prognosis in most HRL patients using HAART,
and their survival approaches those of the HIV-negative lymphoma patients.
This is also partly because of higher mean CD4 counts, which has given HRL
patients more tolerance for chemotherapy [25; 44]. HAART has improved the
overall outcome of NHL, as the overall incidence of HIV-NHL have declined
[25; 35; 36]. HAART has also decreased the mortality rate of HIV-related
Hodgkin lymphoma (HIV-HL) patients who use HAART, thereby changing the
mortality rate at 3 years for HIV-HL patients without HAART, to 5.6 times
of those on HAART. Thus, HAART is correlated with improved prognosis in
HIV-HL cases [31]. We must note that non-AIDS defining cancers (NADC)
are seen to be on the rise, even in the post-HAART era. However, it’s been
reported that early diagnosis and the effective use of HAART will also arrest
this situation [43; 45].
2.2.1 Effects of HAART on Some Specific NHL
Subtypes
A study by Diamond et al. [44], where the San Diego County registry data
were linked with its AIDS registry data to identify some HIV-NHL patients,
showed that the incidence of NHL from the pre- to -post-HAART era de-
creased dramatically (from 29.6 per 1000 person-years pre-HAART to 6.5 per
1000 person-years post-HAART). The proportion of high-grade NHL (which
most study reports to be primarily high-grade immunoblastic DLBCL [31; 32])
also decreased from 38% to 19%, and that of PCNSL decreased from 28% to
17%. They also affirmed that immune reconstitution and diminished cytokine
stimulation afforded by HAART, can result in a decrease in the frequency of
herpesvirus-associated immunoblastic NHL.
HIV-related PCNSL (HIV-PCNSL) is reported to have improved significantly
in the HAART era, as viral load is being decreased by ≥ 0.5 log10 plasma
cells/mL, and CD4 count is increased by 50cells/µL or more [31]. There is
also a very significant and dramatic decline in PCNSL cases in relation to
other HRLs [24; 29; 32]. This is particularly reported to be the most signif-
icant impact of HAART [25; 36]. A significant delay in the development of
PCNSL, and a steady decline in the histologies and sites of this immunoblas-
tic lymphoma, in several HIV-infected PCNSL patients on HAART have also
been observed [25; 32].
PEL is reported to have a poor prognosis even in the post-HAART era, with
or without chemotherapy, and it has extremely minute number of long-term
survivors [35; 36]. Nevertheless, there are a few exceptional reports of HAART-
induced responses [35]. In a recent large multicenter retrospective study of 28
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HIV-positive PEL patients, PEL is shown to have a 1 year overall survival
(OS) rate of 39.3%, with a median survival time of 6.2 months [35]. Their
result suggests that the two most predictive prognostic factors that are inde-
pendently associated with a longer survival of patients are performance status
and HAART use [30; 35].
PBL, which is often treated with chemotherapy has a poor response to treat-
ment therapies. Despite this fact, survival with PBL may be improving in the
HAART era. In the earlier AIDS epidemic, PBL survival was short, with an
average survival time of 5.5 months [31; 41]. A study by Lester et al. [46]
reports that PBL has an average survival duration of 14 months as a response
to HAART in an HIV-infected patient of theirs, but relapsed after the patient
failed to adhere to his HAART regimen for some months. However, the patient
went on complete remission (CR) for 8 months from diagnosis of relapse, af-
ter another combination of chemotherapy. Another study reported that about
50% of HIV-infected PBL patients who used HAART regimens sometimes dur-
ing their lymphoma treatment responded to it, of which most of them (about
90%) were still alive as at the time of publication of their result (about one
year later) [37]. Lester et al. [46] also reported that HAART may afford PBL
patients immunological restitution and virologic control, which may maintain
CR. Prognostic factors for PBL include low CD4 count or viral load history,
oral or gastrointestinal symptoms, or any other primary site of the malignancy,
clinical stage, sex and EBV association [37; 46].
It is pertinent to note that the use of HAART during HIV progression may trig-
ger the development of lymphoma. Pantanowitz et al. [47] reported an abrupt
decline in the viral load, and a rise in the very low CD4 cell count of their
highly deteriorated HIV-infected-EBV-related-PBL patient, who was treated
with a full chemotherapy regimen with HAART. However, they observed an
aggravation of their patient’s case, of which HAART initiation was a transient
cause, like in some other reports. This lymphoma aggravation is suggested to
be a consequence of immune enhancement afforded by HAART, as opposed to
lymphoma progression due to lack of response to HAART. This phenomenon
was referred to as immune reconstitution inflammatory syndrome (IRIS). The
risk factors for an IRIS include low CD4 cell count, presence of infection(s),
and a robust virologic and immunologic response to HAART. Nevertheless,
such aggravations can be eschewed if the optimal time for HAART initiation
is recognised on a per-patient basis.
The study by Diamond et al. [44] also reports that the proportion of intermediate-
grade lymphoma (primarily DLBCL) increased from 33% to 49%, that of BL
increased from 4% to 9%, and the proportion of centroblastic DLBCL increased
from 21% to 44% cases. The increase in some HRL in the post-HAART era,
such as the centroblastic DLBCL and BL can be attributed to the relation of
these HRL subtypes with the immunosuppression level in the patient. These
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two subtypes occur in patients with normal or slightly depreciated CD4 counts
[24; 30; 44].
A ridiculously low CD4 count (< 100cells/µL) is obviously associated with
worse outcomes in HRL. Even in the HAART era, CD4 counts less than
100cells/µL or 50cells/µL in HRL patients, have been shown to predict lower
complete remission (CR) rates [31]. Since HIV patients on HAART regimens
now live longer with chronic HIV infection, but with few OI, HIV-related ma-
lignancies are increasingly conspicuous causes of death in the later stages of
AIDS [24; 32; 48].
2.3 Concormitant Treatment of HRL Patients
with HAART and Chemotherapy
Several studies report that HRL patients treated with chemotherapy and
HAART concormitantly have significant decrease in CD4 count during treat-
ment, but a steady and significant increase in the median CD4 count after
chemotherapy, while still simultaneously under some HAART regimen. Nev-
ertheless, the assumption that CD4 counts depreciates with chemotherapy is
safest, and it is advisable to use oppotunistic infection (OI) prophylaxis con-
sequently [31].
As earlier stated, while some exceptional reports have it that there are HAART-
induced improvement of some NHL cases like PEL [35], several reports also
have it that prolonged remission have been achieved in PEL patients with
the use of HAART alone. This suggests that immune reconstitution plays an
important role in controlling high-grade (aggresive) lymphomas. Hence, it is
suggested that a concormitant treatment with HAART (either by initiating it
or continuing it if the patient is not HAART-naive) as a supportive therapy be
recommended for HIV-positive PEL patients initiating PEL treatment [36].
It is important to note that antiretrovirals may interfere with cytotoxic drug
metabolism, which means that the HAART and/or chemotherapy dosage may
need to be adjusted on an individual patient basis. Zidovudine (AZT), in
most cases causes myelosuppression effects and is hence not recommended to
be used with chemotherapy.
With all these encouraging reports on the improvement of the health of HIV-
HRL patients, by the use of lymphoma treatments (especially chemotherapy)
and concormitant HAART, it is secure for HIV-HRL patients to be admin-
istered chemotherapies (and other treatment therapies when necessary) with
curative intents, and without long-term immune suppression [25; 48]. However,
it should be noted that such concormitant treatments should be prescribed on
an individual patient basis, that is, with respect to individual cases [29].
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2.4 HRL in South Africa: Western Cape
province as a case study
In South Africa, there was an initiation of a national HAART roll-out pro-
gram in 2004. This HAART program have been gaining more grounds over
the years, and its coverage was about 31% as at 2009 [26; 27]. The incidence
and pattern of HRL in the Western Cape (WC) province of South Africa (SA)
was not previously documented prior to the year 2002. An on-going study by
the Tygerberg Lymphoma Study Group (TLSG), in conjunction with some
other institutions is shedding more light on how HIV is changing the inci-
dence and pattern of HRL in the WC province of SA [27]. Their analysis of
documented data shows that incidences of HRL keeps increasing in this geo-
graphical location despite the roll-out of the HAART program in 2004. There
was an increase of HRL cases, from about 5% of all lymphoma cases in 2002,
to 37% of all the lymphoma cases documented in 2009. This is contrary to the
report of many related international studies, which often suggest remarkable
reduction in the incidence of HRL in regions with effective HAART programs
[24; 27].
During this period of data collection, the national HIV treatment policy as
to when patients can receive HAART was that their CD4 cell counts must be
≤ 200 cells/µL. Nevertheless, most patients who present often do at a CD4
cell count of < 100 cells/µL. This is an indicator of a degenarated immune
system, which can hardly be reconstituted (that is, raising the CD4 cell count
to more than 500 cells/µL) even when the patient in such situation is placed
on HAART [27; 38; 49]. This clearly shows that patients often present late,
and thus, usually have deteroriated immune systems which are mostly irreme-
diable. Another consequence of this is that even when those who eventually
get enrolled into the HAART program live longer than they would have, they
will remain significantly immunosuppressed and challenged, thereby develop-
ing immune system-related conditions such as HRLs, as is the case in the WC
province.
Burkitt lymphoma was previously a rare lymphoma subtype in theWC province
of SA, but now, it is the commonest HRL. The next to it are diffuse large B-
cell lymphoma subtypes. Plasmablastic lymphoma is also another new and
unfolding lymphoma subtype in this population. These are pointers to the
fact that HIV is drastically affecting the incidence and emergence of different
subtypes of HRL in this population. Suggested reasons for these inauspicious
developments include inadequate HAART coverage, late presentation of pa-
tients (and thus late commencement of HAART), inconsistent adherence to
HAART regimen, increased age and inefficient viral suppression in patients on
HAART [27; 38].
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HIV-Related Lymphoma Model
3.1 Introduction
While lot of coinfection mathematical models of HIV and cancer (at cell level
[50–52]) and population level ([53]) have been proposed, none of them, to
the best of our knowledge have explored the dynamics of HIV-related cancers
(specifically lymphoma) on a population level, with the different stages of
HIV and cancer coinfection incorporated. The HIV and lymphoma coinfection
model proposed in this study investigates likely factors that are responsible
for the reasons HIV is transforming the incidence, prognosis, and outcomes
of lymphoma (and every other cancer subtypes in general) in HIV-infected
individuals.
This study is a component of the Tygerberg Lymphoma Study Group, that
looks at using expanded laboratory profiling in conjunction with clinical, imag-
ing and demographic methodologies to improve the understanding of how HIV
is transforming the incidence, pattern, prognosis and outcomes of lympho-
proliferative disorders in the Tygerberg catchments area of the Western Cape
province of South Africa.
The major premise of this study is to investigate and understand the asymp-
totic dynamics of HIV-related (or AIDS-defining) malignancies in the human
population, taking the Western Cape province of South Africa as our case
study.
3.2 Model Formulation
We construct a mathematical model that describes the different stages indi-
viduals can progress into during the course of developing lymphoma, or con-
tracting HIV, or contracting HIV after lymphoma has developed in the body,
17
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or developing lymphoma after having contracted HIV. This model conceptu-
alises and demonstrates plausible features of what happens in an HIV and
lymphoma co-infection setting. Since there is a lot of lymphoma cases among
aged people, but less in children, HIV is more predominant among the sexually
active population (15− 49 years), and HIV and lymphoma co-infection occurs
both in the sexually active population and the aging population, we consider
a population N(t), at time t, with ages ranging between 15−80+ years, which
we refer to as adult population.
With respect to the infection and treatment stages, we subdivided the to-
tal population N(t) into distinct (non-intersecting) population classes (com-
partments). Each compartment is characterised by a heterogenous mixing of
individuals within it, while there is a homogenous interaction of individuals
between the non-intersecting classes. Thus, each susceptible individual is as-
sumed to have an equal chance of being infected by an infectious individual
(i.e. population mixes homogenously). The compartments include; the suscep-
tible population S(t), which comprises of individuals that are predisposed to
contracting HIV and developing lymphoma (every individual introduced into
the population is assumed to be susceptible), lymphoma patients IL(t), HIV-
infected patients IH(t), patients co-infected with both HIV and lymphoma ILH ,
lymphoma patients who have been treated for lymphoma and then went into
remission ILR(t), (who will be referred to as Lymphoma patients in remission),
HIV-infected patients who are under a HAART regimen IHT (t), (who will be
referred to as HIV-positive patients under antiretroviral regimen(s)), patients
with both HIV and lymphoma, and who are in remission after some lymphoma
treatment ILHR(t), (who will be referred to as patients with both HIV and lym-
phoma, and in remission), patients with both HIV and lymphoma, and are
using a HAART regimen ILHT (t), patients with both HIV and lymphoma, who
are in remission for lymphoma treatment, and who are using some HAART
regimens ILHTR(t), and patients whose HIV have progressed to AIDS A(t).
The total sexually active population at any given time t, including the old age
population is thus given by
N = S + IL + IH + ILH + ILR + IHT + ILHR + ILHT + ILHTR + A. (3.2.1)
The recruitment of individuals into the class of susceptibles is proportional to
the population, thus, the recruitment rate is given by bN , where b is the crude
birth rate. We let K = bN0, where N0 is the initial population size. The mean
lifetime of an individual is estimated as 1/µ, where µ is the natural mortality
rate, which is common to all the compartments. The (HIV) disease-related
death rate is given by δ. Observe that lymphoma related deaths are omitted
because we assume that when lymphoma patients are not coinfected with HIV
(which can relatively rapidly destroy their immune systems), they either die at
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almost the natural death rate, or they are treated for lymphoma, or they get
infected with HIV, which enables them to move into other population classes
in the model, without necessarily leaving the population pool. The lymphoma
development rate of susceptibles (which are generally HIV-negative individ-
uals) is α1. This model has 3 distinct classes described as being susceptible
to HIV infection. They are S, IL and ILR. The model assumes a non-linear
standard incidence function. The force of infection for class S, is λ1, while
the force of infection for those with lymphoma (classes IL and ILR) is λ2. We
assume different forces of infection for these two groups because individuals in
class S are supposed to be more immunocompetent than those in IL and ILR,
as their immune systems would have been challenged. The forces of infection
λi, i = 1, 2, are given by:
λi =
βi
N
[IH + η1IHT + η2(ILH + ILHR) + η3(ILHT + ILHTR) + η4A] , (3.2.2)
provided λi(t) is redefined at the -neighbourhood of N = 0, for it to be
finite at t = 0 and biologically plausible. The parameters β1 and β2 are the
effective contact rates of HIV infection for susceptible individuals, and for
lymphoma patients (either treated or not) respectively. βi is a product of the
number of contacts, effective or not, per unit time and the risk of infection (or
probability that an infection will occur), also called transmission risk, given
contact between a susceptible and an infectious individual. ηi, i = 1, 2, 3, 4,
are the modification parameters (or adjustment factors), which measure the
relative infectiousness of individuals in IHT , ILH , ILHR, ILHT , ILHTR and A(t)
to the infectiousness of those in IH . Individuals with high viral loads (either
in the acute infection stage; window period, or at the end-stage disease) are
highly infectious [54]. Thus, the likelihood of HIV-infecteds to be infectious is
directly proportional to their viral loads [55]. Hence, we consider 1 ≤ ηi ≤ 2,
for all i ∈ {1, 2, 3, 4}.
We assume that η1 < 1, because of the decrease in the viremia of individuals
in class IHT . We have also assumed that individuals with both HIV and lym-
phoma, and those with HIV and lymphoma, but in remission due to lymphoma
treatment have a higher viremia in relation to individuals with HIV [56], but
using some antiretroviral regimen, thus η2 > η1 and η2 > 1. In like manner,
we assumed that individuals co-infected with HIV and lymphoma, who are
using HAART regimen, and that are either in remission for lymphoma treat-
ment or not, are less infectious (because of lower, treatment-induced viremia)
than individuals who are also co-infected, with lymphoma and HIV, whether
in lymphoma remission or not, thus, η3 < η2 and η3 < 1. Similar, individuals
with both lymphoma and HIV, using HAART regimens, and either in remis-
sion for lymphoma treatment (or who are not on treatment) are considered
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more infectious than individuals with HIV only, but on HAART regimens too.
Thus, η3 > η1.
Individuals with AIDS are considered as the class with the highest level of
viremia, and are thus the most infectious population group. Hence, η4 >
η1, η2, η3, and η4 > 1. Our model assumes that every epidemiological parame-
ter is constant and positive. The lymphoma development rate of HIV-infected
individuals, and the HIV-infectives using antiretroviral regimens is denoted
by α2 and α3 respectively. The probability that a (lymphoma-free) HIV pa-
tient, a patient with both HIV and lymphoma, and a patient with both HIV,
lymphoma, and in remission for lymphoma treatment are recruited into treat-
ment is given by σ1, σ2, and σ3 respectively. Table 3.1 outlines the description
and symbols of state variables used in the model. Every other epidemiological
parameters, with their symbols and description is outlined in Table 3.2.
The flow of individuals between the ten compartments is illustrated by the
model diagram shown in Figure 3.1.
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Figure 3.1: Diagrammatic Structure of the HIV-Lymphoma Model
3.2.1 Model Equations
The dynamical system described by Figure 3.1, our assumptions and param-
eters’ description, is given by the following system of first order ordinary dif-
ferential equations:
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dS
dt
= K − λ1S − (µ+ α1)S (3.2.3a)
dIL
dt
= r1ILR + α1S − λ2IL − (µ+ τ1)IL (3.2.3b)
dILR
dt
= τ1IL − λ2ILR − (µ+ r1)ILR (3.2.3c)
dIH
dt
= λ1S − (µ+ α2 + σ1 + ρ1)IH (3.2.3d)
dILH
dt
= λ2IL + α2IH + r2ILHR − (µ+ τ2 + σ2 + ρ6)ILH (3.2.3e)
dIHT
dt
= σ1IH − (µ+ α3 + ρ2)IHT (3.2.3f)
dILHR
dt
= λ2ILR + τ2ILH − (µ+ r2 + σ3 + ρ5)ILHR (3.2.3g)
dILHT
dt
= σ2ILH + α3IHT + r3ILHTR − (µ+ τ3 + ρ3)ILHT (3.2.3h)
dILHTR
dt
= σ3ILHR + τ3ILHT − (µ+ r3 + ρ4)ILHTR (3.2.3i)
dA
dt
= ρ1IH + ρ2IHT + ρ3ILHT + ρ4ILHTR + ρ5ILHR
+ ρ6ILH − (µ+ δ)A, (3.2.3j)
with initial conditions of the model system given by S(0) = S0, IL(0) =
I0L, IH(0) = I
0
H , ILH(0) = I
0
LH , ILR(0) = I
0
LR, IHT (0) = I
0
HT , ILHR(0) = I
0
LHR,
ILHT (0) = I
0
LHT , ILHTR(0) = I0LHTR, A(0) = A0.
Variables Description
S Susceptible individuals
IL Lymphoma patients
IH HIV-positive patients
ILH Patients with both HIV and lymphoma
ILR Lymphoma patients in remission
IHT HIV-positive patients under antiretroviral regimen(s)
ILHR Patients with both HIV and lymphoma, and in remission
ILHT Patients with both HIV and lymphoma, and under
antiretroviral regimen(s)
ILHTR Patients with both HIV and lymphoma, under
antiretroviral regimen(s) and in remission
A Patients with full-blown AIDS
N Total size of population
Table 3.1: Symbols and description of the variables used in the model
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Parameters Description
K Recruitment rate for susceptibles
µ Natural mortality rate
δ Disease-induced mortality rate
λ1 Force of (HIV) infection of susceptible individuals
λ2 Force of (HIV) infection of lymphoma patients
β1 Effective contact rate of HIV for susceptible individuals
β2 Effective contact rate of HIV for lymphoma patients
α1 Lymphoma development rate of susceptible individuals
α2 Lymphoma development rate of HIV-positive patients
α3 Lymphoma development rate of HIV-positive patients
under antiretroviral regimen(s)
σ1 HIV treatment rate of lymphoma-free HIV patients
σ2 HIV treatment rate of patients with lymphoma and HIV
σ3 HIV treatment rate of patients with lymphoma, HIV,
and in remission
τ1 Lymphoma treatment rate of lymphoma-only patients
τ2 Lymphoma treatment rate of patients with lymphoma and HIV
τ3 Lymphoma treatment rate of patients with lymphoma, HIV,
and are under antiretroviral regimen(s)
r1 Lymphoma relapse rate of lymphoma patients in remission
r2 Lymphoma relapse rate of lymphoma patients with lymphoma
and HIV in remission
r3 Lymphoma relapse rate of lymphoma patients with lymphoma,
HIV, in remission and under antiretroviral regimen(s)
ρ1 Progression rate to full-blown AIDS in HIV patients
ρ2 Progression rate to full-blown AIDS in HIV patients under
antiretroviral regimen(s)
ρ3 Progression rate to full-blown AIDS in patients with lymphoma,
HIV, and under antiretroviral regimen(s)
ρ4 Progression rate to full-blown AIDS in patients with lymphoma,
HIV, under antiretroviral regimen(s), and in remission
ρ5 Progression rate to full-blown AIDS in patients with lymphoma,
HIV, and in remission
ρ6 Progression rate to full-blown AIDS in patients with lymphoma
and HIV
Table 3.2: Symbols and description of the parameters used in the model
3.3 Model Basic Properties
In this section, we investigate and establish some basic properties of the model
system (3.2.3).
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3.3.1 Invariant Region
The model studies variations in the human population under certain condi-
tions. Hence, the state variables and parameters are assumed to be positive
entities for all time values t ≥ 0. We analyse the model system (3.2.3) in
an apposite biologically feasible region Γ. We have the following results with
respect to the feasible region Γ of the model system (3.2.3).
Lemma 3.3.1. The biologically feasible region Γ defined by the compact set:
Γ = {(S, IL, ILR, IH , ILH , IHT , ILHR, ILHT , ILHTR, A) ∈ R10+ : N ≤
K
µ
}
with initial conditions S(0), IL(0), ILR(0), IH(0), ILH(0), IHT (0), ILHR(0), ILHT (0),
ILHTR(0), A(0) > 0, is positively invariant and attracting with respect to the
model system (3.2.3) for all t > 0.
Proof. By summing up the equations of the model system (3.2.3), the total
population size N(t) is seen to be time variable with
dN
dt
= K − µN − δA,
≤ K − µN,
=⇒ dN
dt
+ µN ≤ K.
(3.3.1)
Using the method of the integrating factor (IF) for solving first order ordinary
differential equations (ODE), where
IF = e
∫
µdt,
equation (3.3.1) becomes
d(Neµt)
dt
≤ Ke
∫
µdt (integrate both sides),
=⇒ Neµt ≤ K
µ
eµt + C,
=⇒ N(t) ≤ K
µ
+ Ce−µt.
(3.3.2)
Applying the initial condition, at t = 0, let N(0) = N0, where N0 is the sum
of the initial values of the variables of the model equation, we obtain
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C = N0 − K
µ
.
This implies that
N(t) ≤ K
µ
+
(
N0 − K
µ
)
e−µt,
= N0e
−µt +
K
µ
(
1− e−µt) . (3.3.3)
As t −→∞, we have: lim supt→∞N(t) ≤
K
µ
.
If N(0) ≤ K
µ
, then,
N(t) ≤ N0e−µt + K
µ
(
1− e−µt) ,
=⇒ N(t) ≤ K
µ
e−µt +
K
µ
(
1− e−µt) ,
N(t) ≤ K
µ
.
(3.3.4)
Thus every solution N(t) of equation (3.3.1) satisfies the relation below;
0 ≤ N(t) ≤ N0e−µt + K
µ
(
1− e−µt) , (3.3.5)
where N0 is the sum of all the initial conditions of the variables of the model
system.
If N0 ≤ Kµ , then, the non-negative solutions of equation (3.3.1) are increased
monotonically and are bounded above by K
µ
. On the contrary, if N0 > Kµ ,
then, the non-negative solutions of equation (3.3.1) are monotone decreasing
and bounded below by K
µ
. Nevertheless, in both cases, at limiting equilibrium,
limt→∞N(t) = Kµ .
This implies that any solution S(t), IL(t), ILR(t), IH(t), ILH(t), IHT (t), ILHR(t),
ILHT (t), ILHTR(t), A(t), at t ≥ 0, of (3.2.3) that commences in the positive
orthant R10+ , either remains confined in, enters or approaches Γ asymptotically.
Hence, the region Γ is positively invariant and attracting with respect to the
flow incited by the model system (3.2.3). This completes the proof.
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Thus, in Γ, the model (3.2.3) is mathematically and epidemiologically well-
posed. Hence, it is sufficient to study the dynamics of the flow induced by the
model system (3.2.3) in Γ.
3.3.2 Positivity of Solutions
Epidemiologically, it is absurd to have negative populations. Since the model
system (3.2.3) describes the dynamics of human population, it is consequently
essential to prove that all the state variables of the model system (3.2.3) re-
main non-negative. This is to ensure that the solutions of the system, when
subjected to positive initial conditions, will remain positive for all t > 0. Con-
sequently, we have the following lemma.
Lemma 3.3.2. Given that the initial values of the state variables of the model
system (3.2.3) are non-negative, the model equations (3.2.3a)-(3.2.3j) preserve
positivity of solutions for all time t > 0.
Proof. Suppose that
tˆ = sup{t > 0 : S, IL, ILR, IH , ILH , IHT , ILHR, ILHT , ILHTR, A > 0} ∈ [0, t]
From equation (3.2.3a),
dS
dt
= K − (λ1 + µ+ α1)S,
dS
dt
+ (λ1 + µ+ α1)S = K.
(3.3.6)
Using the integrating factor (IF) given by
IF = exp
{∫ t
0
(µ+ α1 + λ1(ω)) dω
}
= exp
{
[(µ+ α1)t+
∫ t
0
λ1(ω)) dω]
}
,
equation (3.3.6) becomes
d
dt
[
S(t)e[(µ+α1)t+
∫ t
0 λ1(ω)) dω]
]
= Ke[(µ+α1)t+
∫ t
0 λ1(ω)) dω],
=⇒
∫ S(tˆ)
S(0)
d
[
S(t)e[(µ+α1)t+
∫ t
0 λ1(ω)) dω]
]
= K
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt,
=⇒ S(tˆ)e[(µ+α1)tˆ+
∫ tˆ
0 λ1(ω)) dω] − S(0) = K
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt,
(3.3.7)
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=⇒ S(tˆ) = e−[(µ+α1)tˆ+
∫ tˆ
0 λ1(ω)) dω]
[
S(0) +K
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt
]
,
S(tˆ) ≥ Ke−[(µ+α1)tˆ+
∫ tˆ
0 λ1(ω)) dω]
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt.
(3.3.8)
Since the exponential function is always positive, we have
S(tˆ) > 0, ∀ tˆ > 0. (3.3.9)
From equation (3.2.3b),
dIL
dt
= α1S + r1ILR − (λ2(t) + τ1 + µ)IL,
≥ −(λ2(t) + τ1 + µ)IL,
=⇒ dIL
dt
+ (λ2(t) + τ1 + µ)IL ≥ 0.
(3.3.10)
Using the IF given by
IF = e
∫ t
0 [(µ+τ1)+λ2(ω)] dω] = e[(µ+τ1)t+
∫ t
0 λ2(ω) dω],
equation (3.3.10) becomes
∫ IL(tˆ)
IL(0)
d
[
IL(t)e
[(µ+τ1)t+
∫ t
0 λ2(ω) dω]
]
≥ 0,
=⇒ IL(tˆ)e[(µ+τ1)tˆ+
∫ tˆ
0 λ2(ω) dω] ≥ IL(0),
=⇒ IL(tˆ) ≥ IL(0)
(
e−[(µ+τ1)tˆ+
∫ tˆ
0 λ2(ω) dω]
)
,
=⇒ IL(tˆ) > 0 ∀ tˆ > 0.
(3.3.11)
Using a similar procedure as above, from equation (3.2.3c),
dILR
dt
≥ −(λ2(t) + µ+ r1)ILR,
=⇒ dILR
dt
+ (λ2(t) + µ+ r1)ILR ≥ 0.
=⇒
∫ ILR(tˆ)
ILR(0)
d
[
ILR(t)e
[(µ+τ1)t+
∫ t
0 λ2(ω) dω]
]
≥ 0,
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ILR(tˆ) ≥ ILR(0)
(
e−[(µ+τ1)t+
∫ t
0 λ2(ω) dω]
)
,
=⇒ ILR(tˆ) > 0 ∀ tˆ > 0.
(3.3.12)
In like manner, we obtain the following:
From equation (3.2.3d),
dIH
dt
≥ (µ+ α2 + σ1 + ρ1)IH ,
⇒
∫ IH(tˆ)
IH(0)
≥
∫ tˆ
0
−(µ+ α2 + σ1 + ρ1)dt,
⇒ ln
(
IH(tˆ)
IH(0)
)
≥ −(µ+ α2 + σ1 + ρ1)tˆ,
⇒ IH(tˆ) ≥ IH(0)
(
e−(µ+α2+σ1+ρ1)tˆ
)
.
Hence, IH(tˆ) > 0, ∀ tˆ > 0.
(3.3.13)
From equation (3.2.3e),
dILH
dt
≥ (µ+ τ2 + σ2 + ρ6)ILH ,
⇒
∫ ILH(tˆ)
ILH(0)
≥
∫ tˆ
0
−(µ+ τ2 + σ2 + ρ6)dt,
⇒ ln
(
ILH(tˆ)
ILH(0)
)
≥ −(µ+ τ2 + σ2 + ρ6)tˆ,
⇒ ILH(tˆ) ≥ IH(0)
(
e−(µ+τ2+σ2+ρ6)tˆ
)
.
Hence, ILH(tˆ) > 0, ∀ tˆ > 0.
(3.3.14)
From equation (3.2.3f),
dIHT
dt
+ (µ+ α3 + ρ2)IHT ≥ 0,
=⇒ IHT (tˆ) ≥ IHT (0)
(
e−(µ+α3+ρ2)tˆ
)
,
> 0 ∀ tˆ > 0.
(3.3.15)
From equation (3.2.3g),
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dILHR
dt
+ (µ+ r2 + σ3 + ρ5)ILHR ≥ 0,
=⇒ ILHR(tˆ) ≥ ILHR(0)
(
e−(µ+r2+σ3+ρ5)tˆ
)
,
> 0 ∀ tˆ > 0.
(3.3.16)
From equation (3.2.3h),
dILHT
dt
≥ −(µ+ τ3 + ρ3)ILHT ,
dILHT
dt
+ (µ+ τ3 + ρ3)ILHT ≥ 0,
=⇒ ILHT (tˆ) ≥ ILHT (0)
(
e−(µ+τ3+ρ3)tˆ
)
,
> 0 ∀ tˆ > 0.
(3.3.17)
From equation (3.2.3i),
dILHTR
dt
≥ −(µ+ r3 + ρ4)ILHTR,
dILHTR
dt
+ (µ+ r3 + ρ4)ILHTR ≥ 0,
=⇒ ILHTR(tˆ) ≥ ILHTR(0)
(
e−(µ+r3+ρ4)tˆ
)
,
> 0 ∀ tˆ > 0.
(3.3.18)
From equation (3.2.3j),
dA
dt
≥ −(µ+ δ)A,
dA
dt
+ (µ+ δ)A ≥ 0,
=⇒ A(tˆ) ≥ A(0)
(
e−(µ+δ)tˆ
)
,
> 0 ∀ tˆ > 0.
(3.3.19)
Thus, we have shown, in (3.3.6) - (3.3.19), that every solution of the state
variables of model system (3.2.3) will always be positive for all non-negative
initial conditions, at any time tˆ > 0. This completes the proof.
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3.3.3 Existence and Uniqueness of Solutions
Theorem 3.3.3. Solutions of the model system (3.2.3) exists, and is unique
in Γ, for all time t > 0, and for every non-negative initial values of the model
state variables that are non zero.
Proof. Since the right hand side of the model system (3.2.3) is locally Lipschitz
continuous, then local existence and uniqueness of solutions is ascertained.
3.4 Model Equilibria Analysis and the Basic
Reproduction Number
We derive and investigate an equilibrium E0 of the model system (3.2.3), which
we refer to as the HIV-free lymphoma steady state, and the model’s endemic
equilibria E1. We investigate the stability of these steady states using the basic
reproduction number R0.
3.4.1 HIV-free Lymphoma Steady State
For us to consider the model system (3.2.3) in the absence of HIV, every
variable having the impact of HIV is set to zero, i.e. IH = ILH = IHT =
ILHR = ILHT = ILHTR = A = 0. Hence, in the absence of HIV, the model
has the HIV-free lymphoma equilibrium. This is obtained below, by setting
the right-hand side (RHS) of the model system equations (3.2.3a) - (3.2.3j) to
zero.
IH = ILH = IHT = ILHR = ILHT = ILHTR = A = 0 =⇒ λ1 = λ2 = 0.
We obtain
K − q1S∗ = 0, where q1 = µ+ α1,
=⇒ S∗ = K
q1
=
K
µ+ α1
.
(3.4.1)
r1I
∗
LR + α1S
∗ − q2I∗L = 0, where q2 = µ+ τ1,
=⇒ I∗L =
1
q2
[
r1I
∗
LR +
α1K
q1
]
.
(3.4.2)
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τ1I
∗
L − q5I∗LR = 0, where q5 = µ+ r1,
=⇒ I∗LR =
τ1I
∗
L
q5
.
(3.4.3)
Substituting for (3.4.3) in (3.4.2), we obtain:
I∗L
[
1− r1τ1
q2q5
]
=
α1K
q1q2
,
I∗L =
α1K
q1q2[1− φ1] ,
=⇒ I∗LR =
τ1α1K
q1q2q5[1− φ1] ,
(3.4.4)
where
φ1 =
r1τ1
q2q5
,=⇒ 1− φ1 = µ(µ+ r1 + τ1)
(µ+ τ1)(µ+ r1)
.
Thus,
I∗L =
α1K(µ+ r1)
µ(µ+ α1)(µ+ r1 + τ1)
, and
I∗LR =
τ1α1K
µ(µ+ α1)(µ+ r1 + τ1)
.
(3.4.5)
Hence, the model has an equilibrium (which we call the HIV-free lymphoma
steady state) given by
E0 =
(
K
µ+ α1
,
α1K(µ+ r1)
µ(µ+ α1)(µ+ r1 + τ1)
,
τ1α1K
µ(µ+ α1)(µ+ r1 + τ1)
, 0, 0, 0, 0, 0, 0, 0
)
.
(3.4.6)
3.4.2 The Basic Reproduction Number
The basic reproduction number, symbolised by R0 is the "expected number of
secondary cases produced, in a completely susceptible population, by a typical
infected individual during his entire period of infectiousness" [57]. The R0
definition in the context of the proposed model is given later in this chapter.
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The R0 is the most significant quantity in the epidemiology of infectious dis-
eases and is widely used in epidemiological literatures [58]. It is a threshold
parameter that plays a vital role in determining whether a disease can invade
and persist in a (new host) population when one infected individual is intro-
duced into the wholly susceptible population [59; 60]. The threshold criterion
states that "the disease can invade the population if R0 > 1, whereas, it cannot
if R0 < 1" [57]. This is because the threshold parameter has the property that
if R0 < 1, the the disease-free equilibrium (DFE) is locally asymptotically
stable and the disease cannot invade the population, but if R0 > 1, then, the
DFE is unstable and the disease can always invade the population [59; 60].
However, a recent result by van Driessche et al. [60] suggests that a disease
may persist even when the disease free equilibrium is locally stable.
In the computation of R0, the only states (or classes of individuals) considered
are those that pertains to the infected individuals, in which new infections
are differentiated from all other change in state among infected individuals
[57; 58; 60]. The set of equations these states refer to are called the infected
subsystem. It is important to note that R0 is obtained by first decomposing
the linearised infected subsystem of the model. This linear system, which is
described by the Jacobian of the non-linear infected subsystem is evaluated at
the infection/disease-free equilibrium (which as a rule exists) [58; 60]. "Epi-
demiologically, the linearisation reflects that R0 characterises the potential for
initial spread of an infectious agent when it is introduced into a fully sus-
ceptible population, and that we assume that the change in the susceptible
population is negligible during the initial spread" [58].
For our model system (3.2.3), since we are considering two types of diseases, our
infected subsystem is from equations (3.2.3d)-(3.2.3j). Following the procedure
described in [60] (also see [58]), we shall compute R0 as the spectral radius
(largest eigen-value) of the next generation matrix [57] FV −1 as we shall define
shortly.
Note that development of lymphomas by HIV-negative patients, irrespective
of what state they are in, are not considered to be new infections, since lym-
phoma is not an infectious disease. In general, movement of different states of
individuals into any HIV-free lymphoma state (whether in remission or not)
is not considered a transmission term.
Decomposing the infected subsystem (3.2.3d)-(3.2.3j) into the components
F (x) and V (x) as in [60], where F (x) is the column matrix that represents
the rate of appearance of new infections in each of the infected compartments,
V +(x) represents the rate of transfer of individuals into the infected com-
partments and V −(x) represents the rate of transfer of individuals out of the
infected compartments. V −(x) is given by the relation
V (x) = V −(x)− V +(x).
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F (x) =

λ1S
λ2IL
0
λ2ILR
0
0
0

,
=

β1
N
[IH + η1IHT + η2(ILH + ILHR) + η3(ILHT + ILHTR) + η4A]S
β2
N
[IH + η1IHT + η2(ILH + ILHR) + η3(ILHT + ILHTR) + η4A]IL
0
β2
N
[IH + η1IHT + η2(ILH + ILHR) + η3(ILHT + ILHTR) + η4A]ILR
0
0
0

,
V (x) =

(µ+ α2 + σ1 + ρ1)IH
(µ+ τ2 + σ2 + ρ6)ILH − (α2IH + r2ILHR)
(µ+ α3 + ρ2)IHT − σ1IH
(µ+ r2 + σ3 + ρ5)ILHR − τ2ILH
(µ+ τ3 + ρ3)ILHT − (σ2IH + α3IHT + r3ILHTR)
(µ+ r3 + ρ4)ILHTR − (σ3ILHR + τ3ILHT )
(µ+ δ)A− (ρ1IH + ρ2IHT + ρ3ILHT + ρ4ILHTR + ρ5ILHR + ρ6ILH)

.
Following [60] and [58], the matrices F and V for the new infection and transi-
tion terms (which includes other terms related with change in state/condition)
respectively, are defined by
F =
[
∂Fi
∂xj
(E0)
]
and V =
[
∂Vi
∂xj
(E0)
]
, (3.4.7)
where E0 is the Disease-free equilibrium (i.e. our model’s HIV-free lymphoma
steady state) and 1 ≤ i, j ≤ 7, i, j ∈ Z+. Note that F − V is the Jacobian
of the infected subsystem at the HIV-free Lymphoma Steady State (HLSS). F
is the transmission part of the system and it describes the production of new
infections, while V is the transition part and it describes changes in states [58].
The matrices are shown below.
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F =

β1
N∗
S∗
β1
N∗
η2S
∗ β1
N∗
η1S
∗ β1
N∗
η2S
∗ β1
N∗
η3S
∗ β1
N∗
η3S
∗ β1
N∗
η4S
∗
β2
N∗
I∗L
β2
N∗
η2I
∗
L
β2
N∗
η1I
∗
L
β2
N∗
η2I
∗
L
β2
N∗
η3I
∗
L
β2
N∗
η3I
∗
L
β2
N∗
η4I
∗
L
0 0 0 0 0 0 0
β2
N∗
I∗LR
β2
N∗
η2I
∗
LR
β2
N∗
η1I
∗
LR
β2
N∗
η2I
∗
LR
β2
N∗
η3I
∗
LR
β2
N∗
η3I
∗
LR
β2
N∗
η4I
∗
LR
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0 0

,
V =

q3 0 0 0 0 0 0
−α2 q4 0 −r2 0 0 0
−σ1 0 q6 0 0 0 0
0 −τ2 0 q7 0 0 0
0 −σ2 −α3 0 q8 −r3 0
0 0 0 −σ3 −τ3 q9 0
−ρ1 −ρ6 −ρ2 −ρ5 −ρ3 −ρ4 q10

,
where q1 = µ + α1, q2 = µ + τ1, q3 = µ + α2 + σ1 + ρ1, q4 = µ + τ2 + σ2 + ρ6,
q5 = µ+r1, q6 = µ+α3+ρ2, q7 = µ+r2+σ3+ρ5, q8 = µ+τ3+ρ3, q9 = µ+r3+ρ4
and q10 = µ+ δ, qi ∈ R+ (positive constants), ∀ i = 1, 2, . . . , 10.
The next generation matrix for the infected subsystem of model (3.2.3) is
FV −1, with the matrices as defined above. The spectral radius of R0 is given
by
R0 = ρ(FV −1). (3.4.8)
The model’s reproduction number R0 was obtained to be an aggregate of
contributions from the infected compartments of the different stages of the
model system. It is thus given by
R0 = RIH0 +RIHT0 +RILH0 +RILHR0 +RILHT0 +RILHTR0 +RA0 , (3.4.9)
where
RIH0 =
CSβ1
q3
,
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RIHT0 =
(
σ1
q3
)(
CSβ1η1
q6
)
,
RILH0 = A¯
[(
CSβ1η2
q4
)(
α2
q3
)
+
(
CLβ2η2
q4
)
+
(
CRβ2η2
q4
)]
,
RILHR0 = A¯
[(
CSβ1η2
q7
)(
α2
q3
)(
τ2
q4
)
+
(
CLβ2η2
q7
)(
τ2
q4
)
+
(
CRβ2η2
q7
)]
,
RILHT0 = A¯B
[(
CSβ1η3
q8
){(
σ1
q3
)(
α3
q6
)(
1
A¯
)
+
(
α2
q3
)(
σ2
q4
)
+
(
α2
q3
)(
τ2
q4
)
×
(
σ3
q7
)(
r3
q9
)}
+
(
CLβ2η3
q8
){(
σ2
q4
)
+
(
τ2
q4
)(
σ3
q7
)(
r3
q9
)}
+
(
CRβ2η3
q8
){(
σ2
q4
)(
r2
q7
)
+
(
σ3
q7
)(
r3
q9
)}]
,
RILHTR0 = A¯B
[(
CSβ1η3
q9
){(
α2
q3
)(
τ2
q4
)(
σ3
q7
)
+
(
σ1
q3
)(
α3
q6
)(
τ3
q8
)(
1
A
)
+
(
α2
q3
)(
σ2
q4
)(
τ3
q8
)}
+
(
CRβ2η3
q9
){(
σ3
q7
)
+
(
σ2
q4
)(
r2
q7
)(
τ3
q8
)}
+
(
CLβ2η3
q9
){(
τ2
q4
)(
σ3
q7
)
+
(
σ2
q4
)(
τ3
q8
)}]
,
RA0 = A¯B
[(
CSβ1η4
q10
){(
ρ1
q3
)(
1
A¯B
)
+
(
α2
q3
)(
ρ6
q4
)(
1
B
)
+
(
σ1
q3
)(
ρ2
q6
)
×
(
1
A¯B
)
+
(
σ1
q3
)(
α3
q6
)(
ρ3
q8
)(
1
A
)
+
(
α2
q3
)(
σ2
q4
)(
ρ3
q8
)
+
(
α2
q3
)
×
(
τ2
q4
)(
ρ5
q7
)(
1
B
)
+
(
α2
q3
)(
τ2
q4
)(
σ3
q7
)(
ρ3
q8
)(
r3
q9
)
+
(
α2
q3
)(
τ2
q4
)
×
(
σ3
q7
)(
ρ4
q9
)
+
(
α2
q3
)(
σ2
q4
)(
τ3
q8
)(
ρ4
q9
)
+
(
σ1
q3
)(
α3
q6
)(
τ3
q8
)(
ρ4
q9
)
×
(
1
A¯
)}
+
(
CRβ2η4
q10
){(
ρ5
q7
)(
1
B
)
+
(
ρ6
q4
)(
r2
q7
)(
1
B
)
+
(
σ2
q4
)(
r2
q7
)
×
(
ρ3
q8
)
+
(
σ2
q4
)(
r2
q7
)(
τ3
q8
)
+
(
σ3
q7
)(
ρ3
q8
)(
r3
q9
)
+
(
σ3
q7
)(
ρ4
q9
)
+
(
σ2
q4
)
×
(
r2
q7
)(
τ3
q8
)(
ρ4
q9
)}
+
(
CLβ2η4
q10
){(
ρ6
q4
)(
1
B
)
+
(
σ2
q4
)(
ρ3
q8
)
+
(
τ2
q4
)
×
(
ρ5
q7
)(
1
B
)
+
(
τ2
q4
)(
σ3
q7
)(
ρ3
q8
)(
r3
q9
)
+
(
τ2
q4
)(
σ3
q7
)(
ρ4
q9
)
+
(
σ2
q4
)
×
(
τ3
q8
)(
ρ4
q9
)}]
,
and the following psitive constants
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A¯ =
1
1− ξ1 , B =
1
1− ξ2 , ξ1 =
(
r2
q7
)(
τ2
q4
)
, ξ2 =
(
r3
q9
)(
τ3
q8
)
,
CS =
S∗
N∗
, CL =
I∗L
N∗
, and CR =
I∗LR
N∗
.
(3.4.10)
3.4.3 R0 Interpretation
RIH0 =
Csβ1
µ+ α2 + σ1 + ρ1
, is simply the product of the per capita rate of infec-
tion and the average duration of stay of an individual in class IH . This repro-
ductive rate is sometimes referred to as the back of the napkin [61]. It is the
number of HIV-infection cases produced by a single untreated HIV-positive
individual during his/her entire lifetime in class IH , in a totally susceptible
(naive) population.
RIHT0 =
σ1
(µ+ α2 + σ1 + ρ1)︸ ︷︷ ︸
P
× 1
(µ+ α3 + ρ2)︸ ︷︷ ︸
Q
×CSβ1η1︸ ︷︷ ︸
R
.
RIHT0 above, is the product of the fraction (or proportion) of HIV-only positive
indivuals (IH) surviving, at least, to the stage of being treated for HIV (IHT ),
denoted by P, the average infectious period of an individual in class IHT ,
denoted by Q, and the infectivity of individuals in class IHT , denoted by R
respectively. To determine what the Ri0 interpretation of the contributions
of the other infectious compartments, i ∈ {IH , ILH , ILHR, ILHT , ILHTR, A}, to
the model’s basic reproduction number R0 is, it is expedient that we describe
the duration of infectivity of an individual introduced into either the ILHR or
the ILHTR compartments. We illustrate this by considering an extraction of
a subsection from our model. We shall represent the movement of individuals
from ILH to ILHR in a diagrammatic form, as in Fig. 3.2.
I ILH LHR
τ2
r2
µ+ρ
5
+σ 32σ+5
ρ+µ

Figure 3.2: Progression diagram for the movement of individuals (of (3.2.3e) and
(3.2.3g)) from ILH to ILHR
Let
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m1 =
τ2
µ+ τ2 + σ2 + ρ6
, and m2 =
r2
µ+ r2 + σ3 + ρ5
. (3.4.11)
A fraction m1 of HIV-positive lymphoma patients will progress to the class
ILHR, of those in remission after receiving (or being on) lymphoma treatment.
A fraction m2 of HIV-positive lymphoma patients, who are on remission will
relapse and re-enter compartment ILH . This implies that a fractionm1 of HIV-
positive lymphoma patients must have passed through ILHR at least once. A
fraction m21m2 must have passed through ILHR at least twice. In a similar
fashion, if the cycle continues, a fraction mi1m
i−1
2 must have passed through
ILHR at least i times, and the average duration of stay in compartment ILHR,
on each pass is ω1 = 1/q7 (where q7 = µ+r2+σ3+ρ5 and q4 = µ+τ2+σ2+ρ6).
This implies that an individual who moves into class ILHR spends an average
of ω1(m1 +m21m2 +m31m22 + · · · ) time units in ILHR.
ω1(m1 +m
2
1m2 +m
3
1m
2
2 + · · · ) = ω1m1
∞∑
i=0
(m1m2)
i. (3.4.12)
Equation (3.4.12) is a simple infinite series known as the Geometric series. For
this series to converge, the common ration r = m1m2 of the series must be
absolutely less than one.
| m1m2 | =
∣∣∣∣( τ2µ+ τ2 + σ2 + ρ6
)(
r2
µ+ r2 + σ3 + ρ5
)∣∣∣∣ ,
=
∣∣∣∣(τ2q4
)(
r2
q7
)∣∣∣∣ . (3.4.13)
But τ2 < q4 and r2 < q7, which implies that τ2q4 < 1 and
r2
q7
< 1 respectively.
Using the direct proof technique, that for a, b, c, d > 0, if a < b and c < d,
then, ac < bd, we have it that
τ2
q4
r2
q7
< 1 =⇒
∣∣∣∣τ2q4 r2q7
∣∣∣∣ < 1. (3.4.14)
Since equation (3.4.14) is valid, then the geometric series
∞∑
i=0
(m1m2)
i
converges to
1
1−m1m2 . Hence, an individual who moves from the ILH com-
partment into the ILHR compartment will spend an average time unit of
ω1m1
1−m1m2
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over his/her lifetime. Similar evaluation process can be repeated to estimate
the average lifetime duration of an individual in the ILR and ILHTR compart-
ments. Note that
ω1m1
1−m1m2 =
(
τ2
q4q7
)(
1
1− ξ1
)
,
= A¯
(
τ2
q4
1
q7
)
.
(3.4.15)
The infectivity of individuals in compartment ILHR, and who are in this com-
partment as a consequence of having being treated for lymphoma (that is, they
moved from ILH to ILHR), is CLβ2η2. If we multiply this infectivity with the
expression in 3.4.15, we shall obtain
A¯
(
τ2
q4
)(
CLβ2η2
q7
)
,
which is the RILHR0 contribution of individuals who passed through compart-
ment ILHR, by going through the IL and ILH compartments.
Using Theorem 2 of van den Driessche and Watmough [60], the following result
is established.
Theorem 3.4.1. The HIV-free lymphoma steady state (HLSS) E0, which is
our model system (3.2.3)’s disease-free equilibrium (DFE), exists and is locally
asymptotically stable if R0 < 1, otherwise, it is unstable.
In the context of our model, a more general definition for the basic repro-
duction number is the number of secondary cases or new infections generated
by an infectious HIV-positive patient, irrespective of whether the patient has
developed lymphoma or not, irrespective of whether the patient is under a
treatment regimen for HIV only or HIV and lymphoma, when such patient is
introduced into a wholly susceptible host population at the DFE [60]. Since
the presence of the HIV in the human body gives it a higher proclivity for
developing lymphoma and other AIDS defining conditions (ADC), then it is
expected that the eradication of the HIV from the population under study is
expected to significantly reduce the number of lymphoma cases. Hence, epi-
demiologically, Theorem 3.4.1 implies that HIV can be eliminated from the
population under study whenever R0 < 1 (which in turn reduces lymphoma
cases) and HIV will invade the population (which in turn increases lymphoma
cases) whenever R0 > 1. This is always true, provided the initial sizes of
the sub-populations are within the confines of attraction of E0. In order to
establish the stability of this steady state, it is expedient that we show that
the DFE is globally stable.
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Theorem 3.4.2. The disease-free equilibrium E0, of the model system (3.2.3)
is globally asymptotically stable, provided R0 < 1.
Proof. Following Castillo-Chavez et al. [62], we first write the system (3.2.3)
in the form
X˙ = F (X, Y ),
Y˙ = G(X, Y ), G(X,0) = 0,
(3.4.16)
where X = (S, IL, ILR) and Y = (IH , ILH , IHT , ILHR, ILHT , ILHTR, A). Here,
X ∈ R3+ (its components) denotes the number of individuals that are not
infected with HIV, but may have developed lymphoma, and Y ∈ R7+ (its
components) denotes the number of individuals that are infected with HIV,
irrespective of whether they have developed lymphoma or not. We thus denote
the disease-free equilibrium of this system (3.4.16) by Eˆ0 = (X∗,0), where
X∗ = (S∗, I∗L, I
∗
LR).
We have to prove that the following conditions C1 and C2 below are satisfied.
(C1) For X˙(t) = F (X,0), X∗ is globally asymptotically stable.
(C2) G(X, Y ) = AY − Gˆ(X, Y ), Gˆ(X, Y ) ≥ 0 for (X, Y ) ∈ Γ,
where Γ is a positively invariant attracting domain (where the model makes
biological sense), and A = DYG(X∗,0) is an M-matrix (the off-diagonal ele-
ments of A are non-negative).
Let
F (X, Y ) =
 K − λ1S − (µ+ α1)Sr1ILR + α1S − λ2IL − (µ+ τ1)IL
τ1IL − λ2ILR − (µ+ r1)ILR
 , (3.4.17)
=⇒ F (X,0) =
 K − (µ+ α1)Sr1ILR + α1S − (µ+ τ1)IL
τ1IL − (µ+ r1)ILR
 = X˙(t). (3.4.18)
Note that when Y = 0, λ1 = λ2 = 0. The equilibrium point of this subsystem
(3.4.18) is given by
X∗ =
(
K
µ+ α1
,
α1K(µ+ r1)
µ(µ+ α1)(µ+ r1 + τ1)
,
τ1α1K
µ(µ+ α1)(µ+ r1 + τ1)
)
. (3.4.19)
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 3. HIV-RELATED LYMPHOMA MODEL 39
Lemma 3.4.3. The biolgically feasible region Ω defined by the compact set
Ωˆ = {(S, IL, ILR) ∈ R3+ : Nˆ ≤
K
µ
},
with initial conditions S(0), IL(0), ILR(0) > 0 , is positively invariant and
attracting with respect to the model subsystem (3.4.18) for all t > 0, (Nˆ =
S + IL + ILR).
Proof. By summing up the equations of the model system (3.4.18), the total
population size Nˆ(t) is seen to be time variable with
dNˆ
dt
= K − µNˆ,
=⇒ dNˆ
dt
+ µNˆ = K.
(3.4.20)
Using the method of integrating factor (IF) for solving first order ordinary
differential equations (ODE), where
IF = e
∫
µdt,
equation (3.4.20) becomes
d(Nˆeµt)
dt
= Ke
∫
µdt.
We thus have Nˆ(t) =
K
µ
+ Ce−µt.
(3.4.21)
Applying the initial condition, at t = 0, let Nˆ(0) = Nˆ0, where Nˆ0 is the sum
of the initial values of the variables of the model equation, we obtain
C = Nˆ0 − K
µ
=⇒ Nˆ(t) ≤ K
µ
+ (Nˆ0 − K
µ
)e−µt
= Nˆ0e
−µt +
K
µ
(1− e−µt)
(3.4.22)
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As t −→∞, we have: lim supt→∞ Nˆ(t) ≤
K
µ
.
If Nˆ(0) ≤ K
µ
, then,
Nˆ(t) ≤ Nˆ0e−µt + K
µ
(1− e−µt)
=⇒ Nˆ(t) ≤ K
µ
(3.4.23)
Thus every solution Nˆ(t) of equation (3.3.1) satisfies the relation below.
0 ≤ Nˆ(t) ≤ Nˆ0e−µt + K
µ
(1− e−µt), (3.4.24)
where Nˆ0 is the sum of all the initial conditions of the variables of the model
system.
If Nˆ0 ≤ Kµ , then, non-negative solutions of equation (3.4.20) are monotone in-
creasing and are bounded above by K
µ
. On the contrary, if Nˆ0 > Kµ , then, non-
negative solutions of equation (3.4.20) are monotone decreasing and bounded
below by K
µ
. Nevertheless, in both cases, at limiting equilibrium, limt→∞ Nˆ(t) =
K
µ
.
This implies that any solution S(t), IL(t), ILR(t), at t ≥ 0, of (3.4.18) that
commences in the positive orthant R3+, either remains confined in, enters or
approaches Ωˆ asymptotically. Hence, the region Ωˆ is positively invariant and
attracting with respect to the flow incited by the model system (3.4.18). This
completes the proof.
We now show that condition (C1) is satisfied. To show the preclusion of
periodic solutions in the system (3.4.18), we use the Bendixson criterion for
autonomous system as described in [63]. We first need to show that the au-
tonomous system (3.4.18) is an invariant linear subspace. By the definition of
an invariant linear subspace (see Definition A.0.3), we show that the system
(3.4.18) satisfies the conditions [H1] and [H2].
The Jacobian matrix J (S, IL, ILR) of the system (3.4.18) is
J =
−(µ+ α1) 0 0α1 −(µ+ τ1) r1
0 τ1 −(µ+ r1)

= −µI + Aˆ,
(3.4.25)
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where I is a 3×3 identity matrix and Aˆ(S, IL, ILR) is a matrix-valued function
given by
Aˆ =
−α1 0 0α1 −τ1 r1
0 τ1 −r1
 . (3.4.26)
Let Bˆ = (1, 1, 1) be a constant 1× 3 row matrix. The rank of the matrix Bˆ is
r = 1. Then, BˆAˆ = 0 for all (S, IL, ILR) > 0. Hence, conditions [H1] and [H2]
are satisfied, with n = 3, r = 1,Ω = R3+, ν = µ (see Definition A.0.3). Thus,
the model subsystem (3.4.18) is an invariant linear subspace.
We employ Theorem 3.3 of [63] here. To implement this theorem, we construct
the (r+ 2)− th additive compound matrix J [r+2] (see Definition A.0.8) of the
Jacobian matrix J (S, IL, ILR). Since r + 2 = 3 = n, where the matrix J is
actually an n× n matrix, then, the special property that J [3] = tr(J ) is valid
in this case.
tr(J ) = −(3µ+ α1 + τ1 + r1) < −µ. (3.4.27)
Since (3.4.27) is valid, then, by Theorem 3.3 of [63], the subsystem (3.4.18)
has neither periodic solutions, nor homoclinic orbits, nor heteroclinic cycles,
for all values of its parameters. Since the system 3.4.18 satisfies the properties
[H1] and [H2], and Bˆ is a constant matrix, then, Ωˆ is a global invariant 2-
dimensional affine manifold. Furthermore, since the system 3.4.18 has only
one unique critical point X∗, and the fact that Theorem 3.3.1 is valid, then,
by a simple application of the Generalised Poincaré-Bendixson Theorem (see
Definition A.0.7), it suffices to show that the distinct steady stateX∗ is globally
asymptotically stable.
We now go on to prove that condition (C2) is also satisfied.
G(X, Y ) =

λ1S−(µ+α2+σ1+ρ1)IH
λ2IL+α2IH+r2ILHR−(µ+τ2+σ2+ρ6)ILH
σ1IH−(µ+α3+ρ2)IHT
λ2ILR+τ2ILH−(µ+r2+σ3+ρ5)ILHR
σ2ILH+α3IHT +r3ILHTR−(µ+τ3+ρ3)ILHT
σ3ILHR+τ3ILHT−(µ+r3+ρ4)ILHTR
ρ1IH+ρ2IHT +ρ3ILHT +ρ4ILHTR+ρ5ILHR+ρ6ILH−(µ+δ)A

.
(3.4.28)
Clearly, G(X,0) = 0. We shall construct the matrix A = DYG(X∗,0). The
matrix DYG(X, Y ) is given by
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DYG(X, Y ) =
β1S
N
−q3 β1η2S
N
β1η1S
N
β1η2S
N
β1η3S
N
β1η3S
N
β1η4S
N
β2IL
N
+α2
β2η2IL
N
−q4 β2η1IL
N
β2η2IL
N
+r2
β2η3IL
N
β2η3IL
N
β2η4IL
N
σ1 0 −q6 0 0 0 0
β2ILR
N
β2η2ILR
N
+τ2
β2η1ILR
N
β2η2ILR
N
−q7 β2η3ILR
N
β2η3ILR
N
β2η4ILR
N
0 σ2 α3 0 −q8 r3 0
0 0 0 σ3 τ3 −q9 0
ρ1 ρ6 ρ2 ρ5 ρ3 ρ4 −q10

.
(3.4.29)
X∗ = (S∗, I∗L, I
∗
LR), where
S∗ =
K
q1
, I∗L =
α1Kq5
µq1(q5 + τ1)
, I∗LR =
τ1α1K
µq1(q5 + τ1)
. Thus, N∗ =
K
µ
.
We obtain
A = DYG(X∗,0)
=
(
Ψ1 Ψ2
Ψ3 Ψ4
)
,
(3.4.30)
where
Ψ1 =

β1µ
q1
− q3 β1η2µ
q1
β1η1µ
q1
β2α1q5
q1(q5 + τ1)
+ α2
β2η2α1q5
q1(q5 + τ1)
− q4 β2η1α1q5
q1(q5 + τ1)
σ1 0 −q6
 ,
Ψ2 =

β1η2µ
q1
β1η3µ
q1
β1η3µ
q1
β1η4µ
q1
β2η2α1q5
q1(q5 + τ1)
+ r2
β2η3α1q5
q1(q5 + τ1)
β2η3α1q5
q1(q5 + τ1)
β2η4α1q5
q1(q5 + τ1)
0 0 0 0
 ,
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Ψ3 =

β2τ1α1
q1(q5 + τ1)
β2η2τ1α1
q1(q5 + τ1)
+ τ2
β2η1τ1α1
q1(q5 + τ1)
0 σ2 α3
0 0 0
ρ1 ρ6 ρ2
 ,
Ψ4 =

β2η2τ1α1
q1(q5 + τ1)
− q7 β2η3τ1α1
q1(q5 + τ1)
β2η3τ1α1
q1(q5 + τ1)
β2η4τ1α1
q1(q5 + τ1)
0 −q8 r3 0
σ3 τ3 −q9 0
ρ5 ρ3 ρ4 −q10
 .
Using the definition G(X, Y ) = AY − Gˆ(X, Y ) to obtain Gˆ(X, Y ), we have
Gˆ(X, Y ) =

Gˆ1(X, Y )
Gˆ2(X, Y )
Gˆ3(X, Y )
Gˆ4(X, Y )
Gˆ5(X, Y )
Gˆ6(X, Y )
Gˆ7(X, Y )

,
=

β1 [IH+η1IHT+η2(ILH+ILHR)+η3(ILHT+ILHTR)+η4A] Π1
β2 [IH+η1IHT+η2(ILH+ILHR)+η3(ILHT+ILHTR)+η4A] Π2
0
β2 [IH+η1IHT+η2(ILH+ILHR)+η3(ILHT+ILHTR)+η4A] Π3
0
0
0

,
(3.4.31)
where
Π1 =
(
µ
q1
− S
N
)
,
Π2 =
(
α1q5
q1(q5 + τ1)
− IL
N
)
,
Π3 =
(
α1τ1
q1(q5 + τ1)
− ILR
N
)
.
We now show that Gˆ(X, Y ) ≥ 0 for (X, Y ) ∈ Γ, which implies that we must
show that Gˆ1(X, Y ), Gˆ2(X, Y ), Gˆ4(X, Y ), ≥ 0. It suffices to show that:
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(i)
µ
q1
− S
N
≥ 0,
(ii)
α1q5
q1(q5 + τ1)
− IL
N
≥ 0,
(iii)
α1τ1
q1(q5 + τ1)
− ILR
N
≥ 0.
We prove these relations by contradiction. Suppose that
µ
q1
<
S
N
,
α1q5
q1(q5 + τ1)
<
IL
N
,
α1τ1
q1(q5 + τ1)
<
ILR
N
.
(3.4.32)
Using the direct proof technique, that for positive constants a, b, c, d > 0, if
a < b and c < d, then, a + c < b + d, we sum the three relations above to
obtain,
µ
q1
+
α1q5
q1(q5 + τ1)
+
α1τ1
q1(q5 + τ1)
<
S + IL + ILR
N
,
=⇒ (µ+ α1)(q5 + τ1)
q1(q5 + τ1)
= 1 <
S + IL + ILR
N
.
(3.4.33)
However, since N = S+IL+ILR+IH +ILH +IHT +ILHR+ILHT +ILHTR+A,
then by definition, we have the relation
0 < S + IL + ILR < N, =⇒ S + IL + ILR
N
< 1. (3.4.34)
Relations (3.4.33) and (3.4.34) implies that
1 <
S + IL + ILR
N
< 1, =⇒ 1 < 1.
This is a contradiction. Hence, the converse of the relations in (3.4.32) is
true. This implies that relations (i)-(iii) are valid. Hence Gˆ(X, Y ) ≥ 0 for
(X, Y ) ∈ Γ. This completes the proof.
Remark 3.4.4. Note that in a later Theorem in this chapter (Theorem 3.4.5), it
will be seen that the disease-free equilibrium E0 is truly globally asymptotically
stable if R0 < 1, but that is valid only if R0 < Rc0 < 1, where Rc0 is a threshold
called the critical reproduction number.
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3.4.4 Existence of the Endemic Steady States
In order to compute the endemic equilibria of the model system (3.2.3), where
at least one of the infected compartments is not null, we set the right hand
side of the system (3.2.3) to zero, and solve for all its state variables. In this
process, we express the state variables in terms of the forces of infection λ∗1
and λ∗2, where
λ∗1 =
β1
N∗
[I∗H + η1I
∗
HT + η2(I
∗
LH + I
∗
LHR) + η3(I
∗
LHT + I
∗
LHTR) + η4A
∗],
(3.4.35)
λ∗2 =
β2
N∗
[I∗H + η1I
∗
HT + η2(I
∗
LH + I
∗
LHR) + η3(I
∗
LHT + I
∗
LHTR) + η4A
∗],
(3.4.36)
N∗ = S∗ + I∗L + I
∗
H + I
∗
LH + I
∗
LR + I
∗
HT + I
∗
LHR + I
∗
LHT + I
∗
LHTR + A
∗.
(3.4.37)
Observe that
λ2 =
β2 λ1
β1
. (3.4.38)
This implies that λ2 is simply a (positive) constant multiple of λ1. Thus any
qualitative inference(s) made from investigating the polynomial arising from
λ1 also applies to the polynomial equation that ought to arise from λ2.
Thus, the endemic equilibria of the model (3.2.3) are given by
E1 = (S
∗, I∗L, I
∗
H , I
∗
LH , I
∗
LR, I
∗
HT , I
∗
LHR, I
∗
LHT , I
∗
LHTR, A
∗), (3.4.39)
where
S∗ =
K
q1+λ∗1
, (3.4.40a)
I∗L =
K α1 (q5+λ
∗
2)
(q1+λ∗1) (q2 λ
∗
2+q5 λ
∗
2+(λ
∗
2)
2+q2 q5 (1−ξ3)) , (3.4.40b)
I∗LR =
K α1 τ1
(q1+λ∗1) (q2 λ
∗
2+q5 λ
∗
2+(λ
∗
2)
2+q2 q5 (1−ξ3)) , (3.4.40c)
I∗H =
K λ∗1
q3 (q1+λ∗1)
, (3.4.40d)
I∗LH =
K α1 λ
∗
2 (q7 (q5+λ
∗
2)+r2 τ1)
q4 q7 (q1+λ∗1) (1−ξ1) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
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+
K α2 λ
∗
1
q3 q4 (q1+λ∗1) (1−ξ1)
, (3.4.40e)
I∗HT =
K λ∗1 σ1
q3 q6 (q1+λ∗1)
, (3.4.40f)
I∗LHR =
1
q7 (1−ξ1)
[
K q4 α1 λ
∗
2 τ1+K α1 λ
∗
2 (q5+λ
∗
2) τ2
q4 (q1+λ∗1) (q2 λ
∗
2+q5 λ
∗
2+(λ
∗
2)
2+q2 q5 (1−ξ3))
+
K α2 τ2 λ
∗
1
q3 q4 (q1+λ∗1)
]
, (3.4.40g)
I∗LHT =
K α1 λ
∗
2 (q9 σ2 (q7 (q5+λ
∗
2)+r2 τ1)+r3 σ3 (q4 τ1+(q5+λ
∗
2) τ2))
q4 q7 q8 q9 (q1+λ∗1) (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+
K λ∗1 (q4 q7 q9 α3 (1−ξ1) ξ2 σ1+q6 q7 q9 α2 σ2+q6 r3 α2 σ3 τ2)
q3 q4 q6 q7 q8 q9 (q1+λ∗1) (1−ξ1) (1−ξ2)
+
K α3 λ
∗
1 σ1
q3 q6 q8 (q1+λ∗1)
, (3.4.40h)
I∗LHTR =
K α3 λ
∗
1 σ1 τ3
q3 q6 q8 q9 (q1+λ∗1) (1−ξ2)
+
K α2 λ
∗
1 (q8 σ3 τ2+q7 σ2 τ3)
q3 q4 q7 q8 q9 (q1+λ∗1) (1−ξ1) (1−ξ2)
+
K α1 λ
∗
2 (q4 q8 σ3 τ1+q8 (q5+λ
∗
2) σ3 τ2+σ2 (q7 (q5+λ
∗
2)+r2 τ1) τ3)
q4 q7 q8 q9 (q1+λ∗1) (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
,
(3.4.40i)
A∗ =
K
q10 (q1+λ∗1)
(
λ∗1 ρ1
q3
+
λ∗1 ρ2 σ1
q3 q6
+
ρ6 (q7 (q5+λ
∗
2) (q3 α1 λ
∗
2+α2 λ
∗
1 (q2+λ
∗
2))−(q7 r1 α2 λ∗1−q3 r2 α1 λ∗2) τ1)
q3 q4 q7 (1−ξ1) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+
ρ5 (α2 τ2 λ
∗
1 (q2 λ
∗
2+q5 λ
∗
2+(λ
∗
2)
2+q2 q5 (1−ξ3)))
q3 q4 q7 (1−ξ1) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+
ρ5 (q3 α1 λ
∗
2 (q4 τ1+(q5+λ
∗
2) τ2))
q3 q4 q7 (1−ξ1) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+ ρ3
(
α1 λ
∗
2 (q5 q7 q9 σ2+q7 q9 λ
∗
2 σ2+q9 r2 σ2 τ1)
q4 q7 q8 q9 (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+
α1 λ
∗
2 (q4 r3 σ3 τ1+r3 (q5+λ
∗
2) σ3 τ2)
q4 q7 q8 q9 (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+
λ∗1 (q4 q7 q9 α3 σ1−q9 r2 α3 σ1 τ2+q6 α2 (q7 q9 σ2+r3 σ3 τ2))
q3 q4 q6 q7 q8 q9 (1−ξ1) (1−ξ2)
)
+
ρ4 (q3 q6 α1 λ
∗
2 (q8 σ3 (q4 τ1+(q5+λ
∗
2) τ2)+σ2 (q7 (q5+λ
∗
2)+r2 τ1) τ3))
q3 q4 q6 q7 q8 q9 (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
+
ρ4 (λ
∗
1 ((q2+λ
∗
2) (q5+λ
∗
2)−r1 τ1) (q4 q7 α3 (1−ξ1) σ1 τ3))
q3 q4 q6 q7 q8 q9 (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
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+
ρ4 (λ
∗
1 ((q2+λ
∗
2) (q5+λ
∗
2)−r1 τ1) (q6 α2 (q8 σ3 τ2+q7 σ2 τ3)))
q3 q4 q6 q7 q8 q9 (1−ξ1) (1−ξ2) (q2 λ∗2+q5 λ∗2+(λ∗2)2+q2 q5 (1−ξ3))
)
.
(3.4.40j)
Substituting for the steady states above in (3.4.35), we obtain the quartic
polynomial in λ∗1 given by
C14(λ
∗
1)
4 + C13(λ
∗
1)
3 + C12(λ
∗
1)
2 + C11λ
∗
1 = 0, (3.4.41)
where
C14 = −
(
β2
β2
)2
[(q4 q7 q8 q9 (1− ξ1) (1− ξ2) (q6 (q10 + ρ1) + (q10 + ρ2) σ1))
+q6 α2 (r3 (q10 + ρ3) + q8 (q10 + ρ4)) σ3 τ2 + q6 q8 q9 α2 (1− ξ2) (q7 (q10 + ρ6)
+ (q10 + ρ5) τ2) + q4 q7 α3 (1− ξ1) σ1 (q9 (q10 + ρ3) + (q10 + ρ4) τ3)
+q6 q7 α2 σ2 (q9 (q10 + ρ3) + (q10 + ρ4) τ3)] ,
C13 =
β2
β2
[(
β2
β2
)
(− (q3 q6 (q4 q7 q8 q9 q10 (1− ξ1) (1− ξ2) + α1 ((r3 (q10 + ρ3) σ3
+q8 (q9 (1− ξ2) (q10 + ρ5) + (q10 + ρ4) σ3)) τ2 + q7 (q8 q9 (1− ξ2) (q10 + ρ6)
+σ2 (q9 (q10 + ρ3) + (q10 + ρ4) τ3))))))− [(q4 q7 q8 q9 (1− ξ1) (1− ξ2)
× (− (q6 q10 β2) + (q2 + q5) (q6 (q10 + ρ1) + (q10 + ρ2) σ1))) + q5 q6 q10 (q8 + r3)
×α2 σ3 τ2 + q5 q6 α2 (r3 ρ3 + q8 ρ4) σ3 τ2 + (q2 + q5) q6 q8 q9 α2 (1− ξ2)
× (q7 (q10 + ρ6) + (q10 + ρ5) τ2) + q2 q6 α2 (q10 + ρ3) (q7 q9 σ2 + r3 σ3 τ2)
+q5 q6 q7 q10 α2 σ2 (q9 + τ3) + q5 q6 q7 α2 σ2 (q9 ρ3 + ρ4 τ3) + q4 (q2 + q5) q7 α3
× (1− ξ1) σ1 (q9 (q10 + ρ3) + (q10 + ρ4) τ3) + q2 q6 α2 (q10 + ρ4) (q8 σ3 τ2
+q7 σ2 τ3)] + [q4 q7 q8 q9 q10 β2 η1 (1− ξ1) (1− ξ2) σ1 + q6 q8 q9 q10 α2 β2 η2
× (1− ξ2) (q7 + τ2) + q10 β2 η3 (q6 (q8 + r3) α2 σ3 τ2 + q4 q7 α3 (1− ξ1) σ1
× (q9 + τ3) + q6 q7 α2 σ2 (q9 + τ3)) + η4 (q4 q7 q8 q9 β2 (1− ξ1) (1− ξ2)
× (q6 ρ1 + ρ2 σ1) + q6 q8 q9 α2 β2 (1− ξ2) (q7 ρ6 + ρ5 τ2) + q4 q7 α3 β2 (1− ξ1)
×σ1 (q9 ρ3 + ρ4 τ3) + q6 α2 β2 ((r3 ρ3 + q8 ρ4) σ3 τ2 + q7 σ2 (q9 ρ3 + ρ4 τ3)))]] ,
C12 = q4 q6 q7 q8 q9 q10 β2 (q2 + q5) (1− ξ1) (1− ξ2)−D1 +D2 +D3,
(3.4.42)
and
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D1 = [q2 q4 q5 q7 q8 q9 (1− ξ1) (1− ξ2) (1− ξ3) (q6 (q10 + ρ1) + (q10 + ρ2) σ1)
+q2 q5 q6 q8 q9 α2 (1− ξ2) (1− ξ3) (q7 q10 + (q10 + ρ5) τ2) + (1− ξ3) (q7 ρ6
+q2 q5 q6 α2 (q7 q9 (q10 + ρ3) σ2 + (r3 (q10 + ρ3) + q8 (q10 + ρ4)) σ3 τ2)
+q6 q7 α2 (q2 q5 q10 + ρ4) σ2 τ3) + α3 (1− ξ1) (1− ξ3) σ1 (q2 q5 q9 ρ3
+q4 q7 (ρ4 τ3 + q2 q5 q10 (q9 + τ3)))] ,
D2 = [q4 (q2 + q5) q7 q8 q9 q10 β2 η1 (1− ξ1) (1− ξ2) σ1 + (q2 + q5) q6 q8 q9 q10 α2
×β2 η2 (1− ξ2) (q7 + τ2) + (q2 + q5) β2 η3 (q4 q7 q10 α3 (1− ξ1) σ1 (q9 + τ3)
+q6 q10 α2 ((q8 + r3) σ3 τ2 + q7 σ2 (q9 + τ3))) + β2 η4 (q2 q6 α2 (r3 ρ3 + q8 ρ4)
×σ3 τ2 + q5 q6 α2 (r3 ρ3 + q8 ρ4) σ3 τ2 + q2 q6 q7 α2 σ2 (q9 ρ3 + ρ4 τ3) + q5 q6 q7
×α2 σ2 (q9 ρ3 + ρ4 τ3) + (q2 + q5) (q4 q7 q8 q9 (1− ξ1) (1− ξ2) (q6 ρ1 + ρ2 σ1)
+q6 q8 q9 α2 (1− ξ2) (q7 ρ6 + ρ5 τ2) + q4 q7 α3 (1− ξ1) σ1 (q9 ρ3 + ρ4 τ3)))] ,
D3 =
β2
β1
[− [(q3 q4 q6 q7 q8 q9 q10 (q2 + q5 + α1) (1− ξ1) (1− ξ2)) + q3 q6 q8 q9 α1
× (1− ξ2) ((q10 + ρ6) (q5 q7 + r2 τ1) + (q10 + ρ5) (q4 τ1 + q5 τ2)) + q3 q6 α1
× (q9 (q10 + ρ3) σ2 (q5 q7 + r2 τ1) + q10 (q8 + r3) σ3 (q4 τ1 + q5 τ2) + (r3 ρ3
+q8 ρ4) σ3 (q4 τ1 + q5 τ2) + (q10 + ρ4) σ2 (q5 q7 + r2 τ1) τ3)] + q3 q6 q8 q9 q10
×α1 β2 η2 (1− ξ2) (q7 + τ2) + q3 q6 q10 α1 β2 η3 ((q8 + r3) σ3 τ2 + q7 σ2
× (q9 + τ3)) + q3 q6 α1 β2 η4 ((r3 ρ3 + q8 ρ4) σ3 τ2 + q8 q9 (1− ξ2) (q7 ρ6 + ρ5 τ2)
+q7 σ2 (q9 ρ3 + ρ4 τ3))] ,
C11 = − [(q2 q4 q5 q6 q7 q8 q9 q10 (q3 − β1) (1− ξ1) (1− ξ2) (1− ξ3)) + q3 q4 q6 q7
×q8 q9 q10 α1 (1− ξ1) (1− ξ2) (q5 + τ1)] + q2 q4 q5 q7 q8 q9 q10 β1 η1 (1− ξ1)
× (1− ξ2) (1− ξ3) σ1 + η2 (q2 q5 q6 q8 q9 q10 α2 β1 (1− ξ2) (1− ξ3) (q7 + τ2)
+q3 q6 q8 q9 q10 α1 β2 (1− ξ2) ((q4 + r2) τ1 + q5 (q7 + τ2))) + η3 (q3 q6 q10 α1
× β2 ((q8 + r3) σ3 (q4 τ1 + q5 τ2) + σ2 (q5 q7 + r2 τ1) (q9 + τ3)) + q2 q5 q10 β1
× (1− ξ3) (q4 q7 α3 (1− ξ1) σ1 (q9 + τ3) + q6 α2 ((q8 + r3) σ3 τ2 + q7 σ2
× (1 + τ3)))) + η4 (q3 q6 q8 q9 α1 β2 (q3 q6 (r3 ρ3 + q8 ρ4) σ3 (q4 τ1 + q5 τ2)
+ (1− ξ2) (ρ6 (q5 q7 + r2 τ1) + ρ5 (q4 τ1 + q5 τ2)) + q3 q6 σ2 (q5 q7 + r2 τ1)
× (q9 ρ3 + ρ4 τ3)) + β1 (q2 q4 q5 q7 q8 q9 (1− ξ1) (1− ξ2) (1− ξ3) (q6 ρ1
+ρ2 σ1) + q2 q5 q6 q8 q9 α2 (1− ξ2) (1− ξ3) (q7 ρ6 + ρ5 τ2) + q2 q4 q5 q7 α3
× (1− ξ1) (1− ξ3) σ1 (q9 ρ3 + ρ4 τ3) + q2 q5 q6 α2 (1− ξ3) ((r3 ρ3 + q8 ρ4)
×σ3 τ2 + q7 σ2 (q9 ρ3 + ρ4 τ3)))) .
(3.4.43)
λ∗1 can be factored out to give
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λ∗1
[
C14(λ
∗
1)
3 + C13(λ
∗
1)
2 + C12λ
∗
1 + C11
]
= 0, (3.4.44)
which has two solutions, that is, λ∗1 = 0 (which is the disease free equilibrium)
or C14(λ∗1)3 + C13(λ∗1)2 + C12λ∗1 + C11 = 0. Since we are not currently esti-
mating the DFE (that’s been dealt with), then λ1 6= 0. This implies that the
polynomial (3.4.41) reduces to a cubic polynomial given by
H(λ∗1) = C14(λ
∗
1)
3 + C13(λ
∗
1)
2 + C12λ
∗
1 + C11 = 0. (3.4.45)
The new constant term in this cubic polynomial is C11. C11 expressed in terms
of R0 is given by
C11 = −q1q3q4q6q7q8q9q10(q5 + τ1) [1−R0] . (3.4.46)
The existence, and number of endemic equilibria for the model system (3.2.3)
is determined by the existence of, and number of positive roots of the cubic
equation (3.4.45). We investigate and characterise the solutions (roots) of the
cubic polynomial (3.4.45) by using the signs of its coefficients C14, C13, C12 and
C11. Since r2 < q7 and τ2 < q4, then, by direct proof, r2τ2 < q4q7. This implies
that ξ1 = r2τ2q4q7 < 1. Thus, 1 − ξ1 > 0. In like manner, 1 − ξ2, 1 − ξ3, > 0.
Clearly, C14 < 0. If R0 < 1, then C11 < 0. Also, if R0 > 1, then C11 > 0.
In order to determine whether the model (3.2.3) has a unique endemic equilib-
rium or multiple endemic equilibria when R0 > 1, we determine the turning
points of the polynomial equation (3.4.45). We do this by evaluating the first
order derivative of H(λ∗1) and equate it to zero. This gives
H ′(λ∗1) = 3C14(λ
∗
1)
2 + 2C13λ
∗
1 + C12 = 0. (3.4.47)
The turning points of equation (3.4.45) (using the quadratic formula to eval-
uate the roots of (3.4.47)) are given by
(λ∗1)1,2 =
−C13 ±
√
C213 − 3C12C14
3C14
. (3.4.48)
The discriminant of solutions (3.4.48) is 4 = C213 − 3C12C14. We investigate
the nature of the roots (3.4.48) by analysing possible signs of the discriminant
4. If 4 < 0, then H(λ∗1) has no real turning points, which implies that H(λ∗1)
is a strictly monotonic function. We investigate the monotonicity of H(λ∗1)
by examining the sign of H ′(λ∗1) (equation (3.4.47)). We use completing the
squares method to convert H ′(λ∗1) into the sum of a square and a constant
term. We obtain
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H ′(λ∗1) = 3C14
[(
λ∗1 +
C13
3C14
)2
+
1
9C214
(3C12C14 − C213)
]
. (3.4.49)
If 4 < 0, then 3C12C14 − C213 > 0. Since C14 < 0, then H ′(λ∗1) < 0. This
implies that the polynomial function H(λ∗1) in (3.4.45) is strictly monotone
decreasing. Note that H(0) = C11 > 0 if R0 > 1. Hence, H(λ∗1) has only one
positive real root, and consequently only one endemic equilibrium.
If 4 = 0, then H ′(λ∗1) has only one real root with multiplicity two. This
implies that (λ∗1)1 = (λ∗1)2 = − C133C14 . 4 = 0 implies that 3C12C14 − C213 = 0,
which also implies that H ′(λ∗1) < 0. This indicates that H(λ∗1) is a decreasing
funtion. H ′(λ∗1) has only one root which is − C133C14 , and it has multiplicity
two. H ′′(λ∗1) = 6C14λ∗1 + 2C13. We observe that H ′′(− C133C14) = 0. This means
that the turning point (λ∗1)1 = (λ∗1)2 = − C133C14 is a point of inflexion for H(λ∗1).
Since the only stationary point of H(λ∗1) in this case is a point of inflexion,
H(0) = C11 > 0 for R0 > 1, and H(λ∗1) is a decreasing function, then, H(λ∗1)
has only one positive real root, and consequently only one endemic equilibrium.
For 4 > 0, we consider two cases; C12 < 0 and C12 > 0. If C12 < 0, then
C12C14 > 0. This means that
√4 < C13. Irrespective of the sign of C13,
H ′(λ∗1) has two real positive and distinct roots. This implies that H(λ∗1) has
two positive turning points. Since H(0) = C11 > 0 for R0 > 1, then, H(λ∗1)
has at least one positive real root, and consequently at least one endemic
equilibrium.
If C12 > 0, then C12C14 < 0, which implies that
√4 > C13. For C13 > 0,
H ′(λ∗1) has two real roots of opposite signs. Since H(0) = C11 > 0 for R0 > 1,
then, H(λ∗1) has one positive root. For C13 < 0, H ′(λ∗1) has two negative real
roots. Since H(0) = C11 > 0 for R0 > 1, then, H(λ∗1) has only one positive
real root, and consequently only one endemic equilibrium.
Furthermore, we use the Descartes’ Rule of Signs [64] to explore the existence
of endemic equilibrium (or equilibria) for R0 < 1, and investigate the possi-
bility of a backward bifurcation (that is a likelihood of the system (3.2.3) to
be bistable with both its DFE and endemic equilibrium/equilibria coinciding
at R0 < 1). C14 < 0 and C11 < 0 when R0 < 1. If C13 > 0 and C12 < 0, then,
equation (3.4.45) can be expressed as
H(λ∗1) = −C14(λ∗1)3 + C13(λ∗1)2 − C12λ∗1 − C11 = 0. (3.4.50)
There are only two sign changes in equation (3.4.50), which implies that
(3.4.50) can only have two positive roots. This means that equation (3.4.45)
has two endemic equilibria.
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If C13 > 0 and C12 > 0, then, equation (3.4.45) can be expressed as
H(λ∗1) = −C14(λ∗1)3 + C13(λ∗1)2 + C12λ∗1 − C11 = 0. (3.4.51)
There are only two sign changes in equation (3.4.51), which implies that
(3.4.51) has two positive roots. This means that equation (3.4.45) has two
endemic equilibria.
If C13 < 0 and C12 < 0, then, equation (3.4.45) can be expressed as
H(λ∗1) = −C14(λ∗1)3 − C13(λ∗1)2 − C12λ∗1 − C11 = 0. (3.4.52)
There are are no sign changes in (3.4.52), whic implies that (3.4.51) will have
no positive root.
If C13 < 0 and C12 > 0, then, equation (3.4.45) can be expressed as
H(λ∗1) = −C14(λ∗1)3 − C13(λ∗1)2 + C12λ∗1 − C11 = 0. (3.4.53)
There are two sign changes in equation (3.4.53), which implies that (3.4.53)
has two positive roots. This means that equation (3.4.45) has two endemic
equilibria.
The theorem below summarises the existence of endemic equilibria of the model
system (3.2.3).
Theorem 3.4.5. The model system (3.2.3)
(i) has no endemic equilibrium if R0 < Rc0 < 1, where Rc0 is a threshold
called the critical R0.
(ii) has at least one endemic equilibrium in Γ, if R0 > 1.
(iii) has two endemic equilibria for some parameter values of R0 within the
range Rc0 < R0 < 1. Within this range, one endemic equilibrium and the
DFE are locally stable.
(iv) has no endemic equilibrium otherwise.
Remark 3.4.6. Since the system possesses two endemic equilibria when Rc0 <
R0 < 1, then, the DFE E0 is not globally asymptotically stable for R0 < 1,
except if R0 < Rc0.
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Proposition 3.4.7. The model system (3.2.3) exhibits backward bifurcation
for R0 < 1.
Remark 3.4.8. The consequence of Proposition 3.4.7 is that bringing R0 below
unity is not sufficient to eradicate the disease when introduced into a wholly
susceptible population. If this must be achieved, then, R0 must be brought
below the critical value Rc0, or Rc0 must be raised. The critical value Rc0 is a
threshold after both the DFE and the endemic equilibrium(s) co-exist. Note
that because the DFE is locally asymptotically stable, the disease will not
return if it is eradicated.
We give a description of the critical value Rc0 by investigating the possible
roots (3.4.48) of the quadratic turning point 3.4.47, of equation (3.4.45). As
earlier stated, the roots of equation (3.4.47) (using the quadratic formula) are
given by equation (3.4.48).
Let
(λ∗1)1 =
−C13 +
√
C213 − 3C12C14
3C14
,
(λ∗1)2 =
−C13 −
√
C213 − 3C12C14
3C14
.
(3.4.54)
Let (λ∗1)c be the root that corresponds to the critical R0. The discriminant of
roots (3.4.48) is 4 = C213− 3C12C14. Remember that C14 < 0. If 4 < 0, then,
we cannot estimate the (real) roots of the turning points H ′(λ∗1).
Consider 4 < 0. If C12 > 0, then
√4 > C13. If in addition C13 > 0,
then, (λ∗1)1, (λ∗1)2 < 0. This case is invalid as we are only interested in the
positive root(s) H ′(λ∗1). On the other hand, if C13 < 0, then, (λ∗1)1 < 0 and
(λ∗1)2 > 0. This summarily implies that if 4 < 0, C12 > 0, and C13 < 0, then,
(λ∗1)c = (λ
∗
1)2.
If C12 < 0, then
√4 < C13. If in addition C13 > 0, then, (λ∗1)1, (λ∗1)2 > 0. This
implies that the turning points of H(λ∗1) are in the positive (first) quadrant of
the λ∗1−H(λ∗1) plane. This suggests that there can be three endemic equilibria
(when a vertical line is drawn across the λ∗1−H(λ∗1) plane). We do not consider
this case as there are only two endemic equilibria when Rc0 < R0 < 1. On the
contrary, if C13 < 0, then (λ∗1)1 > 0 and (λ∗1)2 < 0. Thus, for 4 < 0, C12 < 0,
and C13 < 0, (λ∗1)c = (λ∗1)1.
Consider 4 = 0. H ′(λ∗1) will have only one root with multiplicity two, given
by
(λ∗1)1 = (λ
∗
1)2 = −
C13
3C14
. (3.4.55)
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If C13 > 0, then, (λ∗1)1 > 0. On the other hand, if C13 < 0, then, (λ∗1)1 < 0.
Thus, for 4 = 0 and C13 > 0, (λ∗1)c = (λ∗1)1 = (λ∗1)2.
Below is a summary of the only plausible conditions for (λ∗1)c, such that
H(λ∗1)c = Rc0;
(i) (λ∗1)c = (λ∗1)2, for C12 > 0, C13 < 0, and C213 − 3C12C14 > 0.
(ii) (λ∗1)c = (λ∗1)1, for C12 < 0, C13 < 0, and C213 − 3C12C14 > 0.
(iii) (λ∗1)c = (λ∗1)1 = (λ∗1)2, for C13 > 0, and C213 − 3C12C14 = 0.
3.5 Numerical Simulations
In order to illustrate the theoretical results of the preceding analysis, and
to study the dynamics of the model system (3.2.3), even the effects of its
various parameters, we integrate the system (3.2.3), using the fourth order
Runge-Kutta method. Table 3.3 displays the lymphoma data obtained by the
TLSG, which we used to fit the model. We do not have adequate information
on the annual proportion of HIV patients on HAART, lymphoma patients in
remission or their age range for this particular data. The parameter values used
in the numerical simulations are given in the Table 3.4. Lymphoma incidence
data (for both HIV-infected and HIV-free patients) for the years 2002-2012,
were obtained from the Tygerberg Lymphoma Study Group (TLSG) of the
Tygerberg Hospital (TH), Stellenbosch University, Western Cape province,
South Africa.
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
HIV +ve 2 15 17 16 35 43 43 48 32 53 55
HIV -ve 33 106 95 62 147 133 150 131 150 185 144
Total 35 111 112 78 182 176 193 179 182 238 194
Table 3.3: The number of lymphoma cases per year for HIV positive (HIV+) and
HIV negative (HIV−) individuals, data obtained from the TLSG, [27].
Many of the parameter values used have not been clinically or experimentally
estimated. In the estimation of our parameters, we aim at obtaining the most
suitable parameters that will ensure coherence between numerically obtained
data, and clinically observed data. To do this, the unknown parameters can be
obtained by an iterative method (which may not be efficient), or by fitting the
model to real data, through the use of scientific packages. These packages aim
at (statistically) finding parameters that give the best fit. An example of such
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packages is the least suqare curve fit routine (lsqcurvefit), built into Matlab.
One can write a code (e.g a Matlab code) which takes a range of paramaters
values (lower and upper bounds of parameters), from which paramaters values
that fit the model best can be sampled and optimised by the least suqare curve
fit routine, with respect to the model system, and the set of observed data.
Thus, in order to facilitate the illustration of the dynamics of the model, we
simulate the model using several assumed parameters, within realistic biolog-
ical and epidemiological ranges. Some of the assumed parameters obtained
coincide with the parameter estimates of the least-square curve fit scheme,
which were used to fit the model to data. While many of these parameters
could also be applicable in other HIV-related malignancy setting, and in other
regions of the world, we restrict our simulation to the particular incidence
of HIV-related lymphoma in the Western Cape province of South Africa, for
which some parameters are know. Known model parameters include demp-
graphic parameters: µ,b (birth rate), and δ.
3.5.1 Parameter Estimation
The 2013 mid-year population estimate by Statistics South Africa (StatsSA)
[65], reports that the average life expectancy of the people of Western Cape,
South Africa, from 2001-2006 was 56.6 and 63.7 years (average is 60.15 years),
from 2006-2011 was 60.6 and 66.1 years (average is 63.35 years), and from 2011-
2016 was 64.2 and 70.1 years (average is 67.15 years) for males and females
respectively. The corresponding mortality rates for each year sections are
0.01663yr−1, 0.01579yr−1 and 0.01489yr−1 respectively. Hence, the mortality
rate we used for the model was sampled from the range (0.014-0.017), of which
the sampled value that fits our model is 0.017. In like manner, the (crude)
birth rate of the people of the Western Cape of South Africa from 2001-2006 is
about 21.7 childbirths per 1000 people per year, i.e. (0.0217yr−1), from 2006-
2011, it is about 20.7 childbirths per 1000 people per year, i.e. (0.0207yr−1),
and from 2011-2016, it is about 19.0 childbirths per 1000 people per year,
i.e. (0.0190yr−1) [65]. Thus, the birth rate (b) used in the model simulation
was sampled from the range (0.020-0.025). We estimate the recruitment rate
K = bN0.
In the estimation of the effective contact rates β1 and β2, we supposed that
lymphoma patients have lesser effective contacts with HIV-infected individuals,
in comparison with susceptibles (β1 > β2). This is because lymphoma patients
are (assumed) sick and immunocompromised. Since HIV-positive patients have
a higher proclivity to developing lymphoma, we assumed that their lymphoma
development rates α2 and α3, irrespective of whether they are on treatment,
are higher than that of HIV-negative patients α1, that is α2, α3 > α1. Several
studies have reported that treatment of HIV with HAART have caused a
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decline in the incidence of some lymphoma subtypes, such as HIV-PCNSL and
DLBCL (see 2.2.1), while it has caused an increase in the incidence of some
lymphoma subtypes (that occurs mostly in patients with normal or slightly
depreciated CD4 counts), such as BL and centroblastic DLBCL. Due to this
fact, we could not definitely assume which is greater of α2 and α3. However,
our model fit to data suggests that α3 > α2, which could imply that many
of the patients, in the population under study, develops lymphoma after their
initiation of HAART. This could be attributed to very late presentation of cases
(when lyphoma is worse and CD4 count is dangerously low; many present at
a CD4 count of < 100cells/µL) and lack of adherence to HAART treaments.
Parameter values for these assumptions were obtained during our fitting of
model to data.
Furthermore, we assumed that the viral infection of patients with HIV, and
those co-infected with HIV and lymphoma progresses to AIDS, at a faster
rate, than every other patients in such classes but in one kind of treatment
or the other, that is, ρ1, ρ6 > ρ2, ρ3, ρ4, ρ5. We also assumed that the rate
at which the viral infection of patients co-infected with HIV and lymphoma,
and using HAART, and those co-infected with HIV and lymphoma, but in
remission after being treated for lymphoma, advance to the AIDS stage, are
about the same, and faster than the rate at which patients co-infected with
HIV and lymphoma, but using HAART and in remission progresses to AIDS,
that is, ρ3, ρ5 > ρ4. However, theoretically, we suppose that patients who
have been co-infected with HIV and lymphoma (and in treatment for both
illnesses), have been more immunocompromised than patients infected with
HIV alone and using HAART, we assumed that the rate at which the viral
infection of the former progresses to AIDS is faster than the rate at which
the latter progresses to AIDS, that is, ρ4 > ρ2. Parameter values for these
assumptions, and every other unknown parameters were obtained during our
fitting of model to data. All the parameter values used, with their ranges and
description, for our model simulation and validation are displayed in Table 3.4.
The population we fitted to our model is that of Western Cape. However, the
clinical data we are fitting to our model is from Tygerberg Hospital, which
covers about half the population of Western Cape. Our source of data for
the population under consideration is from StatsSA. For coherence of data, we
halved the population of the adult population (15+) to get the total number
of susceptibles for the purpose of our data fit to model. The susceptible pop-
ulation used to set the initial conditions of the model, for the year 2002-2012
can be found in [65–75].
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Table 3.4: Parameter values and ranges used in numerical simulation
Parameters Description Range Point value Source
K Recruitment rate for susceptibles (43000-44000) 43049yr−1 Demo
µ Natural mortality rate (0.015-0.017) 0.017yr−1 Demo
δ Disease-induced mortality rate (0.0015-0.0025) 0.002yr−1 Demo
β1 Effective contact rate of HIV for sus-
ceptible individuals
(0.0088-0.0093) 0.009yr−1 Estimated
β2 Effective contact rate of HIV for lym-
phoma patients
(0.0018-0.0022) 0.002yr−1 Estimated
α1 Lymphoma development rate of HIV-
negative patients
(0.000080-0.0000885) 0.000082yr−1 Estimated
α2 Lymphoma development rate of HIV-
positive patients
(0.000134-0.000136) 0.000135yr−1 Estimated
α3 Lymphoma development rate of HIV-
positive patients under antiretroviral
regimen(s)
(0.078-0.082) 0.08yr−1 Estimated
σ1 HIV treatment rate of lymphoma-free
HIV patients
(0.031-0.035) 0.034yr−1 Estimated
σ2 HIV treatment rate of patients with
lymphoma and HIV
(0.00067-0.00072) 0.0007yr−1 Estimated
σ3 HIV treatment rate of patients with
lymphoma and HIV, and in remission
(0.00078-0.00083) 0.0008yr−1 Estimated
τ1 Lymphoma treatment rate of
lymphoma-only patients
(0.990-0.995) 0.99yr−1 Estimated
τ2 Lymphoma treatment rate of patients
with lymphoma and HIV
(0.118-0.125) 0.122yr−1 Estimated
τ3 Lymphoma treatment rate of patients
with lymphoma and HIV, and are un-
der antiretroviral regimen(s)
(0.77-0.80) 0.78yr−1 Estimated
r1 Lymphoma relapse rate of lymphoma
patients in remission
(0.0018-0.0022) 0.002yr−1 Estimated
r2 Lymphoma relapse rate of lymphoma
patients with lymphoma and HIV in re-
mission
(0.050-0.057) 0.055yr−1 Estimated
r3 Lymphoma relapse rate of lymphoma
patients with lymphoma and HIV, in
remission and under antiretroviral reg-
imen(s)
(0.38-0.42) 0.4yr−1 Estimated
ρ1 Progression rate to full-blown AIDS in
HIV patients
(0.009-0.011) 0.01yr−1 Estimated
ρ2 Progression rate to full-blown AIDS in
HIV patients under antiretroviral regi-
men(s)
(0.001-0.0012) 0.001yr−1 Estimated
ρ3 Progression rate to full-blown AIDS in
patients with lymphoma and HIV, and
under antiretroviral regimen(s)
(0.0068-0.0072) 0.007yr−1 Estimated
ρ4 Progression rate to full-blown AIDS in
patients with lymphoma and HIV, un-
der antiretroviral regimen(s) and in re-
mission
(0.0049-0.0053) 0.005yr−1 Estimated
ρ5 Progression rate to full-blown AIDS in
patients with lymphoma and HIV, and
in remission
(0.0068-0.0071) 0.007yr−1 Estimated
ρ6 Progression rate to full-blown AIDS in
patients with lymphoma and HIV
(0.0098-0.0099) 0.01yr−1 Estimated
η1 Modification parameter for class IHT (0.50-0.52) 0.5 Estimated
η2 Modification parameter for classes ILH
and ILHR
(1.30-1.32) 1.3 Estimated
η3 Modification parameter for classes
ILHT and ILHTR
(0.7-0.72) 0.7 Estimated
η4 Modification parameter for class A (1.59-1.62) 1.6 Estimated
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3.5.2 Sensitivity Analysis
Using the Latin Hypercube Sampling (LHS) technique, we investigate and
quantify the uncertainties and sensitivity of the response of the model system
3.2.3, to a range of 1000 samples each of varying input parameter values, as de-
scribed in Table 3.4. To excute this, we observe the response ofR0 to the varia-
tion of the predictors (input model parameters). The LHS is a stratified Monte
Carlo sampling scheme, which is efficient for simultaneously obtaining unprej-
udiced sampling of all predictors, in a multi-dimensional parameter space, for
the purpose of executing an uncertainty analysis [76; 77]. Uncertainty analysis
is a method that can be used to evaluate the variability (prediction impre-
cision) in the response (R0 of our model system), which is a consequence of
the uncertainty in estimating our predictor variables. Sensitivity analysis is
a method that can extend an uncertainty analysis, by demonstrating which
predictors makes important contribution to the prediction imprecision of the
response, and consequently, the model system [76; 77].
Sensitivity analysis can be performed by calculating the Partial Rank Cor-
relation Coefficients (PRCCs) for each predictor obtained by LHS, and the
response variable, in order to rank the input parameters with respect to their
contribution to the uncertainty of the response variable. The use of PRCCs
aids the assessment of the statistical relationship between the predictors and
response(s), as it demonstrates the degree of monotonicity between particular
predictors and outcome [76; 77]. The sign of the PRCC of an input parameter
depicts the particular kind of qualitative affiliation it has with the outcome
variable. When a predictor has a positive PRCC value, it simply implies that
when it is increased, the outcome variable will increase and when it is de-
creased, the outcome variable will also decrease. Input parameter values that
have the largest (absolutely) valued (either being originally positive or nega-
tive) PRCCs are the parameters in which the uncertainty in estimating them
are most critical, in affecting the variability of the outcome variable [77].
In this model, the used data was not analysed for statistical independency of
its input parameters, hence, we must report that this model is being used as
a thought experiment to examine the independent effects of each predictor on
the response (R0) of the HIV infection) [77]. The input parameters may be
interdependent, however, the independent effects of the input parameters on
the response is very paramount in this analysis as it determines how impor-
tant the uncertainty in estimating each input parameters is, in contribution
to the variability of the response. PRCC measures this independent effects,
irrespective of whether any correlations exist between any of the input pa-
rameters [77]. In this analysis, PRCC was used to distinguish and measure
this statistical influence, importantly the monotonicity of the predictors on
the response. We must note that if the model’s input parameters are statis-
tically independent, the LHS would consequently use a marginal distribution,
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which will ensure that our uncertainty analysis’ outcome will not competently
exhibit the prediction imprecision of the model. To conduct sensitivity and un-
certainty analysis on our model, the sampling and sensitivity analysis methods
used in SaSAT (Sampling and Sensitivity Analysis Tools) were implemented
[76]. It is worthy of note that if there is colinearity between the input param-
eters, the robustness of the model results may not be compromised because
the sampling and sensitivity analysis methods used in SaSAT [76] incorporate
statistical dependencies (see [76–79]).
Figure 3.6 is the tornado plot of the PRCC of all the predictors of our model
system as described in Table 3.4. It connotes the importance of the uncertainty
of individual predictor, with respect to their contribution to the variability in
the basic reproduction number R0 of the HIV infection, as described by the
model system 3.2.3. Tornado plots are used for illustrating the results of
sensitivity analysis [76]. Input parameter with positive PRCCs are depicted
by bar plots to the right, and with positive calibration on the horizontal axis,
while input parameter with negative PRCCs are depicted by bar plots to the
left, and with negative calibration on the horizontal axis. In order to evaluate
the monotonicity between chosen predictors, those with high (absolute) value
of PRCC, and the response R0, we plot the scatter plot of their PRCCs, and
examine the plot. For our analysis, we displayed predictors with significant
monotonic (statistical) relationship with the response R0; those whose varying
PRCCs are either monotone increasing or decreasing.
Figures 3.3 and 3.4 display the Monte Carlo simulations of a range of 1000
samples for three input parameters with the highest absolute PRCC values.
Figure 3.3 is the scatter plot of the natural mortality rate µ, in relation to R0.
It depicts that R0 is monotone decreasing with an increasing natural mortality
rate µ. µ has the strongest correlation with R0. Figure 3.4 is the scatter plot
of , in relation to R0. It shows that R0 is monotone increasing with increasing
values of the effective contact rate of HIV for susceptible individuals, β1. It
implies that if the effective contact rate, which breeds the transmission of HIV
infection between susceptibles and HIV infecteds, is drastically reduced, HIV
infection will go into extinction.
Figure 3.5 is the boxplot of R0, which graphically depicts some of its statistical
measures, such as its median. The boxplot shows that the overall median of
R0 > 1. This suggets that the current epidemic of the incidence of cancers in
HIV-infected individuals may not always be restrained or eradicated.
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Figure 3.3: Scatter plot of the natural mortality rate, µ, in relation to R0.
Figure 3.4: Scatter plot of the effective contact rate of HIV for susceptible individ-
uals, β1, in relation to R0.
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Figure 3.5: Boxplot of R0.
Figure 3.6: Tornado plot of the PRCC of the input parameters of our model system
as described in Table 3.4
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3.5.3 Results
We now exhibit the general dynamics of lymphoma (representing all HIV-
related malignancies) in the HIV-infected and HIV-free population, using the
fit of our model to the TLSG data. Fig. 3.7 is a graphical representation that
shows the yearly incidence of lymphoma in individuals who are not infected
with HIV from 2002-2012. It depicts that the incidence of lymphoma cases
in HIV-negative patients increased significantly between 2002 and 2006, after
which it increases only slightly significantly. The relatively low (declining)
incidence of lymphoma in 2004 and 2005 as shown by the actual data, could
be attributed to inadequate access to lymphoma data (in those years) by the
TLSG.
Fig. 3.8 shows that the incidence of lymphoma cases in patients co-infected
with lymphoma and HIV steadily increased from 2002-2012. The decrease in
its incidence between 2004 and 2005, is also attributed to the lack of sufficient
access to data by the TLSG. Fig. 3.9 demonstrates that the cummulative
incidence of all lymphoma cases steadily increased from 2002-2006, after which
the incidence slowly increases.
Figure 3.7: Incidence of lymphoma-only cases
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Figure 3.8: Incidence of lymphoma in HIV-infected individuals
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Figure 3.9: Incidence of lymphoma in both HIV-infected and HIV-negative indi-
viduals (Total Lymphoma Cases = IL + ILH , as shown in Table 3.3)
Our model can be used as a predictive tool. We can thus make projection on
the future of the epidemic, assuming that the status quo remains the same,
that is, no policy shift occurs, human behaviour remains constant, etc. Fig.
3.10 depicts the projected changes in the incidence of lymphoma only cases,
up to year 2020. It shows that the incidence will continue to increase if the
current status quo (every factor affecting the development of lymphoma, such
as environmental hazards, immunocompression, old age, iatrogenic causes, etc)
remains the same. Fig. 3.11 depicts the projected changes in the incidence of
lymphoma in HIV-infected patients, up till 2020. It shows that the number of
cases will continue to rise, though not exponentially. Fig. 3.12 demonstrates
projected change in the incidence of all lymphoma cases, up to year 2020. It
also predicts an increase in lymphoma cases.
Note that the fact that there are some treatments incorporated into the model,
such as the HAART regimen, and other lymphoma treatment, does not neces-
sarily cause a decline in the incidence of lymphoma in HIV-infected individuals.
This is because our model flow allows individuals under treament to be infec-
tious, which is biologically relevant. Also, lymphoma-only patients, who have
been treated are also allowed to have relapses with some probability (as de-
picted by some of the model’s parameter values). In addition, since HAART,
HIV-infected patients live longer, and the incidence infection is still on the rise.
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 3. HIV-RELATED LYMPHOMA MODEL 64
Figure 3.10: A Projection of the incidence of lymphoma-only cases
Hence, the pool of individuals with HIV, and that are developing lymphoma
(as a consequence of immune suppression and dysfunction) are also on the rise.
The effective coverage of HAART, as at 2011, in the Western Cape province
of South Africa, is about 31% [27]. In order to estimate the effect of increasing
the effective coverage of HAART, as an intervention strategy in controlling the
incidence of lymphoma in HIV-infected individuals, we consider scenarios in
which the effective HAART coverage of all HIV-patients eligible for HAART
is 30%, and increases to 60%, 80% and 100%. One reason for this is because
several studies (as reviewed in Chapter 2) have reported that HAART use may
alter or even correct the development of some lymphoma subtypes (and some
other HIV-related malignancies). Using projections, Fig. 3.13 depicts the four
scenarios generated for the incidence of lymphoma in patients co-infected with
HIV and lymphoma. Fig. 3.14 depicts the four scenarios generated for the
incidence of all lymphoma cases.
To effectively discuss the observed pattern in Figures 3.13 and 3.14, we show
only the projected parts of the graphs. In Fig. 3.15 and Fig. 3.16, we magnify
the scenarios in Figures 3.13 and 3.14 respectively, in order to see the effect
of the four scenarios closely. For instance, the ‘60% HAART Coverage’ in Fig.
3.15 shows that about a 30% projected increase in the effective delivery of
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Figure 3.11: A Projection of the incidence of lymphoma in HIV-infected individuals
antiretroviral drugs to those eligible for them by 2014, will cause a 5% decline
in the incidence of lymphoma (in HIV-infectives) by the year 2020. The two
other scenarios (80% and 100% effective HAART delivery) even show a more
significant projected derease in the incidence of lymphoma, with the 100% ef-
fective HAART coverage predicting a more rapid decline of about 8% in the
incidence of lymphoma (in HIV-infectives) by 2020. In like manner, interpre-
tation of the scenario illustrated by Fig. 3.16, which is for all lymphoma cases,
can also be made.
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Figure 3.12: A Projection of the incidence of lymphoma in both HIV-infected and
HIV-negative individuals (Total Lymphoma Cases = IL + ILH , as shown in Table
3.3)
3.5.4 Discussion
In this study, we present a mathematical model that explains the dynamics
of HIV-related malignancies, with a closer look at the incidence of lymphoma
in the Western Cape province of South Africa. We analysed the model qual-
itatively using its reproduction number R0. The model has an HIV-free lym-
phoma steady state which is locally stable when R0 < 1 and globally stable
when R0 < Rc0 < 1, where Rc0 is the critical R0. When R0 < 1, the model
has multiple endemic equilibria, which makes it to exhibit a backward bifurca-
tion, and it has at least one endemic equilibrium when R0 > 1. We observed
that when R0 < Rc0 < 1, HIV can be eradicated from the population under
study. If HIV is eradicated from the population, then the incidence of the
development of lymphoma in HIV patients is drastically reduced, and perhaps
eradicated too.
We performed numerical simulations for the model. We fitted the model to
lymphoma data, with the aim of making use of the model parameters that
gives the best fit of our model to the data, in order to obtain lymphoma inci-
dence curves. In order to determine which parameters have the most signifi-
cant impact on the prediction imprecision of our model’s R0, and to evaluate
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Figure 3.13: A scenario analysis of the incidence of lymphoma, for four different
effective HAART coverage of HIV-infected individuals who has lymphoma (ILH).
Figure 3.14: A diagrammatic illustration of the incidence of all lymphoma cases
(Total Lymphoma Cases = IL + ILH , as shown in Table 3.3), for four different
effective HAART coverage of HIV-infected individuals who has lymphoma.
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Figure 3.15: A magnified scenario analysis of the incidence of lymphoma, for four
different effective HAART coverage of HIV-infected individuals who has lymphoma
(ILH).
the variability in R0 as those parameters varies, we carried out a sensitivity
analysis using the Latin Hypercube Sampling (LHS) technique. This analysis
demonstrates that the two parameters which are of the greatest impact on R0
are µ, the natural mortality rate (most negatively sensitive to R0), and β1,
the effective contact rate of HIV for susceptible individuals (most positively
sensitive to R0). An increase in β1 increases the value of R0. This suggests
that some social intervention programs, beside HAART roll-out can be used to
control the epidemic. Such programs may include increasing of the awareness
of the public and educational campaigns on HIV and its significant relation to
the development of malignant tumours, which even often times kills faster and
in a shorter time than the HIV infection alone.
Since our model can be used as a predictive tool, we did a projection of the
incidences of lymphoma in four scenarios. The scenario analysis present some
probable trends the epidemic will take from 2014-2020, based on different
percentage increase in the roll-out and uptake of effective of HAART coverage
(as an intervention strategy) in the Western Cape province of South Africa.
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 3. HIV-RELATED LYMPHOMA MODEL 69
Figure 3.16: A magnified diagrammatic illustration of the incidence of all lym-
phoma cases (Total Lymphoma Cases = IL + ILH , as shown in Table 3.3), for four
different effective HAART coverage of HIV-infected individuals who has lymphoma.
In 2011, the effective HAART coverage of the Western Cape province of South
Africa was about 31% [27]. We discovered that an increase in the roll-out and
effective use of HAART has a significant effect on the future of the epidemic,
as a steady decline was observed in the incidence of lymphoma in HIV-infected
individuals, which in turn caused a decline in the total lymphoma incidence. A
30% increase (that is a 60% effective HAART coverage) in the current roll-out
of HAART in 2014 will cause a 5% decrease in the incidence of HRL by 2020,
while a 70% increase will cause an 8% decrease in the incidence of HRL by
2020.
Furthermore, in the validation of this model, we had much predictors in com-
parison with the number of data points fitted. Despite the fact that we have
done some statistical analysis on the basic reproduction number of the model,
we must note that our efforts to ensure that the complex model explain the
peculiarities of the limited lymphoma data fitted could result in overfitting.
However, overfitting has been mitigated to a certain degree by the parameter
sensitivity test. We may not be able to excuse the lymphoma data used from
having some noise and/or slight inaccuracies, thus, it could have imposed some
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errors (perhaps very little) on our model results, and thus (slightly) reduce the
strength of the future demographic predictions presented in the model results.
In conclusions, it is pertinent to note that an age structured population model
could have been appropriate for this population growth process. However,
considering the complexity of the model, splitting the population into several
age divisions will only complicate the model more and make its analysis un-
feasible. Nevertheless, we must also note that tracking the population with
respect to age may facilitate the incorporation of some crucial attributes of the
growth process being modelled, which will in turn make the model more realis-
tic. It may also make the model one that better explores future demographics
[80; 81].
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Chapter 4
CD4 Cell Count Driven
HIV-Lymphoma Model
4.1 Introduction
The viral load of an HIV infected individual’s body is often a predictor of how
badly damaged the immune system is. It is expected that the lower the viral
load, the lower the effectiveness of the HIV in depleting the immune system
of the body, and thus, the lower the chances of developing any HIV-related
cancer. Sathekge et al. [82] showed that there is an inverse correlation between
the CD4 cell count and the viral load (also see [83]). This suggests that in
order to decrease the viramea of an HIV infected individual, it may suffice to
lower the viral load to an undetectable level, which in turn boosts the immune
system and as a consequence increases the CD4 cell count.
Reports have shown that there may not be complete immune reconstitution if
HAART is commenced when a patient’s CD4 cell count is highly depreciated
[49]. A close relationship between a low CD4 cell count and the risk of death
has been established [84]. A study by Guiguet et al [85] reports that the
most predictive risk factor for all cancers, with anal cancer as an exception,
is a patient’s CD4 cell count. They also reported that despite the fact that
many of their patients were under combination antiretroviral therapy (cART),
their patients’ immunodeficiency prior to treatment was a great determinant
of their immunological recovery. Patients most at risk of death were those
with CD4 cell count of < 200 cells /µL. Consequently, we look at the HIV
and lymphoma scenario with a special consideration for the categorisation of
individuals with respect to their CD4 cell counts.
The aim of the study in this chapter is to examine the dynamic of the incidence
of lymphoma in HIV patients, with respect to their CD4 cell counts. We
investigate factors that the CD4 cell count level of an HIV patient affects,
71
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and by how much it affects them. Such factors include the rate at which
the patients will be treated for lymphoma and HIV, and the rate at which
lymphoma develops in HIV patients. We also see how the CD4 cell count of
patients infected with HIV, and of those who have developed lymphoma after
HIV infection, affects the number of days they spend in the hospital. This
implies that factors that can be influenced, in order to increase the number
of HIV infected patients with high CD4 cell counts > 350 cells/µL, and thus
cause a decline in the number of HIV infected patients with low CD4 cell
counts < 350 cells/µL should be investigated.
The number of days a patient spends in the hospital and the patient’s particu-
lar condition are some of the determinants of the cost of treating a patient. A
South African study by Badri et al. [86] shows that patients with an increased
severity of the HIV infection (AIDS patients) incur a more expensive hospital
treatment cost in comparison with their more immunocompetent counterparts.
This, they report, is likely related to AIDS-related conditions. They also report
that the use of HAART is a very cost-effective intervention in the management
of the HIV in the South African population, and perhaps in other sub-Saharan
African populations. It is expedient that we conduct this study as it can affect
governmental health policies, as to whether it is more cost effective to treat
HIV infected patients at an earlier stage (with higher CD4 cell counts) than
that which the current national policy has. An example is the national policy
in South Africa, which only allows patients to be treated antiretrovirally when
their CD4 cell count is < 350 cells/µL [87; 88]. It also shows how the CD4
cell count of HIV infected individuals affects the number of reported cases of
lymphoma incidence, especially in the Western Cape of South Africa, which is
our population of study.
4.2 Model Formulation
We construct a mathematical model that describes the different stages in which
individuals are and can progress into, giving particular attention to individuals
who are HIV infected, irrespective of whether they have developed lymphoma
or not, or whether they are in any kind of treatment or not. We do this by
classifying them into different categories with respect to their CD4 cell counts
(and invariably their viral load). We classified every HIV infected patient’s
CD4 cell counts into three categories viz; patients with CD4 cell count > 350
cells/µL (which we call the class one (1) individuals), patients with CD4 cell
counts that are within the closed set [200, 350] cells/µL (which we call the
class two (2) individuals), and patients with CD4 cell count < 200 cells/µL
(which we call the class three (3) individuals). This model conceptualises and
clearly exhibits the feasible scenario that can be seen in an HIV and lymphoma
co-infection setting.
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We consider a population N(t), at time t, with ages ranging between 15 and
80 years, which we refer to as adult population. This is because lymphoma
cases are much more predominant in the adult population than in the children
population, with ages ranging between 0−14 years. We also consider an adult
population because HIV is more predominant among the sexually active pop-
ulation whose ages ranges from 15−49 years, and because HIV and lymphoma
co-infection occurs mostly in both the sexually active population and the aging
population.
We subdivide this adult population N(t), into ten distinct population classes,
putting their infection and treatment stages into consideration. The model
assumes a heterogenous mixing of individuals within the same compartment,
but a homogenous mixing of individuals between non-intersecting classes. This
implies that each susceptible individual is assumed to have an equal chance
of being infected by an infectious individual (i.e. population mixes homoge-
nously). The model also assumes that relapse after lymphoma treatment is
negligible, which implies that individuals move out of the lymphoma-related
classes with some probability after they must have been treated for their lym-
phoma subtypes. In addition, in order not to complicate the already complex
model, the class of individuals infected with HIV only (IH) was not categorised
into different CD4 cell count classes.
The compartments the model is subdivided into include; the susceptible popu-
lation S(t), which comprises of individuals that are predisposed to contracting
HIV and developing lymphoma (every individual introduced into the popula-
tion is assumed to be susceptible), lymphoma patients IL(t), HIV-infected pa-
tients IH(t), HIV-infected patients who are under a HAART regimen IHT (t),
(who will be referred to as HIV-positive patients under antiretroviral regi-
men(s)), patients co-infected with both HIV and lymphoma, and classified
into either of classes one, two, or three, which we denote by IaLH , IbLH , IcLH
respectively, and patients co-infected with both HIV and lymphoma, under
some antiretroviral regimen, and classified into either of classes one, two, or
three, which we denote by IaLHT , IbLHT and IcLHT respectively. The total adult
population is thus given by
N = S + IL + IH + IHT + I
a
LH + I
b
LH + I
c
LH + I
a
LHT + I
b
LHT + I
c
LHT . (4.2.1)
The recruitment of individuals into the class of susceptibles is proportional to
the population, thus, the recruitment rate K is given by bN , where b is the
crude birth rate (this differs from the superscript b). We thus let K = bN0,
where N0 is the initial total population size. The mean lifetime of an individual
is estimated as 1/µ, where µ is the natural mortality rate, which is common
to all the compartments. The (HIV) disease-related death rates are given
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by δ1 and δ2. The lymphoma development rate of susceptibles (which are
generally HIV-negative individuals) is α1. This model has 2 non-intersecting
classes described as being susceptible to HIV infection. They are the S and IL
compartments. The model assumes a non-linear standard incidence function.
The force of infection for class S, is λ1, while the force of infection for class
IL is λ2. We assume different forces of infection for these two groups because
individuals in class S are assumed to be more immunocompetent than those
in IL, as the latter has a compromised immune system. The forces of infection
λi, i = 1, 2, are given by:
λi =
βi
N
[IH+η1(I
a
LH+I
b
LH)+η2(I
c
LH+I
c
LHT )+η3(I
a
LHT+I
b
LHT )+η4IHT ], (4.2.2)
provided λi(t) is redefined at the -neighbourhood of N = 0, for it to be fi-
nite at t = 0 and biologically plausible. β1 and β2 are the effective contact
rates of HIV for susceptible individuals, and for lymphoma patients respec-
tively. βi is a product of the number of contacts, effective or not, per unit
time and the risk of infection (or probability that an infection will occur),
also called transmission risk, given contact between a susceptible and an in-
fectious individual. ηi, i = 1, 2, 3, 4, are the modification parameters (or ad-
justment factors), which measures the relative infectiousness of individuals in
IHT , I
a
LH , I
b
LH , I
c
LH , I
a
LHT , I
b
LHT and IcLHT to the infectiousness of those in IH .
Individuals with high viral loads (either in the acute infection stage; window
period, or at the end-stage disease) are highly infectious [54]. Thus, the like-
lihood of HIV-infecteds to be infectious is directly proportional to their viral
loads [55]. Hence, we consider 1 ≤ ηi ≤ 2, for all i ∈ {1, 2, 3, 4}.
Since the CD4 cell count is inversely proportional to the viral load of an HIV
infected patient, then, the model reasonably assumes that patients with lower
CD4 cell counts have higher viremia and thus a higher infectiousness than
other HIV infected individuals with higher CD4 cell counts, who consequently
have lower viremia and thus a lower infectiousness. As a result of this, we
made additional feasible assumptions. Individuals co-infected with HIV and
lymphoma, and in either of classes one or two, are assumed to have more
viremia (they are neither treated for HIV or lymphoma) than individuals co-
infected with HIV and lymphoma who are also in either of class one or two,
but on antiretroviral treatment for HIV. Thus, η1 > η4, and η4.
Similarly, we assumed that η3 > η4, since patients co-infected with HIV and
lymphoma, in classes one or two, and under antiretroviral treatment are as-
sumed to be more immunocompromised than individuals who are infected
with HIV alone, and under some antiretroviral treatment. Furthermore, indi-
viduals co-infected with HIV and lymphoma and in class three (whether on
antiretroviral treatment or not) are considered the most immunocompromised
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 4. CD4 CELL COUNT DRIVEN HIV-LYMPHOMA MODEL 75
individuals of all the classes (they have the highest level of viremia), for which
reason they are assumed to be the most infectious of all the classes. Thus,
η2 > 1, η1, η3, and η4. Outlined in Table 4.1 are the descriptions and symbols
of state variables used in the model. Table 4.2 also outlines other epidemio-
logical parameters, with their symbols and descriptions.
The schematic flow of individuals between the ten compartments is illustrated
by the model diagram shown in Figure 4.1.
S
IL ILH I I
II
I
I
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LH LH
LHT LHT LHT
IH
( µ+ 2+ τδ 5 )
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Figure 4.1: Diagrammatic structure of the HIV-Lymphoma cum CD4 cell count
driven model system
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Variables Description
S Susceptible individuals
IL Lymphoma patients
IH HIV-positive patients
IHT HIV-positive patients under antiretroviral regimen(s)
IaLH Patients with both HIV and lymphoma and whose CD4 cell count
is > 350 cells/µL
IbLH Patients with both HIV and lymphoma and whose CD4 cell count
ranges between [200, 350] cells/µL
IcLH Patients with both HIV and lymphoma and whose CD4 cell count
is < 200 cells/µL
IaLHT Patients with both HIV and lymphoma, under antiretroviral regimen(s),
and with CD4 cell count that is > 350 cells/µL
IbLHT Patients with both HIV and lymphoma, under antiretroviral regimen(s),
and with CD4 cell count that ranges between [200, 350] cells/µL
IcLHT Patients with both HIV and lymphoma, under antiretroviral regimen(s),
and with CD4 cell count that is < 200 cells/µL
N Total size of (adult) population
Table 4.1: Symbols and description of the variables used in the model
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Parameters Description
K Recruitment rate for susceptibles
µ Natural mortality rate
δ1 Disease and low CD4 cell count induced mortality rate
(for individuals in class IcLH)
δ2 Disease and low CD4 cell count induced mortality rate
(for individuals in class IcLHT )
λ1 Force of (HIV) infection of susceptible individuals
λ2 Force of (HIV) infection of lymphoma patients
β1 Effective contact rate of HIV for susceptible individuals
β2 Effective contact rate of HIV for lymphoma patients
α1 Lymphoma development rate of susceptible individuals
α2 Lymphoma development rate of HIV-positive patients
(into class IaLH)
α3 Lymphoma development rate of HIV-positive patients
under antiretroviral regimen(s) (into class IaLHT )
α4 Lymphoma development rate of HIV-positive patients
under antiretroviral regimen(s) (into class IbLHT )
α5 Lymphoma development rate of HIV-positive patients
under antiretroviral regimen(s) (into class IcLHT )
σ1 HIV treatment rate of lymphoma-free HIV patients
σ2 HIV treatment rate of patients with lymphoma and HIV
and in class IaLH
σ3 HIV treatment rate of patients with lymphoma and HIV
and in class IbLH
σ4 HIV treatment rate of patients with lymphoma and HIV
and in class IcLH
τ1 Lymphoma treatment rate of lymphoma-only patients
τ2 Lymphoma treatment rate of patients with lymphoma
and HIV and in either class IaLH or IbLH
τ3 Lymphoma treatment rate of patients with lymphoma
and HIV and in class IcLH
τ4 Lymphoma treatment rate of patients with lymphoma, HIV,
under antiretroviral regimen(s) and in class IaLHT or IbLHT
τ5 Lymphoma treatment rate of patients with lymphoma, HIV,
under antiretroviral regimen(s) and in class IcLHT
γ1 CD4 cell count declination rate (rate of immune system
deteroriation) of individuals in class IaLH
γ2 CD4 cell count declination rate (rate of immune system
deteroriation) of individuals in class IbLH
ρ1 CD4 cell count upswing rate (rate of immune system
amelioration) of individuals in class IcLHT
ρ2 CD4 cell count upswing rate (rate of immune system
amelioration) of individuals in class IbLHT
Table 4.2: Symbols and description of the parameters used in the model
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4.2.1 Model Equations
The dynamical system described by the schematic diagram , Figure 4.1, our
assumptions and parameters’ description, is given by the following system of
ordinary differential equations:
dS
dt
= K − λ1S − (µ+ α1)S, (4.2.3a)
dIL
dt
= α1S − λ2IL − (µ+ τ1)IL, (4.2.3b)
dIH
dt
= λ1S − (µ+ σ1 + α2)IH , (4.2.3c)
dIHT
dt
= σ1IH − (µ+ α3 + α4 + α5)IHT , (4.2.3d)
dIaLH
dt
= λ2IL + α2IH − (µ+ τ2 + σ2 + γ1)IaLH , (4.2.3e)
dIbLH
dt
= γ1I
a
LH − (µ+ τ2 + σ3 + γ2)IbLH , (4.2.3f)
dIcLH
dt
= γ2I
b
LH − (µ+ δ1 + τ3 + σ4)IcLH , (4.2.3g)
dIaLHT
dt
= σ2I
a
LH + α3IHT + ρ2I
b
LHT − (µ+ τ4)IaLHT , (4.2.3h)
dIbLHT
dt
= σ3I
b
LH + α4IHT + ρ1I
c
LHT − (µ+ τ4 + ρ2)IbLHT (4.2.3i)
dIcLHT
dt
= σ4I
c
LH + α5IHT − (µ+ δ2 + τ5 + ρ1)IcLHT , (4.2.3j)
with initial conditions of the model system given by S(0) = S0, IL(0) =
IL0, IH(0) = IH0, I
a
LH(0) = (I
a
LH)0, I
b
LH(0) = (I
b
LH)0, I
c
LH(0) = (I
c
LH)0,IaLHT (0) =
(IaLHT )0,IbLHT (0) = (IbLHT )0 and IcLHT (0) = (IcLHT )0, all positive constants.
4.3 Basic Properties of the Model
4.3.1 Invariant Region
The model system (4.2.3) studies human population variations under certain
conditions of biological and mathematical interest. State variables and pa-
rameters are thereby assumed to be positive, since their negativity makes no
biological sense. We analyse the model system (4.2.3) in an apposite biologi-
cally feasible region Ω. We show that the system is dissipative, in that every
viable solution is uniformly bounded in a proper subset Ω of R10+ . Hence the
following lemma.
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Lemma 4.3.1. The biologically feasible region Ω defined by the compact set:
Ω = {(S, IL, IH , IHT , IaLH , IbLH , IcLH , IaLHT , IbLHT , IcLHT ) ∈ R10+ : N ≤
K
µ
}
with initial conditions S(0), IL(0), IH(0), IHT (0), IaLH(0), IbLH(0), IcLH(0), IaLHT (0),
IbLHT (0), I
c
LHT (0) > 0, is positively invariant and attracting with respect to the
model system (4.2.3) for all t > 0.
Proof. We sum up the equations of the model (4.2.3), and the total adult
population N(t) is time variable with
dN
dt
= K − µN − τ1IL − τ2IaLH − τ2IbLH − (δ1 + τ3)IcLH − τ4IaLHT − τ4IbLHT
− (δ2 + τ5)IcLHT ,
≤ K − µN,
=⇒ dN
dt
+ µN ≤ K.
(4.3.1)
Using the integrating factor e
∫
µdt,
equation (4.3.1) becomes
d(Neµt)
dt
≤ Ke
∫
µdt (integrate both sides),
=⇒ Neµt ≤ K
µ
eµt + C,
=⇒ N(t) ≤ K
µ
+ Ce−µt.
(4.3.2)
When t = 0, N(0) = N0 (the sum of all the initial values of the state variables
of the model), we obtain
C = N0 − K
µ
.
=⇒ N(t) ≤ K
µ
+ (N0 − K
µ
)e−µt,
= N0e
−µt +
K
µ
(1− e−µt).
(4.3.3)
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 4. CD4 CELL COUNT DRIVEN HIV-LYMPHOMA MODEL 80
As t −→∞, we have: lim supt→∞N(t) ≤
K
µ
.
Whenever N(0) ≤ K
µ
,
N(t) ≤ N0e−µt + K
µ
(1− e−µt),
=⇒ N(t) ≤ K
µ
.
(4.3.4)
Hence, every solution N(t) of equation (4.3.1) satisfies the relation below;
0 ≤ N(t) ≤ N0e−µt + K
µ
(1− e−µt), (4.3.5)
where N0 is the sum of all the initial conditions of the variables of the model
system.
Whenever N0 ≤ Kµ , positive solutions of equation (4.3.1) are increasingly
monotonically and are bounded above by K
µ
. On the other hand, whenever
N0 >
K
µ
, non-negative solutions of equation (4.3.1) are monotone decreasing
and bounded below by K
µ
. Nevertheless, in both cases, at limiting equilibrium,
limt→∞N(t) = Kµ .
Consequently, any solution
S(t), IL(t), IH(t), IHT (t), I
a
LH(t), I
b
LH(t), I
c
LH(t), I
a
LHT (t), I
b
LHT (t), I
c
LHT (t),
at t ≥ 0, of (4.2.3) that starts in the positive orthant R10+ , either remains
confined in, enters or asymptotically approaches Ω. Therefore, the region Ω
is positively invariant and attracting with respect to the flow incited by the
model system (4.2.3). This completes the proof.
Hence, in Ω, the model (4.2.3) is mathematically and epidemiologically well-
posed. Thus, it is sufficient to study the dynamics of the flow induced by the
model system (4.2.3) in Ω.
4.3.2 Positivity of Solutions
It is salient we prove that all the state variables of the model system (4.2.3)
remain non-negative for all time t > 0. This is to certify that the model
system is biologically meaningful, and to ensure that solutions of the system,
when subjected to positive initial conditions, will remain positive for all t > 0.
Hence the following lemma.
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Lemma 4.3.2. Given that the initial values of the state variables of the model
system (4.2.3) are non-negative, the model equations (4.2.3a) - (4.2.3j) preserve
positivity of solutions for all time t > 0.
Proof. Assume that
tˆ = sup{t > 0 : S, IL, IH , IHT , IaLH , IbLH , IcLH , IaLHT , IbLHT , IcLHT > 0} ∈ [0, t]
From equation (4.2.3a),
dS
dt
= K − (λ1 + µ+ α1)S,
dS
dt
+ (λ1 + µ+ α1)S = K.
(4.3.6)
Using the method of integrating factor (IF) for solving first order ordinary
differential equations (ODE), where
IF = e
∫ t
0 (µ+α1+λ1(ω)) dω = e[(µ+α1)t+
∫ t
0 λ1(ω)) dω],
is a suitable IF.
Equation (4.3.6) becomes
d
dt
[
S(t)e[(µ+α1)t+
∫ t
0 λ1(ω)) dω]
]
= Ke[(µ+α1)t+
∫ t
0 λ1(ω)) dω]
=⇒
∫ S(tˆ)
S(0)
d
[
S(t)e[(µ+α1)t+
∫ t
0 λ1(ω)) dω]
]
= K
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt
(4.3.7)
=⇒ S(tˆ) = e−[(µ+α1)tˆ+
∫ tˆ
0 λ1(ω)) dω]
[
S(0) +K
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt
]
S(tˆ) ≥ e−[(µ+α1)tˆ+
∫ tˆ
0 λ1(ω)) dω]
∫ tˆ
0
e[(µ+α1)t+
∫ t
0 λ1(ω)) dω] dt
S(tˆ) > 0, ∀ tˆ > 0.
(4.3.8)
From equation (4.2.3b),
dIL
dt
= α1S − (λ2(t) + τ1 + µ)IL,
≥ −(λ2(t) + τ1 + µ)IL,
=⇒ dIL
dt
+ (λ2(t) + τ1 + µ)IL ≥ 0.
(4.3.9)
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Using the IF given by
IF = e
∫ t
0 [(µ+τ1)+λ2(ω)] dω] = e[(µ+τ1)t+
∫ t
0 λ2(ω) dω],
equation (4.3.9) becomes
∫ IL(tˆ)
IL(0)
d
[
IL(t)e
[(µ+τ1)t+
∫ t
0 λ2(ω) dω]
]
≥ 0,
=⇒ IL(tˆ)e[(µ+τ1)tˆ+
∫ tˆ
0 λ2(ω) dω] ≥ IL(0),
=⇒ IL(tˆ) ≥ IL(0)
(
e−[(µ+τ1)tˆ+
∫ tˆ
0 λ2(ω) dω]
)
,
=⇒ IL(tˆ) > 0 ∀ tˆ > 0.
(4.3.10)
From equation (4.2.3c),
dIH
dt
≥ (µ+ σ1 + α2)IH ,
⇒
∫ IH(tˆ)
IH(0)
≥
∫ tˆ
0
−(µ+ σ1 + α2)dt,
⇒ ln
(
IH(tˆ)
IH(0)
)
≥ −(µ+ σ1 + α2)tˆ,
⇒ IH(tˆ) ≥ IH(0)e−(µ+σ1+α2)tˆ.
Hence, IH(tˆ) > 0, ∀ tˆ > 0.
(4.3.11)
From equation (4.2.3d),
dIHT
dt
≥ (µ+ α3 + α4 + α5)IHT ,
⇒
∫ IHT (tˆ)
IHT (0)
≥
∫ tˆ
0
−(µ+ α3 + α4 + α5)dt,
⇒ ln
(
IHT (tˆ)
IHT (0)
)
≥ −(µ+ α3 + α4 + α5)tˆ,
⇒ IHT (tˆ) ≥ IHT (0)e−(µ+α3+α4+α5)tˆ.
Hence, IHT (tˆ) > 0, ∀ tˆ > 0.
(4.3.12)
Similarly, from equation (4.2.3e),
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 4. CD4 CELL COUNT DRIVEN HIV-LYMPHOMA MODEL 83
dIaLH
dt
≥ (µ+ τ2 + γ1 + σ2)IaLH ,
⇒ IaLH(tˆ) ≥ IaLH(0)e−(µ+τ2+γ1+σ2)tˆ.
Hence, IaLH(tˆ) > 0, ∀ tˆ > 0.
(4.3.13)
From equation (4.2.3f),
dIbLH
dt
≥ (µ+ τ2 + γ2 + σ3)IbLH ,
⇒ IbLH(tˆ) ≥ IbLH(0)e−(µ+τ2+γ2+σ3)tˆ.
Hence, IbLH(tˆ) > 0, ∀ tˆ > 0.
(4.3.14)
From equation (4.2.3g),
dIcLH
dt
≥ (µ+ δ1 + τ3 + σ4)IcLH ,
⇒ IcLH(tˆ) ≥ IcLH(0)e−(µ+δ1+τ3+σ4)tˆ.
Hence, IcLH(tˆ) > 0, ∀ tˆ > 0.
(4.3.15)
From equation (4.2.3h),
dIaLHT
dt
≥ (µ+ τ4)IaLHT ,
⇒ IaLHT (tˆ) ≥ IaLHT (0)e−(µ+τ4)tˆ.
Hence, IaLHT (tˆ) > 0, ∀ tˆ > 0.
(4.3.16)
From equation (4.2.3i),
dIbLHT
dt
≥ (µ+ τ4 + ρ2)IbLHT ,
⇒ IbLHT (tˆ) ≥ IbLHT (0)e−(µ+τ4+ρ2)tˆ.
Hence, IbLHT (tˆ) > 0, ∀ tˆ > 0.
(4.3.17)
From equation (4.2.3j),
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dIcLHT
dt
≥ (µ+ δ2 + τ5 + ρ1)IcLHT ,
⇒ IcLHT (tˆ) ≥ IcLHT (0)e−(µ+δ2+τ5+ρ1)tˆ.
Hence, IcLHT (tˆ) > 0, ∀ tˆ > 0.
(4.3.18)
Thus, equations (4.3.8)-(4.3.18) shows that every solution of the state variables
of model system (4.2.3) will always be positive for all non-negative initial
conditions, at any time tˆ > 0. This completes the proof.
4.3.3 Existence and Uniqueness of Solutions
Theorem 4.3.3. Solutions of the model system (4.2.3) exists, and is unique
in Ω, for all time t > 0, and for every non-negative and non-zero initial values
of the state variables of the model.
Proof. Since the right hand side of the model system (4.2.3) is locally Lipschitz
continuous, then local existence and uniqueness of solutions is ascertained.
4.4 Equilibria Analysis of the Model
In this section, analytic results of the model system (4.2.3) are displayed.
We analyse the system by finding the model equilibria and investigate their
stability analyses using the basic reproduction number Rˆ0.
4.4.1 CD4-HIV-free Lymphoma Steady State (CHLSS)
In the absence of the HIV in our model system, that is, setting IH = IHT =
IaLH = I
b
LH = I
c
LH = I
a
LHT = I
b
LHT = I
c
LHT = 0, we first obtain an equilib-
rium point which we refer to as the CD4 Count-Categorised System HIV-free
Lymphoma Steady State. For the purpose of brevity, we will refer to this as
the CD4-HIV-free Lymphoma Steady State (CHLSS), and it is denoted by Eˆ0.
This was obtained by setting the right hand side of the system (4.2.3) to zero
and we determined the state variables.
Note that
IH = IHT = I
a
LH = I
b
LH = I
c
LH = I
a
LHT = I
b
LHT = I
c
LHT = 0 =⇒ λ1 = λ2 = 0.
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We have
K − p1S∗∗ = 0, where p1 = µ+ α1
=⇒ S∗∗ = K
p1
=
K
µ+ α1
(4.4.1)
α1S
∗∗ − p2I∗∗L = 0, where p2 = µ+ τ1
=⇒ I∗∗L =
α1K
p1p2
=
α1K
(µ+ α1)(µ+ τ1)
(4.4.2)
Hence, the model system (4.2.3) has an equilibrium point, the CD4-HIV-free
Lymphoma Steady State Eˆ0, and it is given by
Eˆ0 =
(
K
µ+ α1
,
α1K
(µ+ α1)(µ+ τ1)
, 0, 0, 0, 0, 0, 0, 0, 0
)
. (4.4.3)
Note that
N∗∗ =
K(µ+ τ1 + α1)
(µ+ α1)(µ+ τ1)
. (4.4.4)
4.4.2 Model Basic Reproduction Number
Using the same procedure as in Subsection 3.4.2, we obtain the reproduction
number Rˆ0 of the model system (4.2.3).
Let
CˆS =
S∗∗
N∗∗
,
CˆL =
I∗∗L
N∗∗
.
The matrices Fˆ and Vˆ , which represent the transmission part and transition
part respectively, of the infected subsystem (4.2.3c) - (4.2.3j) are given by
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Fˆ =

CˆSβ1 CˆSβ1η4 CˆSβ1η1 CˆSβ1η1 CˆSβ1η2 CˆSβ1η3 CˆSβ1η3 CˆSβ1η2
0 0 0 0 0 0 0 0
CˆLβ2 CˆLβ2η4 CˆLβ2η1 CˆLβ2η1 CˆLβ2η2 CˆLβ2η3 CˆLβ2η3 CˆLβ2η2
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0

,
(4.4.5)
and
Vˆ =

p3 0 0 0 0 0 0 0
−σ1 p4 0 0 0 0 0 0
−α2 0 p5 0 0 0 0 0
0 0 −γ1 p6 0 0 0 0
0 0 0 −γ2 p7 0 0 0
0 −α3 −σ2 0 0 p8 −ρ2 0
0 −α4 0 −σ3 0 0 p9 −ρ1
0 −α5 0 0 −σ4 0 0 p10

, (4.4.6)
where p1 = µ+α1, p2 = µ+ τ1, p3 = µ+σ1 +α2, p4 = µ+α3 +α4 +α5, p5 =
µ+τ2+σ2+γ1, p6 = µ+τ2+σ3+γ2, p7 = µ+δ1+τ3+σ4, p8 = µ+τ4, p9 = µ+
τ4+ρ2, p10 = µ+δ2+τ5+ρ1, pi ∈ R+ (positive constants), ∀ i = 1, 2, · · · , 10.
The next generation matrix for the infected subsystem of model (4.2.3) is
Fˆ Vˆ −1, with the matrices as defined above and the spectral radius of Rˆ0 is
given by
Rˆ0 = ρ(FV −1). (4.4.7)
The reproduction number Rˆ0 of the model (4.2.3) was obtained to be an
aggregate of contributions from the infected compartments of the different
stages of the model system. It is given by
Rˆ0 = RˆIH0 + RˆIHT0 + RˆI
a
LH
0 + RˆI
b
LH
0 + RˆI
c
LH
0 + RˆI
a
LHT
0 + RˆI
b
LHT
0 + RˆI
c
LHT
0 , (4.4.8)
where
RˆIH0 =
CˆS β1
p3
,
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RˆIHT0 =
CˆS β1 η4 σ1
p3 p4
,
RˆIaLH0 =
1
p5
[
CˆS α2 β1 η1
p3
+ CˆL β2 η1
]
,
RˆIbLH0 =
1
p6
[
CˆS α2 β1 γ1 η1
p3 p5
+
CˆL β2 γ1 η1
p5
]
,
RˆIcLH0 =
1
p7
[
CˆS α2 β1 γ1 γ2 η2
p3 p5 p6
+
CˆL β2 γ1 γ2 η2
p5 p6
]
,
RˆIaLHT0 =
1
p8
[
CˆL β2 η3
(
σ2
p5
+
γ1 ρ2 σ3
p5 p6 p9
+
γ1 γ2 ρ1 ρ2 σ4
p5 p6 p7 p9 p10
)
+ CˆS β1 η3
(
α3 σ1
p3 p4
+
α4 ρ2 σ1
p3 p4 p9
+
α5 ρ1 ρ2 σ1
p3 p4 p9 p10
+
α2 σ2
p3 p5
+
α2 γ1 ρ2 σ3
p3 p5 p6 p9
+
α2 γ1 γ2 ρ1 ρ2 σ4
p3 p5 p6 p7 p9 p10
)]
,
RˆIbLHT0 =
1
p9
[
CˆL β2 η3
(
γ1 σ3
p5 p6
+
γ1 γ2 ρ1 σ4
p5 p6 p7 p10
)
+ CˆS β1 η3
(
α4 σ1
p3 p4
+
α5 ρ1 σ1
p3 p4 p10
+
α2 γ1 σ3
p3 p5 p6
+
α2 γ1 γ2 ρ1 σ4
p3 p5 p6 p7 p10
)]
,
RˆIcLHT0 =
1
p10
[
CˆL β2 γ1 γ2 η2 σ4
p5 p6 p7
+ CˆS β1 η2
(
α5 σ1
p3 p4
+
α2 γ1 γ2 σ4
p3 p5 p6 p7
)]
.
4.4.3 Rˆ0 Interpretation
RˆIH0 =
CˆS β1
µ+ σ1 + α2
, is simply the product of the per capita rate of infection
and the average duration of stay of an individual in class IH . This reproductive
rate is sometimes referred to as the back of the napkin [61]. It is the number
of HIV-infection cases produced by a single untreated HIV-positive individual
during his/her entire lifetime in class IH , in a wholly susceptible population.
RˆIaLH0 =
1
µ+ τ2 + σ2 + γ1︸ ︷︷ ︸
i
×
CˆS β1 η1︸ ︷︷ ︸
j
× α2
µ+ σ1 + α2︸ ︷︷ ︸
k
+ CˆL β2 η1︸ ︷︷ ︸
l
 .
RˆIaLH0 above is the sum of two terms. We explain each summand of this term
with respect to the letters they are represented with. The terms denoted by
i,j and k are the average infectious period of an individual in compartment
IaLH , the infectivity of individuals in class IaLH (who developed lymphoma after
they became infected with HIV), and the proportion of HIV-infected indivuals
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who developed lymphoma and progressed to class IaLH respectively. The term
denoted by l is the infectivity of individuals in class IaLH , who actually had
lymphoma before they got infected with the HIV, and thus have passed through
class IL.
Implementing Theorem 2 of van den Driessche and Watmough [60], the fol-
lowing result is established.
Theorem 4.4.1. The CD4-HIV-free Lymphoma Steady State (CHLSS) Eˆ0, of
the model system (4.2.3) is globally asymptotically stable, provided Rˆ0 < 1.
Proof. Still following Castillo-Chavez et al. [62], we first write the system
(4.2.3) in the form:
Xˆ ′ = F (Xˆ, Yˆ )
Yˆ ′ = G(Xˆ, Yˆ ), G(Xˆ,0) = 0,
(4.4.9)
where Xˆ = (S, IL) and Yˆ = (IH , IHT , IaLH , IbLH , IcLH , IaLHT , IbLHT , IcLHT ). Here,
Xˆ ∈ R2+ (its components) denotes the number of individuals that are not
infected with HIV, but may have developed lymphoma, and Yˆ ∈ R8+ (its com-
ponents) denotes the number of individuals that are infected with HIV, irre-
spective of whether they have developed lymphoma or not, or are on antiretro-
viral treatment or not, or of their CD4-count category. We thus denote the
disease-free equilibrium of this system by Eˇ0 = (Xˆ∗,0), where Xˆ∗ = (S∗∗, I∗∗L ).
To ascertain the asymptotic global stability of the endemic state Eˆ0, we have
to show that the following conditions C1 and C2 below are satisfied.
(C1) For Xˆ ′(t) = F (Xˆ,0), Xˆ∗ is globally asymptotically stable.
(C2) G(Xˆ, Yˆ ) = AY − Gˆ(Xˆ, Yˆ ), Gˆ(Xˆ, Yˆ ) ≥ 0 for (Xˆ, Yˆ ) ∈ Γˆ,
where Γˆ is a positively invariant attracting domain (where the model makes
biological sense), and A = DYG(X∗,0) is an M-matrix (the off-diagonal ele-
ments of A are non-negative).
Let
F (Xˆ, Yˆ ) =
(
K − λ1S − (µ+ α1)S
α1S − λ2IL − (µ+ τ1)IL
)
, (4.4.10)
=⇒ F (Xˆ,0) =
(
K − (µ+ α1)S
α1S − (µ+ τ1)IL
)
= Xˆ ′(t). (4.4.11)
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Observe that Yˆ = 0 when λ1 = λ2 = 0. The unique equilibrium point of this
subsystem (4.4.11) is given by:
Xˆ∗ =
(
K
µ+ α1
,
α1K
(µ+ α1)(µ+ τ1)
)
. (4.4.12)
The biologically feasible region for the new system Xˆ ′(t) = F (Xˆ,0) is the
positively invariant, attracting, and compact set
Γˆ = {(S, IL) ∈ R2+ : Nˇ ≤
K
µ
, Nˇ = S + IL}.
The prove of this is exactly similar to that of Lemma 3.4.3.
In order to prove condition (C1), we first establish the fact the the steady
state Xˆ∗ is locally asymptotically stable. We use the Jacobian J(S, IL) of the
subsystem 4.4.11, at Xˆ∗. It is given by
J =
(−(µ+ α1) 0
α1 −(µ+ τ1)
)
. (4.4.13)
We observe that J = J(Xˆ∗), since it is a constant matrix. J is a triangular
matrix, and the eigenvalues of a triangular matrix are its main diagonal entries.
Thus, the eigenvalues of J are λ1 = −(µ + α1) λ2 = −(µ + τ1), λ1, λ2 < 0.
This implies that the steady state Xˆ∗ is locally asymptotically stable.
To show that this unique steady state Xˆ∗ is globally asymptotically stable, we
prove that the existence of periodic solutions are precluded from the subsystem
4.4.11. We rule out these periodic orbits in Γˆ using the Dulac’s criteria (see
Definition A.0.6)
Let
M(S, IL) = K − (µ+ α1)S, (4.4.14)
N(S, IL) = α1S − (µ+ τ1)IL. (4.4.15)
Let
Θ(S, IL) =
1
SIL
, S > 0, IL > 0 (4.4.16)
be a Dulac function.
We define another function Φ below. We see that
Φ =
∂(MΘ)
∂S
+
∂(NΘ)
∂IL
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= −
(
K
S2IL
+
α1
I2L
)
< 0, ∀ S > 0, IL > 0. (4.4.17)
This shows that the system (4.4.11) has no periodic solutions (or limit cycles)
in the compact set Γˆ. Since we have shown that the unique steady state Xˆ∗
is locally asymptotically stable, then, by a simple application of Poincaré-
Bendixson Theorem, it suffices to show that the unique steady state Xˆ∗ of the
subsystem 4.4.11 is globally asymptotically stable.
We now prove that the condition (C2) is also satisfied.
G(Xˆ, Yˆ ) =

λ1S − (µ+ σ1 + α2)IH
σ1IH − (µ+ α3 + α4 + α5)IHT
λ2IL + α2IH − (µ+ τ2 + σ2 + γ1)IaLH
γ1I
a
LH − (µ+ τ2 + σ3 + γ2)IbLH
γ2I
b
LH − (µ+ δ1 + τ3 + σ4)IcLH
σ2I
a
LH + α3IHT + ρ2I
b
LHT − (µ+ τ4)IaLHT
σ3I
b
LH + α4IHT + ρ1I
c
LHT − (µ+ τ4 + ρ2)IbLHT
σ4I
c
LH + α5IHT − (µ+ δ2 + τ5 + ρ1)IcLHT

. (4.4.18)
Since every element of the matrix G(Xˆ, Yˆ ) contains some HIV component,
clearly, G(Xˆ,0) = 0. Next, we construct the matrix A = DYˆG(Xˆ∗,0). The
matrix DYˆG(Xˆ, Yˆ ) is given by
DYˆG(Xˆ, Yˆ ) =
β1S
N
−p3 β1η4S
N
β1η1S
N
β1η1S
N
β1η2S
N
β1η3S
N
β1η3S
N
β1η2S
N
σ1 −p4 0 0 0 0 0 0
β2IL
N
+α2
β2η4IL
N
β2η1IL
N
−p5 β2η1IL
N
β2η2IL
N
β2η3IL
N
β2η3IL
N
β2η2IL
N
0 0 γ1 −p6 0 0 0 0
0 0 0 γ2 −p7 0 0 0
0 α3 σ2 0 0 −p8 ρ2 0
0 α4 0 σ3 0 0 −p9 ρ1
0 α5 0 0 σ4 0 0 −p10

.
(4.4.19)
Xˆ∗ = (S∗∗, I∗∗L ), where
S∗∗ =
K
p1
, I∗∗L =
α1K
p1p2
. Thus, N∗∗ =
K(α1 + p2)
p1p2
.
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We obtain
A = DYˆG(Xˆ∗,0)
=
(
Ψˆ1 Ψˆ2
Ψˆ3 Ψˆ4
)
,
(4.4.20)
where
Ψˆ1 =

β1p2
(α1 + p2)
− p3 β1p2η4
(α1 + p2)
β1p2η1
(α1 + p2)
β1p2η1
(α1 + p2)
σ1 −p4 0 0
β2α1
(α1 + p2)
+ α2
β2α1η4
(α1 + p2)
β2α1η1
(α1 + p2)
− p5 β2α1η1
(α1 + p2)
0 0 γ1 −p6

,
Ψˆ2 =

β1p2η2
(α1 + p2)
β1p2η3
(α1 + p2)
β1p2η3
(α1 + p2)
β1p2η2
(α1 + p2)
0 0 0 0
β2α1η2
(α1 + p2)
β2α1η3
(α1 + p2)
β2α1η3
(α1 + p2)
β2α1η2
(α1 + p2)
0 0 0 0

,
Ψˆ3 =

0 0 0 γ2
0 α3 σ2 0
0 α4 0 σ3
0 α5 0 0
 ,
Ψˆ4 =

−p7 0 0 0
0 −p8 ρ2 0
0 0 −p9 ρ1
σ4 0 0 −p10
 .
Using the definition G(Xˆ, Yˆ ) = AYˆ − Gˆ(Xˆ, Yˆ ) to obtain Gˆ(Xˆ, Yˆ ), we have:
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Gˆ(Xˆ, Yˆ ) =

Gˆ1(Xˆ, Yˆ )
Gˆ2(Xˆ, Yˆ )
Gˆ3(Xˆ, Yˆ )
Gˆ4(Xˆ, Yˆ )
Gˆ5(Xˆ, Yˆ )
Gˆ6(Xˆ, Yˆ )
Gˆ7(Xˆ, Yˆ )
Gˆ8(Xˆ, Yˆ )

,
=

β1
[
IH+η1(I
a
LH+I
b
LH)+η2(I
c
LH+I
c
LHT )+η3(I
a
LHT+I
b
LHT )+η4IHT
]
Πˆ1
0
β2
[
IH+η1(I
a
LH+I
b
LH)+η2(I
c
LH+I
c
LHT )+η3(I
a
LHT+I
b
LHT )+η4IHT
]
Πˆ2
0
0
0
0
0

,
(4.4.21)
where
Πˆ1 =
(
p2
(α1 + p2)
− S
N
)
,
Πˆ2 =
(
α1
(α1 + p2)
− IL
N
)
.
We now show that Gˆ(Xˆ, Yˆ ) ≥ 0 for (Xˆ, Yˆ ) ∈ Γˆ, which implies that we must
show that Gˆ1(Xˆ, Yˆ ), Gˆ3(Xˆ, Yˆ ), ≥ 0. It suffices to show that:
(i)
p2
(α1 + p2)
− S
N
≥ 0 ,
(ii)
α1
(α1 + p2)
− IL
N
≥ 0.
We prove these relations by contradiction. Suppose that:
p2
(α1 + p2)
<
S
N
,
α1
(α1 + p2)
<
IL
N
.
(4.4.22)
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Using the direct proof technique, that for a, b, c, d > 0, if a < b and c < d,
then, a+ c < b+ d, we sum the three relations above to obtain,
p2
(α1 + p2)
α1
(α1 + p2)
<
S + IL
N
,
=⇒ (α1 + p2)
(α1 + p2)
= 1 <
S + IL
N
.
(4.4.23)
However, since N = S + IL, then by definition, we have it that
=⇒ S + IL
N
= 1. (4.4.24)
Relations (4.4.23) and (4.4.24) implies that
1 < 1.
This is a contradiction. Hence, the converse of the relations in (4.4.22) is
true. This implies that relations (i) and (ii) are valid. Hence Gˆ(X, Y ) ≥ 0 for
(Xˆ, Yˆ ) ∈ Γˆ. This completes the proof.
4.4.4 Existence of the Endemic Equilibria
In order to compute the endemic equilibria of the model system (4.2.3), , where
at least one of the infected compartments is non-zero, we set the right hand
side of the system (3.2.3) to zero, and solve for all its state variables. The state
variables are expressed in terms of the forces of infection λ∗∗1 and λ∗∗2 , where
λ∗∗1 =
β1
N∗∗
[I∗∗H + η1((I
a
LH)
∗∗ + (IbLH)
∗∗) + η2((IcLH)
∗∗ + (IcLHT )
∗∗) (4.4.25)
+ η3((I
a
LHT )
∗∗ + (IbLHT )
∗∗) + η4I∗∗HT ], (4.4.26)
λ∗∗2 =
β2
N∗∗
[I∗∗H + η1((I
a
LH)
∗∗ + (IbLH)
∗∗) + η2((IcLH)
∗∗ + (IcLHT )
∗∗) (4.4.27)
+ η3((I
a
LHT )
∗∗ + (IbLHT )
∗∗) + η4I∗∗HT ], (4.4.28)
N∗∗ = S∗∗ + I∗∗L + I
∗∗
H + I
∗∗
HT + (I
a
LH)
∗∗ + (IbLH)
∗∗ + (IcLH)
∗∗ (4.4.29)
+ (IaLHT )
∗∗ + (IbLHT )
∗∗ + (IcLHT )
∗∗. (4.4.30)
Note that
λ2 =
β2 λ1
β1
. (4.4.31)
This implies that λ2 is simply a (positive) constant multiple of λ1. Thus any
qualitative inference(s) made from investigating the polynomial arising from
λ1 also applies to the polynomial equation that ought to arise from λ2.
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Hence, the endemic equilibria of the model (4.2.3) are given by
Eˆ1 = (S
∗∗, I∗∗L , I
∗∗
H , I
∗∗
HT , (I
a
LH)
∗∗, (IbLH)
∗∗, (IcLH)
∗∗, (IaLHT )
∗∗, (IbLHT )
∗∗, (IcLHT )
∗∗),
(4.4.32)
where
S∗∗ =
K
p1 + λ∗∗1
, (4.4.33)
I∗∗L =
K α1
(p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
, (4.4.34)
I∗∗H =
K λ∗∗1
p3 (p1 + λ∗∗1 )
, (4.4.35)
I∗∗HT =
K λ∗∗1 σ1
p3 p4 (p1 + λ∗∗1 )
, (4.4.36)
(IaLH)
∗∗ =
K (p3 α1 λ
∗∗
2 + α2 λ
∗∗
1 (p2 + λ
∗∗
2 ))
p3 p5 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
, (4.4.37)
(IbLH)
∗∗ =
K γ1 (p3 α1 λ
∗∗
2 + α2 λ
∗∗
1 (p2 + λ
∗∗
2 ))
p3 p5 p6 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
, (4.4.38)
(IcLH)
∗∗ =
K γ1 γ2 (p3 α1 λ
∗∗
2 + α2 λ
∗∗
1 (p2 + λ
∗∗
2 ))
p3 p5 p6 p7 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
, (4.4.39)
(IaLHT )
∗∗ = K λ∗∗1
(
(p9 α3 + α4 ρ2) σ1
p3 p4 p8 p9 (p1 + λ∗∗1 )
+
α2 (p6 p9 σ2 + γ1 ρ2 σ3)
p3 p5 p6 p8 p9 (p1 + λ∗∗1 )
(4.4.40)
+
ρ1 ρ2 (p5 p6 p7 α5 σ1 + p4 α2 γ1 γ2 σ4)
p3 p4 p5 p6 p7 p8 p9 p10 (p1 + λ∗∗1 )
)
+
K α1 λ
∗∗
2 (p6 p7 p9 p10 σ2 + γ1 ρ2 (p7 p10 σ3 + γ2 ρ1 σ4))
p5 p6 p7 p8 p9 p10 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
,
(IbLHT )
∗∗ =
K α1 γ1 λ
∗∗
2 (p7 p10 σ3 + γ2 ρ1 σ4)
p5 p6 p7 p9 p10 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
(4.4.41)
+
K λ∗∗1 (p5 p6 p7 (p10 α4 + α5 ρ1) σ1 + p4 α2 γ1 (p7 p10 σ3 + γ2 ρ1 σ4))
p3 p4 p5 p6 p7 p9 p10 (p1 + λ∗∗1 )
,
(IcLHT )
∗∗ =
K p5 p6 p7 α5 λ
∗∗
1 (p2 + λ
∗∗
2 ) σ1
p3 p4 p5 p6 p7 p10 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
(4.4.42)
+
K p4 γ1 γ2 (p3 α1 λ
∗∗
2 + α2 λ
∗∗
1 (p2 + λ
∗∗
2 )) σ4
p3 p4 p5 p6 p7 p10 (p1 + λ∗∗1 ) (p2 + λ
∗∗
2 )
.
Substituting for the steady states above in (4.4.26), we obtain the quadratic
polynomial
A(λ∗∗1 )
2 +B(λ∗∗1 ) + C = 0, (4.4.43)
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where
A = β2 (p5 p6 p7 (p9 p10 α3 + p8 (p10 α4 + p9 (p10 + α5) + α5 ρ1)
+ (p10 α4 + α5 ρ1) ρ2) σ1 + p4 (p10 (p9 (p5 p6 p7 p8 + α2 (p8 γ1 (p7 + γ2)
+p6 p7 (p8 + σ2))) + p7 α2 γ1 (p8 + ρ2) σ3) + α2 γ1 γ2 (p8 (p9 + ρ1)
+ρ1 ρ2) σ4)) ,
B = p2 β1 (p5 p6 p7 (p9 p10 α3 + p8 (p10 α4 + p9 (p10 + α5) + α5 ρ1)
+ (p10 α4 + α5 ρ1) ρ2) σ1 + p4 (p10 (p9 (p5 p6 p7 p8 + α2 (p8 γ1 (p7 + γ2)
+p6 p7 (p8 + σ2))) + p7 α2 γ1 (p8 + ρ2) σ3) + α2 γ1 γ2 (p8 (p9 + ρ1)
+ρ1 ρ2) σ4)) + β2 (p3 p4 (p10 (p9 (p5 p6 p7 p8 + α1 (p8 γ1 (p7 + γ2)
+p6 p7 (p8 + σ2))) + p7 α1 γ1 (p8 + ρ2) σ3) + α1 γ1 γ2 (p8 (p9 + ρ1)
+ρ1 ρ2) σ4)− β1 (p5 p6 p7 (p8 (p9 (α5 η2 + p10 η4) + η3 (p10 α4 + α5 ρ1))
+η3 (p9 p10 α3 + (p10 α4 + α5 ρ1) ρ2)) σ1 + p4 (p10 (p5 p6 p7 p8 p9
+α2 (p9 (p8 (p7 (p6 + γ1) η1 + γ1 γ2 η2) + p6 p7 η3 σ2) + p7 γ1 η3
× (p8 + ρ2) σ3)) + α2 γ1 γ2 (p8 (p9 η2 + η3 ρ1) + η3 ρ1 ρ2) σ4))) ,
C = − (β1 (− (p2 p3 p4 p5 p6 p7 p8 p9 p10) + p2 p5 p6 p7 β1 (p8 (p9 (α5 η2
+p10 η4) + η3 (p10 α4 + α5 ρ1)) + η3 (p9 p10 α3 + (p10 α4 + α5 ρ1) ρ2)) σ1
+p2 p4 p10 β1 (p5 p6 p7 p8 p9 + α2 (p9 (p8 (p7 (p6 + γ1) η1 + γ1 γ2 η2)
+p6 p7 η3 σ2) + p7 γ1 η3 (p8 + ρ2) σ3)) + p3 p4 p10 α1 (− (p5 p6 p7 p8 p9)
+β2 (p9 (p8 (p7 (p6 + γ1) η1 + γ1 γ2 η2) + p6 p7 η3 σ2) + p7 γ1 η3 (p8 + ρ2) σ3))
+p4 (p2 α2 β1 + p3 α1 β2) γ1 γ2 (p8 (p9 η2 + η3 ρ1) + η3 ρ1 ρ2) σ4)) .
(4.4.44)
The existence, and number of endemic equilibria for the model system (4.2.3)
is determined by the existence of, and number of positive roots of the quadratic
equation (4.4.43). We investigate and characterise the solutions (roots) of the
quadratic polynomial (4.4.43) by using the quadratic formula to get its roots,
and analyse them under different conditions. The roots of equation (4.4.43)
are given by
(λ∗∗1 )1,2 =
−B ±√B2 − 4AC
2A
. (4.4.45)
The constant term C can be expressed in terms of Rˆ0, and it is given by
C = β1p3p4p5p6p7p8p9p10(p2 + α1)
[
1− Rˆ0
]
. (4.4.46)
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From equation (4.4.46), if Rˆ0 > 1, then C < 0. On the other hand, if Rˆ0 < 1,
then C > 0. We consider three cases of the discriminant Θ of equation (4.4.45),
where Θ = B2 − 4AC.
We consider the existence of endemic equilibria for Rˆ0 > 1, C < 0 and A > 0.
If Θ = 0, then, λ∗∗1 )1, (λ∗∗1 )2 =
−B
2A
. If B < 0, then (λ∗∗1 )1, (λ∗∗1 )2 > 0. This
implies that equation (4.4.43) has exactly one positive root with multiplicity
two (a double root). If B > 0, then (λ∗∗1 )1, (λ∗∗1 )2 < 0, that is equation (4.4.43)
has exactly one negative root with multiplicity two. Hence, if Rˆ0 > 1, C <
0, A > 0,Θ = 0 and B < 0, then the model system (4.2.3) has only one
endemic equilibrium.
Consider Θ > 0. If B > 0, then, (λ∗∗1 )1 > 0 and (λ∗∗1 )2 < 0. This implies that
the quadratic equation (4.4.43) has two distinct roots of opposite signs. Thus,
for Rˆ0 > 1, C < 0, A > 0,Θ > 0 and B > 0, the model system (4.2.3) has only
one endemic equilibrium.
If B < 0, then, (λ∗∗1 )1 > 0, (λ∗∗1 )2 > 0. This implies that the quadratic equation
(4.4.43) has two distinct positive roots. Thus, for Rˆ0 > 1, C < 0, A > 0,Θ > 0
and B < 0, the model system (4.2.3) has two endemic equilibria.
If Θ > 0, then the quadratic equation (4.4.43) has no real solutions. This is of
no interest to us.
We investigate the existence of endemic equilibria when Rˆ0 < 1.
When Θ > 0, then,
√
Θ < B since AC > 0. If B > 0, then the quadratic
equation (4.4.43) has two distinct negative roots. However, If B < 0, it has
two distinct roots of opposite signs. This implies if Rˆ0 < 1, C > 0, A > 0, and
B < 0, then the model system (4.2.3) has exactly one endemic equilibrium.
Obviously, equation (4.4.43) has no real solution if Θ < 0.
The theorem below summarises the existence of endemic equilibria of the model
system (4.2.3).
Theorem 4.4.2. The model system (4.2.3)
(i) has no endemic equilibrium if Rˆ0 < Rˆc0 < 1, where Rˆc0 is a threshold
called the critical Rˆ0.
(ii) has at most two endemic equilibria in Ω, if Rˆ0 > 1.
(iii) has a unique endemic equilibrium in Ω, for some parameter values of Rˆ0
within the range Rˆc0 < Rˆ0 < 1.
(iv) has no endemic equilibrium otherwise.
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Proposition 4.4.3. The model system (4.2.3) exhibits backward bifurcation
for Rˆ0 < 1.
Remark 4.4.4. Proposition 4.4.3 implies that bringing Rˆ0 below unity is does
not suffice for the eradication of the incidence of lymphoma (cancers in general)
in HIV-infected individuals when HIV is introduced into a wholly susceptible
population. In order to achieve this main goal of epidemiology (bringing the
disease into extinction), Rˆ0 must be brought below the critical value Rˆc0, or
Rˆc0 must be raised. The critical value Rˆc0 is a threshold after both the DFE
and the endemic equilibrium(s) co-exist.
To estimate the critical value Rˆc0 , we set the discriminant Θ of the polynomial
(4.4.43) to zero, and make Rˆ0 the subject of the relation. This new term is
the critical value Rˆc0 of the system (4.2.3), and it is given by
Rˆc0 = 1−
B2
4Aβ1p3p4p5p6p7p8p9p10(p2 + α1)
. (4.4.47)
4.5 Numerical Simulations
In this section, we present the results of the numerical simulations for the
model (4.2.3). These numerical simulations, which are being used to demon-
strate the theoretical concepts of our model, were carried out using the fourth
order Runge-Kutta scheme in Matlab. Using lymphoma incidence data of the
Western Cape province of South Africa, which was obtained from the Tyger-
berg Lymphoma Study Group (TLSG), we fit our model to the available data.
Table 4.3 displays lymphoma data classified according to CD4 cell count for
population classes IaLH and IcLH . Table 4.4 shows the parameter values used
in these simulations. Many of these parameters values are assumed values,
obtained through iterative methods, in such a way that the values presented
are those which best fit our lymphoma data. Nevertheless, the parameters
used are those which are epidemiologically relevant.
4.5.1 Parameter Estimation
Using the 2001-2006, 2006-2011 and 2011-2016 mid-year population estimates
by Statistics South Africa (StatsSA), we obtain the average life-expectancy
of the population of the Western Cape province, and they are 60.15, 63.35,
and 67.15 years (for the three year sections) respectively. We thus evaluate
the mortality rates that corresponds to these three averages, and we obtain
0.01663, 0.01579 and 0.01489 years respectively. We thus sampled the natural
mortality rate from the range (0.014-0.017), for which 0.017 best fits our model
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[65]. In like manner, we obtain the crude birth rate b, of the Western Cape
province population as a sample from the range (0.020-0.025).
Since PBL has also been reported in immunocompetent patients and HAART
has improved its prognosis, in that the survival rate as increased by 2.5 [31;
41; 46]. Thus, we assumed that the HIV treatment rate of patients with
lymphoma, HIV, and in class IaLH is 2.5 times that of those in class IcLH , that
is α2 = 2.5α4.
The report by Diamond et al [44] show that the incidence of some HRL has
almost doubled in the post-HAART era (see Subsection 2.2.1). Thus, we
assumed that the lymphoma development rate of HIV positive patients under
antiretroviral treatment (into class IaLHT ) is twice the lymphoma development
rate of HIV-positive patients (into class IaLH), that is α3 = 2α2. Consequently,
we also assumed that α4, α5 > α2.
We obtained lymphoma incidence data from the Tygerberg Lymphoma Study
Group (TLSG), Tygerberg Hospital, Western Cape (WC) province of South
Africa (SA). The population under study is that of the WC province of SA, of
which the Tygerberg Hospital covers about half of them.
Table 4.3: Lymphoma Data Classified According to CD4 Cell Count for Classes
IaLH and I
c
LH
Population Class 2007 2008 2009 2010 2011
IaLH 4 6 15 8 9
IcLH 8 13 29 15 15
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Table 4.4: Parameter values and ranges used in numerical simulation
Parameters Description Range Point value Source
K Recruitment rate for susceptibles (43000-44000) 43049yr−1 Demo
µ Natural mortality rate (0.006-2) 0.017yr−1 Demo
δ1 Disease and low-CD4 cell count in-
duced mortality rate (for IcLH)
(0.0015-0.003) 0.002yr−1 Demo
δ2 Disease and low-CD4 cell count in-
duced mortality rate (for IcLH)
(0.0015-0.0025) 0.0015yr−1 Demo
β1 Effective contact rate of HIV for sus-
ceptible individuals
(0.001-0.003) 0.002yr−1 Estimated
β2 Effective contact rate of HIV for lym-
phoma patients
(0.005-0.01) 0.009yr−1 Estimated
α1 Lymphoma development rate for sus-
ceptible individuals
(0.00006-0.0001) 0.0000974yr−1 Estimated
α2 Lymphoma development rate of HIV-
positive patients (into class IaLH)
(0.00002-0.00004) 0.00003315yr−1 Estimated
α3 Lymphoma development rate of HIV-
positive patients under antiretroviral
regimen(s) (into class IaLHT )
(0.00005-0.00008) 0.0000663yr−1 Estimated
α4 Lymphoma development rate of HIV-
positive patients under antiretroviral
regimen(s) (into class IbLHT )
(0.00004-0.00007) 0.00005yr−1 Estimated
α5 Lymphoma development rate of HIV-
positive patients under antiretroviral
regimen(s) (into class IcLHT )
(0.00008-0.0002) 0.0001yr−1 Estimated
σ1 HIV treatment rate of lymphoma-free
HIV patients
(0.031-0.035) 0.034yr−1 Estimated
σ2 HIV treatment rate of patients with
lymphoma, HIV, and in class IaLH
(0.001-0.003) 0.002yr−1 Estimated
σ3 HIV treatment rate of patients with
lymphoma, HIV, and in class IbLH
(0.0006-0.00083) 0.0007yr−1 Estimated
σ4 HIV treatment rate of patients with
lymphoma, HIV, and in class IcLH
(0.00078-0.00083) 0.0008yr−1 Estimated
τ1 Lymphoma treatment rate of
lymphoma-only patients
(0.99-1.5) 1.09yr−1 Estimated
τ2 Lymphoma treatment rate of patients
with lymphoma, HIV, and in either
class IaLH or IbLH
(0-4) 0.23yr−1 Estimated
τ3 Lymphoma treatment rate of patients
with lymphoma, HIV, and in class IcLH
(0.0004-0.0007) 0.0005yr−1 Estimated
τ4 Lymphoma treatment rate of patients
with lymphoma, HIV, under antiretro-
viral regimen(s) and in class IaLHT or
IbLHT
(0.9-1.5) 1.12yr−1 Estimated
τ5 Lymphoma treatment rate of patients
with lymphoma, HIV, under antiretro-
viral regimen(s) and in class IcLHT
(0.004-0.007) 0.005yr−1 Estimated
γ1 CD4 cell count declinataion rate of pa-
tients in class IaLH
(0.08-0.2) 0.1yr−1 Estimated
γ2 CD4 cell count declinataion rate of pa-
tients in class IbLH
(8-9) 9yr−1 Estimated
ρ1 CD4 cell count upswing rate of patients
in class IcLHT
(0.08-0.2) 0.1yr−1 Estimated
ρ2 CD4 cell count upswing rate of patients
in class IbLHT
(1.0-1.5) 1.2yr−1 Estimated
η1 Modification parameter for classes IaLH
and IbLH
(0.6-0.8) 0.7 Estimated
η2 Modification parameter for classes IcLH
and IcLHT
(1.30-1.32) 1.3 Estimated
η3 Modification parameter for classes
IaLHT and IbLHT
(0.5-0.72) 0.6 Estimated
η4 Modification parameter for class IHT (0.4-0.6) 1.6 Estimated
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4.5.2 Sensitivity Analysis
Using the same assumptions and procedure as in Subsection 3.5.2, we conduct
sensitivity analysis on the model system (4.2.3). Figure 4.5 is a tornado plot
of the Partial Rank Correlation Coefficient (PRCC) of the input parameters
of our model system, as described in Table 4.4. It illustrates the results of the
sensitivity analysis done on our model system [76]. It shows that the model’s
input parameter with the most negative PRCC is the natural mortality rate
µ, while that with the most positive PRCC is the modification parameter η4.
We plotted scatter plots of the significant PRCC’s. However, we have only
displayed those ones which exhibit significant statistical relationships with Rˆ0
as they vary.
Figures 4.2 and 4.3 are scatter plots obtained from the Monte Carlo simu-
lations of 1000 samples, of the natural mortality rate µ, and the lymphoma
treatment rate of patients with HIV and lymphoma (who are in class IaLH or
IbLH). The figures shows how the variation of the aformentioned parameters
affect the response Rˆ0. Figure 4.2 shows that Rˆ0 is monotone decreasing as µ
increases. Figure 4.3 also shows that Rˆ0 is monotone decreasing as the lym-
phoma treatment rate of patients with HIV, lymphoma, and in either of classes
IaLH or IbLH) increases. This implies that a decrease in the number of patients
who have both HIV and lymphoma, but not on any antiretroviral treatment
(but rather on lymphoma treatment only) will cause a decrease in Rˆ0 value,
which in turn could lead to a control of the epidemic.
Figure 4.4 displays the statistical measures of Rˆ0 on a boxplot. It shows that
the median of Rˆ0 < 1 for this run. However, the median of Rˆ0 > 1 for
many other simulations. This means that the epidemic will always remain
(uneradicated) in the population under study.
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Figure 4.2: A scatter plot of the natural mortality rate, µ, as it relates to Rˆ0. Note
that Rˆ0 = R0 in this diagram.
Figure 4.3: A scatter plot of the lymphoma treatment rate of patients with HIV
and lymphoma (who are in class IaLH or I
b
LH), as it relates to Rˆ0. Note that Rˆ0 = R0
in this diagram.
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Figure 4.4: A boxplot of Rˆ0.
Figure 4.5: Tornado plot of the PRCC of the input parameters of our model system
as described in Table 4.4
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4.5.3 Results
We show the dynamics of lymphoma (and other HIV-related cancers) in the
HIV-infected and uninfected population, using the fit of our model to the
TLSG data. Figure 4.6 demonstrates that there is a steady increase in the
incidence of lymphoma in patients with both HIV and lymphoma and whose
CD4 cell count is > 350 cells /µL, from 2007-2011. It shows that a relatively
high number of cases were recorded in the year 2009, thus making the data
point of that year an outlier, in comparison with other data points. This is a
consequence of a high access of the TLSG to clinical lymphoma data in 2009.
Figure 4.7 depicts a rapid increase in the incidence of lymphoma in patients
with both HIV and lymphoma and whose CD4 cell count is < 200 cells /µL,
from 2007-2008, after which it steadily increases from 2008-2011. The 2009
data point is also observed to be an outlier due to high access to clinical data by
the TLSG. Figure 4.8 is a graphical comparison of the incidence of lymphoma
in patients with HIV, lymphoma, and whose CD4 cell count is < 200 cells
/µL, with those patients whose CD4 cell count is > 350 cells /µL. It shows
that more patients with depreciated CD4 cell count (< 200 cells /µL) develop
lymphoma in comparison with patients with higher CD4 cell count (> 350
cells /µL), from 2007-2011. This trend is consistent over the 5 years simulated
period.
Figure 4.9 demonstrates that there is a steady increase in the incidence of
lymphoma in patients with both HIV and lymphoma, under antiretroval reg-
imen(s), and with CD4 cell count that is > 350 cells /µL, from 2007-2011.
This simulation has no data points because of the inavailability of lymphoma
incidence data for this incidence, as the TLSG could not obtain adequate pa-
tient information with respect to this. This in actual fact has been clinically
proven as several lymphoma subtypes develop only after the commencement of
HAART. This is a result of several prognostic factors, such as the immunosup-
pression level in patients and immune reconstitution inflammatory syndrome
(IRIS) (see Subsection 2.2.1).
Figure 4.10 demonstrates that there is a steady and non-trivial rise in the
incidence of lymphoma in patients with both HIV and lymphoma, under an-
tiretroval regimen(s), and with CD4 cell count that is < 200 cells /µL. Figure
4.11 compares the incidence of lymphoma in patients with both HIV and lym-
phoma, under antiretroval regimen(s), and with CD4 cell count that is < 200
cells /µL, with that of those patients whose CD4 cell counts are > 350 cells
/µL. It shows that despite being on HAART regimen, much more patients
with depreciated CD4 cell counts (< 200 cells /µL) develop lymphoma, in
comparison to those patients with slightly normal or high CD4 cell counts
(> 350 cells /µL). The increase in the number of patients in the former cate-
gory was rapid between 2007-2011, while the number of patients in the latter
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category only increased slowly and by a little amount over the 5 years period.
This is an indicator that a low CD4 cell count is highly crucial in the prog-
nosis of the incidence of lymphoma (and other cancer types) in HIV-infected
patients.
Figure 4.6: Incidence of lymphoma in patients with both HIV and lymphoma and
whose CD4 cell count is > 350 cells /µL
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Figure 4.7: Incidence of lymphoma in patients with HIV and lymphoma, and whose
CD4 cell count is < 200 cells /µL
Figure 4.8: Incidence of lymphoma in patients with HIV, lymphoma and whose
CD4 cell count is < 200 cells /µL, and of those whose CD4 cell count is > 350 cells
/µL
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Figure 4.9: Incidence of lymphoma in patients with HIV and lymphoma, under
antiretroval regimen(s), and with CD4 cell count that is > 350 cells /µL
Figure 4.10: Incidence of lymphoma in patients with HIV and lymphoma, under
antiretroval regimen(s), and with CD4 cell count that is < 200 cells /µL
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Figure 4.11: Incidence of lymphoma in patients with HIV and lymphoma, under
antiretroval regimen(s), and with CD4 cell count that is < 200 cells /µL, and those
whose CD4 cell count is > 350 cells /µL
Since the use of HAART has been reported to decrease the incidence of some
lymphoma subtypes, we use our model as a predictive tool, by considering
different scenarios created by different percentage coverages of the rollout of
HAART. The first scenario considered is the 30% effective HAART rollout,
which is about the effective HAART coverage in the Western Cape province
of South Africa as at 2011 [27]. We also considered three other scenarios that
has to do with some increase in the effective HAART coverage of the Western
Cape province of South Africa, viz 30%, 50% and 70% increase.
Figure 4.12 displays the projection and scenario analysis of the incidence of
lymphoma in patients with both HIV and lymphoma and whose CD4 cell count
is > 350 cells /µL for various effective HAART coverage. Figure 4.13 displays
the projection and scenario analysis of the incidence of lymphoma in patients
with both HIV and lymphoma and whose CD4 cell count is < 200 cells /µL
for various effective HAART coverage. For us to clearly observe and discuss
the effects of the increase in the effective HAART coverage as seen in Figures
4.12 and 4.13, we display magnified views of the patterns shown in Figures
4.12 and 4.13 in Figures 4.14 and 4.15 respectively.
Figure 4.16 depicts the projection and scenario analysis of the incidence of
lymphoma in patients with both HIV and lymphoma and whose CD4 cell
count is < 200 cells /µL, and of those whose CD4 cell count is > 350 cells
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/µL for various effective HAART coverage. It shows that the incidence of
cases of the former group is higher than that of the latter. Figure 4.17 is an
accentuated scenario analysis of the incidence of lymphoma in patients with
both HIV and lymphoma and whose CD4 cell count is < 200 cells /µL, and
of those whose CD4 cell count is > 350 cells /µL for various effective HAART
coverage.
Figure 4.18 is a projection and scenario analysis of the incidence of lymphoma
in patients with both HIV and lymphoma, under antiretroval regimen(s), and
with CD4 cell count that is > 350 cells /µL for various effective HAART
coverage. Figure 4.20 is a magnified version of it. It shows that an increase in
effective HAART coverage, will increase the number of HIV cum lymphoma
patients with a CD4 cell count that is > 350 cells /µL, that will be enrolled
in the HAART treatment. Figure 4.19 is a projection and scenario analysis of
the incidence of lymphoma in patients with both HIV and lymphoma, under
antiretroval regimen(s), and with CD4 cell count that is < 200 cells /µL for
various effective HAART coverage. Figure 4.21 is its accentuated version. It
also shows that when there is an increase in HAART roll-out, more lymphoma
patients with a CD4 cell count of < 200 cells /µL will be enrolled in HAART
treatment.
Figure 4.12: A projection and scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma and whose CD4 cell count is > 350 cells /µL
for various effective HAART coverage.
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Figure 4.13: A projection and scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma and whose CD4 cell count is < 200 cells /µL
for various effective HAART coverage.
Figure 4.14: An accentuated scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma and whose CD4 cell count is > 350 cells /µL
for various effective HAART coverage.
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Figure 4.15: An accentuated scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma and whose CD4 cell count is < 200 cells /µL
for various effective HAART coverage.
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Figure 4.16: A projection and scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma and whose CD4 cell count is < 200 cells /µL,
and of those whose CD4 cell count is > 350 cells /µL for various effective HAART
coverage.
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Figure 4.17: An accentuated scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma and whose CD4 cell count is < 200 cells
/µL, and of those whose CD4 cell count is > 350 cells /µL for various effective
HAART coverage.
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Figure 4.18: A projection and scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma, under antiretroval regimen(s), and with CD4
cell count that is > 350 cells /µL for various effective HAART coverage.
Figure 4.19: A projection and scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma, under antiretroval regimen(s), and with CD4
cell count that is < 200 cells /µL for various effective HAART coverage.
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Figure 4.20: An accentuated scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma, under antiretroval regimen(s), and with
CD4 cell count that is > 350 cells /µL for various effective HAART coverage.
Figure 4.21: An accentuated scenario analysis of the incidence of lymphoma in
patients with both HIV and lymphoma, under antiretroval regimen(s), and with
CD4 cell count that is < 200 cells /µL for various effective HAART coverage.
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4.5.3.1 Discussion
In this chapter, we formulated a mathematical model that describes the dy-
namics of HIV-related cancers, whereby special consideration was given to
the different classes of CD4 cell count levels an HIV-infected patient can fall
into. Qualitative analysis of the model was done using its Rˆ0 and Rˆc0 thresh-
olds, which are the basic reproduction number and the critical reproduction
number respectively. We observed that the model’s CD4-HIV-free lymphoma
steady state is globally stable only if Rˆ0 < Rˆc0. In addition, we saw that when
Rˆ0 < 1, the model exhibits a backward bifurcation since the model has a
unique endemic equilibrium, for some parameter values of Rˆ0 within the range
Rˆc0 < Rˆ0 < 1. When Rˆ0 < Rˆc0 < 1, HIV can be eradicated from the studied
population.
Numerical simulations were also carried out for the model. Lymphoma data
from the TLSG were fitted to the model to obtain lymphoma incidence curves.
We observed that the incidence of lymphoma in patients with highly depreci-
ated CD4 cell count is upswinging at an alarming rate, and earlier HAART
administration is recommended. We also carried out sensitivity analysis of the
model parameters. The implementation of Latin hypercube sampling which
makes use of Partial rank correlation coefficients (PRCC) shows that the two
parameters that have the most negative effect on the value of Rˆ0, when var-
ied, are µ, the natural mortality rate and τ2, the lymphoma treatment rate of
patients with HIV and lymphoma (who are in class IaLH or IbLH).
Similar to the projections of Subsection 3.5.3 (Chapter 3), we used the model
as a predictive tool by projecting the incidences of lymphoma in four different
scenarios. Similarly, the results shows that an increase in the roll-out and
effective use of HAART has a significant declination effect on the incidence of
the epidemic in the nearest future.
Our model results buttresses the fact that patients with low CD4 cell counts
have a higher risk of developing AIDS or death [89–91]. Using the model, it
has been shown that more patients with very low CD4 cell count (< 200 cells
/µL) developed lymphoma between 2007 and 2011, in comparison with those
who have a slightly normal to high CD4 cell count (> 350 cells /µL). Two
major factors that should be considered when an ART decision is being made
for a patient are the patient’s viral load and CD4 cell count [92]. Our model
shows that more incidences of lymphoma development will occur if patients
are being treated at a CD4 cell count of < 200 cells /µL, as opposed to a CD4
cell count of > 350 cells /µL. However, the current problem of the increasing
rise in the incidence of HRL is not just that of the CD4 cell count-related
national antiretroviral commencement policy, but that of late presentation.
The average CD4 cell count on presentation, of a South African HIV-infected
individual is about 85 cells /µL [93].
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This implies that if patients continue to present late, more lymphoma cases
will develop and may actually escalate at an uncontrollable rate. Thus, we
suggest that more awareness programmes be rolled out to educate the general
populace on the importance of HIV-infected individuals presenting their cases
early, and the likely risks of developing a disastrous cancer that they could
incur if they fail to do so. The control of this epidemic in the Western Cape
province of South Africa may be pivotal on this. We also suggest that it will
yield better results, and will in the long run cost less, if patients are being
treated at a CD4 cell count of > 350 cells /µL, as fewer serious cases will be
treated, which will reduce the cost of paying for longer days and more serious
cases in the hospital.
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The use of HAART have been seen to be effective in the continuous declina-
tion of the rate at which HIV-infected patients develop cancer [43; 45]. This
could imply that if every patient eligible for the HAART is getting it, faith-
fully adhering to it, and actually commencing their HAART treatment before
they become immunosuppressed (often a result of low CD4 cell count), then,
the incidence of HRL, and HRC in general will drastically decline, and per-
haps go into extinction (that is the patients live the normal average life-time
of HIV-negative individuals without developing an HRC). Nancy et al. [45]
reports that factors that determine if an HIV-infected patient will develop an
AIDS defining cancer (ADC) include a low CD4 cell count, and the non-use
of HAART.
A study by a UK Collaborative HIV Cohort (UK CHIC) [89; 90] reports that
patients with low CD4 cell counts have a higher risk of developing AIDS or
death. They reported this with some confidence interval, and with different
CD4 cell counts category. They particularly discovered that for patients with a
CD4 cell count > 350 cells /µL, each additional increase of 100 CD4 cells /µL
significantly reduces the chance of the development of AIDS (and consequently
ADC) in the HIV-infected patients. This implies that patients with CD4 cell
count > 350 cells /µL have a better prognosis, than those whose CD4 cell count
< 350 cells /µL. The worst prognosis expectedly was observed in patients
with CD4 cell count < 200 cells /µL, as they have a high risk of developing
AIDS (consequently ADC) or even death. Their report suggests that the
use of antiretroviral therapy, which can afford patients immune reconstitution
and thus CD4 cell count upswing, can be used to cause a decline in the risk
of developing AIDS, AIDS-defining illnesses (such as ADC), and even death
amongst HIV-infected individuals.
Another study by a large North American AIDS Cohort Collaboration on
Research and Design [91], which involved over 8, 000 HIV-infected individuals,
reports that HIV-infected patients who commence antiretroviral treatment at
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high CD4 cell counts, between 350 and 500 cells /µL have a significant lower
risk of death than those whose CD4 cell count is < 350 cells /µL before
antiretroviral therapy was commenced. They thus suggests that antiretroviral
therapy be commenced at a CD4 cell count of 351− 500 cells /µL, as opposed
to the current recommendation of < 350 cells /µL.
In this study, we present two mathematical models on the dynamics of HIV-
related malignancies. We implemented the use of ordinary differential equa-
tions in the comprehension of these dynamics. The first model, which was
presented in Chapter 3 explain the dynamics of HIV-related malignancies by
describing the different stages individuals can progress into during the course of
lymphoma development and treatment in an HIV setting. The second model,
which was presented in Chapter 4, describes the dynamics of HIV-related can-
cers, by giving specific deliberation to the different classes of CD4 cell count
levels an HIV-infected patient can fall into.
Qualitative analyses and numerical simulations of both models were done by
using their reproduction numbers R0 (for the first model), Rˆ0 and Rˆc0 (for the
second model). The first model has a locally stable HIV-free lymphoma steady
state when R0 < 1 and is globally stable when R0 < Rc0 < 1, where Rc0 is the
criticalR0. The second model has a globally stable HIV-free lymphoma steady
state only if Rˆ0 < Rˆc0. Both models exhibit backward bifurcation when their
reproduction numbers are less than one, that is, R0, Rˆ0 < 1. The existence of
backward bifurcation implies that there is the co-existece of a stable disease-
free and endemic equilibrium(s) when the models’ reproduction numbers are
less than one. In the first model, HIV can be eradicated from the population
under study if R0 < Rc0 < 1, and also in the second model if Rˆ0 < Rˆc0 < 1.
To obtain lymphoma incidence curves, lymphoma data from the TLSG were
fitted to the two models. We also carried out sensitivity analyses using the
Latin Hypercube Sampling (LHS) technique which makes use of Partial rank
correlation coefficients (PRCC). The purpose of this implementation is to de-
termine which parameters have the most significant impact on the prediction
imprecision of the models’ reproduction numbers, and to evaluate the variabil-
ity in the reproduction numbers as those parameters varies. In both models,
the most negatively sensitive parameter is the natural mortality rate µ. An-
other highly sensitive parameter in the first model is β1, the effective contact
rate of HIV for susceptible individuals (most positively sensitive to R0). An-
other highly sensitive parameter in the second model is τ2, the lymphoma
treatment rate of patients with HIV and lymphoma (who are in class IaLH or
IbLH).
In order to use the models as predictive tools, we did projections of the in-
cidences of lymphoma in four scenarios. The scenario analysis present some
probable trends the epidemic will take from 2014-2020, based on different per-
centage increase in the roll-out and uptake of effective of HAART coverage (as
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an intervention strategy) in the Western Cape province of South Africa. In
both models, the results show that an increase in the roll-out and effective use
of HAART has a significant declination effect on the incidence of lymphoma
in HIV-infected individuals, which will in turn result in a decline in the total
lymphoma incidence in the nearest future. It will also increase the number of
HIV and lymphoma patients who will get enrolled into the HAART program.
Specifically, the second model shows that the incidence of lymphoma in pa-
tients with highly depreciated CD4 cell count is upswinging at an alarming
rate, and earlier HAART administration is recommended.
The models presented in this study suggest that some social intervention pro-
grams, beside HAART roll-out can be used to control the epidemic. Such
programs may include an increase in the awareness of the public to, and ed-
ucational campaigns on HIV and its significant relation to the development
of cancers. The second model particularly shows that patients with low CD4
cell counts have a higher risk of developing AIDS (and AIDS-related cancers
consequently) or death. It also suggests that there will be an upswing in the
incidences of lymphoma development if patients are being treated at a CD4
cell count of < 200 cells /µL (which is often the case, due to late presentation
of cases), as opposed to a CD4 cell count of > 350 cells /µL.
In conclusion, we suggest that more awareness programs be rolled out to edu-
cate the general populace on the importance of HIV-infected individuals pre-
senting their cases early, and the likely risks of developing a disastrous cancer
that they could incur if they fail to do so. This will assist in alleviating the
governmental financial burden brought by the treatment of HIV-related ma-
lignancies, by reducing the cost of treating patients with HIV, and the few
who may unavoidably develop some HRCs. The control of this epidemic in
the Western Cape province of South Africa may be pivotal on this. We also
suggest that it will yield better prognosis of HRL if patients are being treated
at a CD4 cell count of > 350 cells /µL.
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Mathematical Tools
We give some exposition on the mathematical tools used in the qualitative
analyses of the models presented in this work.
Definition A.0.1. (Lozinskii˘ Measure µ (X)) LetX be an n×n square matrix
and be an induced matrix norm. The associated logarithm norm µ of X is
defined as
µ(X) = lim
h→0+
‖I + hX‖ − 1
h
, (A.0.1)
where I is an n × n identity matrix, and h ∈ R+. The Lozinski˘i measure is
otherwise known as the logarithmic norm. (A.0.1) is sometimes expressed as
the right-hand derivative
µ(X) = D+|I + hX|h=0. (A.0.2)
The value of µ (X) depends on the matrix norm it induces. ‖ · ‖ denotes any
norm in Rn [94].
The Lozinski˘i measure µ(X) satisfies the following properties [95]:
1. µ(X) ≤ ‖X‖.
2. µ(γX) = γµ(X), for γ ≥ 0.
3. µ(X + Y ) = µ(X) + µ(Y ), where Y is a matrix of the same dimension
as X.
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Definition A.0.2. (Convex Set) Let F be a vector space over the real num-
bers. A set D ⊂ F is said to be convex if, for all x and y in D, and all t ∈ [0, 1],
the point
(1− t)x+ ty
is in D. Geometrically, this means that every point on the line segment con-
necting x and y is in D.
Definition A.0.3. Let Ω ⊂ Rn be a convex open set, and x 7−→ f(x) ∈ Rn a
C1 function defined in Ω. We consider the autonomous system (of differential
equations) in Rn
x′ = f(x) (A.0.3)
under the following assumptions:
(H1) The Jacobian matrix ∂f/∂x of the vector field f of (A.0.3) can be written
as
∂f
∂x
(x) = −νI + A(x) for all x ∈ Ω, (A.0.4)
where ν is a constant and x 7−→ A(x) is an n×n matrix-valued function.
(H2) There exists a constant matrix B with rank B = r such that
BA(x) = 0 for all x ∈ Ω. (A.0.5)
The non-linear system (A.0.3) satisfying (H1) and (H2) is called an invariant
linear subspace [63; 96].
Definition A.0.4. (Simply Connected Set) A simply connected set D ⊂ R2
is a connected set having the property that every simple closed curve in D
cannot continuously shrink (within D) to a point. Geometrically, a simply
connected set D is one without any holes.
Definition A.0.5. (Bendixson’s Criterion) Suppose D is a simple connected
open set of R2. We define a two-dimensional autonomous system
dx
dt
= f(x, y)
dy
dt
= g(x, y)
(A.0.6)
If the expression div(f, g) ≡ ∂f/∂x + ∂g/∂y is not identically zero and does
not change sign in D, then, there are no periodic orbits of the autonomous
system (A.0.6) (or its closed orbit lying entirely) in D.
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Definition A.0.6. (Dulac’s Criterion) Suppose D is a simple connected open
set of R2 and B(x, y) is a real-valued C1 function in D. If the expression
div(Bf,Bg) =
∂(Bf)
∂x
+
∂(Bg)
∂y
(A.0.7)
is not identically zero and does not change sign in D, then there are no periodic
solutions of the autonomous system (A.0.6) in D.
The function B(x, y) is called a Dulac function. Dulac’s criterion is a general-
isation of Bendixson’s Criterion, in the special case where B(x, y) = 1.
Definition A.0.7. (Generalised Poincaré-Bendixson theorem) Suppose a tra-
jectory Γ of a planar system is forward invariant in a compact set K that
contains a finite number of critical points, i.e. Γ+ ⊂ K. Then ω(Γ) is either
• a critical point
• a periodic orbit
• a finite number of critical points p1, p2, . . . , pk and a countable number
of limit orbits (heteroclinics and/or homoclinics) whose α and ω limit
sets belong to {p1, p2, . . . , pk} [97].
This theorem is also known as the Poincaré-Bendixson Trichotomy.
Definition A.0.8. (Additive Compound Matrix ) Let M be an n× n matrix,
integer 1 ≤ k ≤ n, and M [k] denote the k-th additive compound matrix of M .
This is an L× L matrix, L = (n
k
)
, defined by
M [k] = D+(I + hX)
(k)|h=0, (A.0.8)
where B(k) is the k-th exterior power of an n × n matrix B, and D+ is the
right-hand derivative with respect to h. In the special cases k = 1, k = n, we
find
M [1] = M, M [k] = Tr(M), (A.0.9)
where Tr(M) signifies the trace of the matrix M . The term additive is used
since
(M +N)[k] = M [k] +N [k],
and the map M →M [k] is linear [94; 98].
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